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1. Introduction. 
Dynamic development and automation of medicinal chemistry approaches lead to an 
increased demand of compounds for biological evaluation.  
The search for novel therapeutics is based on four major strategies: 
a) Screening of natural and synthetic compound libraries - mixture of compounds 
b) Screening of random compound collections, combinatorial chemistry 
c) Focused compound collections - literature based drug design 
d) Computational drug design 
As an early approach to produce numerous compounds and complex libraries in microgram 
quantities, split-and-mix synthesis in combination with solid phase organic chemistry was 
used.1-2 Limited success from biological screening with regard to false-positives and problems 
with identification of active ingredients in the screened mixtures, due to insufficient 
purification and quality control methods, was the major drawback of the strategy.3 The high 
expectations placed upon early combinatorial libraries remained therefore unfulfilled. 
The mentioned problems were avoided by high throughput screening of random compound 
collections. The approach is based on the investigation of a series of single, characterized 
compounds with defined purity criteria. When no specific structure or substructure is 
obligatory as a starting point the approach initially requires a large number of diverse 
compounds in order to increase the chance to identify a compound of the novel biological 
target or an alternative lead structure for a known target.2 In addition to the collection sizes 
the probability to find a hit molecule might be further increased by using structural motifs that 
are appearing frequently in potent drugs and drug candidates or by selecting scaffolds which 
are straightforward to prepare and allow the synthesis of highly diverse compounds.2,4 
Further improvement in drug development was reached by generation of focused collections. 
The main task of this approach is not necessarily to provide large numbers of compounds but 
rather to improve hit rates by exploring molecular space. The term focused is not clearly 
defined. One category are target-family oriented collections that consist of compounds 
specifically designed to target certain protein families. Such sets of compounds require up to 
50000 molecules. More specific collections address a certain target protein and therefore the 
number of compounds may decrease to 2000, designed around a specific scaffold class. In a 
hit-to-lead or lead-optimization the compound number is smaller, around 20-500.3  
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Careful and smart design of libraries is crucial for the success in respect of physicochemical 
properties of molecules. The design principles can vary depending on the purpose of a 
collection. For a hit finding or target-oriented collection a basic tool is Lipinski’s rule of five.4 
Advances in molecular biology, protein engineering, and biophysical techniques are providing 
structural information about therapeutic targets, which are of great importance for creation of 
active candidates. Incorporation of key structures and recognition elements for receptor 
binding that are relevant to the particular biological target is often essential. However, the 
prediction of the influence of the specific lead modification is highly limited, due to the 
changes of ligand binding affinity or certain biological effects caused by nonspecific 
inhibition phenomena. Therefore often structure-based discovery strategies still require the 
preparation of many ‘designed’ compounds.3,5  
To increase the efficiency of the drug discovery process efforts are focused on computer-
based techniques that assist drug development. Software programs are used for the creation of 
the corresponding virtual compound library, and the selection of the compounds to be 
synthesized and screened based on drug-likeness. There are enzyme pocket-homology models 
available for enzymes, which are used to assess proposals for new scaffolds taking into 
consideration their fit into binding pockets. Additionally more sophisticated tools, such as 
docking, pharmacophore- or QSAR (Quantitative Structure-Activity Relationship)-based 
models might be used in combination with or instead of other mentioned approaches in more 
advanced stages of lead optimization.2-8  
Experimental methods which promise to shorten the drug discovery and development time or 
its cost are eagerly taken up. One of the useful technique is combinatorial chemistry, that 
allows the preparation of a large number of structurally related compounds either as mixtures 
in the same reaction vessel or individually by parallel synthesis. Combinatorial collections 
have been prepared using both solution chemistry and solid phase synthesis or by the 
combination of both. The great power of the high-throughput chemistry techniques is clearly 
seen when they are integrated with other tools used in drug discovery.2-8 
An extensive advance and success enhancement in medicinal chemistry and drug discovery is 
nowadays achieved by combining the speed power of combinatorial chemistry with the 
precision of structure-based design and potential of computational methods. 
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2. Objectives. 
The aim of this study is the discovery of novel lead structures in a search for antifungal and 
antidiabetic therapeutics by applying two drug discovery concepts, a screening of random 
compound collections and a focused drug design, both supported by solid phase and solution 
phase combinatorial chemistry. 
In the first part of the dissertation the search for antifungals based on a random high 
throughput screening is discussed. The compounds should be generated by the diversity-
oriented combinatorial synthesis. 
The focus of this work is placed on pyridines 1 and the fused pyridine system of 
pyrazolopyridines 2 as promising scaffolds due to the high probability to identify biologically 
active lead structures (Scheme 1).  
Scheme 1. General structures of the investigated scaffolds. 
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The objective of this study is to establish straightforward synthetic protocols for the 
generation of the desired molecules 1 and 2 and to prepare subsets of compounds varying only 
on the certain substituents in the pyridine ring 1.  
The synthesized compounds should be evaluated for their antifungal properties and toxicity in 
an in vitro cellular assay and result in the identification of the lead structure. 
The second part of the dissertation is dedicated to the rational design, synthesis and 
preliminary biological screening of novel DPP-4 inhibitors as antidiabetics. Literature search 
and structural data available for this target support the design of potential protein ligands that 
are based on pyridine rings and involve important structural motifs for the high binding 
affinity. In this context the intention is to synthesize novel pyridines as DPP-4 inhibitors and 
to establish their synthesis, starting with the scaffold 1, described in the first part of this study. 
The synthesized, isolated and analytically characterized collections should be then evaluated 
for DPP-4 inhibition and selectivity over related DPP-8, allowing a structure activity 
relationship discussion. 
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3. Pyridines as scaffolds for antifungals and antidiabetics. 
In respect to the main goals of the dissertation, this part of the work is focused on the active 
compounds based on the pyridine ring in the field of antifungal research and in the 
development of antidiabetics. The review presents active agents already on the market, but 
also examples from the recent literature of compounds with promising in vitro activity. 
The significance of pyridines was recognized in the 1930s when niacin 3 was used for the 
prevention of dermatitis and dementia. Since the middle of the last century, pyridine 
derivatives supported progress in understanding chemistry of biological systems, because they 
participate in biochemical processes. In many enzymes the prosthetic pyridine nucleotide 
(NADP) is involved in various reduction-oxidation reactions. Other important activity of 
pyridine in biological systems is its presence in the vitamins niacin 3 and pyridoxin 4 (vitamin 
B6) but also in highly toxic alkaloids such as nicotine 5 (Scheme 2).9 Pyridines find 
ubiquitous applications in medicaments10 and in agrochemicals.11 In the pharmaceutical 
industry, pyridine forms the nucleus of over 7000 existing drugs.9 Search in DrugBank 
(containing nearly 4800 drug entries and 1350 FDA-approved small molecule drugs) for the 
pyridine ring in approved medicaments gave 104 hits (similarity threshold = 0.7).10 They are 
addressed to a number of the various targets. The leading group are antimicrobials (isoniazid 
6) and histamine h1 antagonists such as pheniramine 7, but also anticancer, analgesic, and 
antidepressant agents (Scheme 2). 
Scheme 2. Structures of some biologically active pyridines. 
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3. 1 Pyridines as antifungal agents. 
Pyridines are extensively investigated for its antifungal activity as therapeutics or for 
agricultural use.  
Up to date there is only one approved antifungal drug on the market based on the 2-pyridone 
skeleton (Scheme 3).10 Ciclopiroxolamine 8, a drug with a long history, is marketed 
worldwide, as a topical antifungal agent. It shows in vitro activity against a number of fungi 
such as T. rubrum, T. mentagrophytes, M. canis, E. floccosum, H. capsulatum, S. schenckii, T. 
glabrata, B. dermatitidis, Candida species and Aspergillus species. It is mainly used against 
skin mycoses and vaginal candidosis. It is also effective in the treatment of dermatophytoses. 
The drug exhibits no significant toxicity and is well tolerated after topical administration.12 
An important feature of 8 is that it does not cause Candida albicans to develop resistance 
even with long-term treatment and, in addition, it is an excellent anti-inflammatory agent. In 
contrast to the other topical antifungals, the mode of action of ciclopiroxolamine is poorly 
understood. It has no effect on sterol synthesis, but was shown to inhibit several metal-
dependent enzymes. S. H. Leem et al. screened the drug against several Saccharomyces 
cerevisiae mutants. Results suggested that ciclopiroxolamine may exert its effect by 
disrupting DNA repair, cell division signals and structures as well as some elements of 
intracellular transport.13  
Scheme 3. Structure of the antifungal ciclopiroxolamine. 
N O
OH
NH2
OH
8
 
A number of pyridine-based compounds are used in the crop protection as fungicides (Scheme 
4). They mainly affect sterol biosynthesis in membranes, but also mitosis and cell division or 
respiration process.11,14 
Pyrifenox 9 is a systematic fungicide with protective and curative action absorbed by the 
leaves and roots and translocated acropetally. The compound 9 as well as buthiobate 15 was 
proved to be an inhibitor of ergosterol biosynthesis.15-16 It is used for the control of powdery 
mildew, scab and other pathogenic Ascomycetes, Basidiomycetes, Deuteromycetes in vines, 
fruits and vegetables.11  
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Pyroxychlor 13 possess its antifungal activity due to DNA synthesis inhibition. It is used for 
controlling phycomycetous soliborne pathogens (e.g. Pythium aphanidermatum).17 
Fluazinam 20 has an uncoupling activity on mitochondrial oxidative phosphorylation. It is 
used to treat grey mould on vines, apple scab, Phytophthora infestans on potatoes.11
 
Various pyridine N-oxide derivatives possess antibacterial and antifungal activity. Due to 
their broad spectrum antimicrobial activity they were used in shampoos as antidandruff agents 
and in cosmetics as preservatives. Dipyrithione 16 was incorporated into shampoos as its 
magnesium sulfate adduct.11,18 
Scheme 4. Pyridine-based fungicides. 
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The scientific journals and patent literature show that there is ongoing search for novel potent 
antifungals and pyridines. 
A series of publications reported SAR studies based on the hit structure 21 obtained from the 
screening of 12800 antifungal drug candidates, inhibitors of the methionine aminopeptidase 
(MetAP).19 The pyridine-2-carboxylic acid derivatives 21-23 have shown submicromolar 
inhibition of the two enzyme type (Scheme 5, 23: IC50 = 130 nM for EcMetAP1 and IC50 = 
380 nM for ScMetAP1). These compounds represent the first small-molecule MetAP 
inhibitors with novel structures different from alkylating Fumagillin derivatives and peptidic 
bestatin-based MetAP inhibitors. 
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Scheme 5. Examples of the MetAP inhibitors. 
N
O
N
H
N
S N
O
N
H
N
S
O
O
N
O
N
H
N
S
NH
O
21 22 23
 
M. S. Yar et al. reported a series of pyrazolyl-4-pyridylmethanones that has been tested 
against baceria Staphylococcus aureus, Escherichia coli, as well as for its antifungal activity 
against Aspergillus fumigatus and Candidas: C. albicans, C. krusei, C. glabrata.20 The 
minimum inhibitory concentration (MIC) of the two most active derivatives 24a-b was less 
than 0.5 µg/mL and they were equally active as the standard drugs Ofloxacin and Fluconazole 
(Scheme 6). 
Scheme 6. Structure of the antifungal pyrazolyl-4-pyridylmethanones. 
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Pyridines substituted with the chalcone moiety 25 have been reported as potent antifungals 
(Scheme 7).21  
Scheme 7. Antifungal chalcones 25. 
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Their antibacterial activity against B. pumilis, B. subtilis, E. coli and P. vulgaris was 
comparable to that of Penicillin and comparable to Fluconazole when the antifungal 
properties against A. niger and Penicillium chrysogenum were tested at the concentration of 
1000 µg/mL. 
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Scheme 8. Antifungal pyridinium salts. 
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Some substituted benzylidenehydrazinylpyridinium derivatives bearing benzyl, ethylphenyl 
and propylphenyl groups on the pyridinium nitrogen were synthesized and screened for 
possible antibacterial and antifungal activities against Staphylococcus aureus, Escherichia 
coli, Pseudomonas aeruginosa and Candida albicans. The compound 26 was the most active 
in the series against many strains of bacteria and fungi (Scheme 8).22a 
Recently another series of pyridinium salts substituted with phosphonoxymethyl group was 
patented for its antifungal activity against a number of fungi (Scheme 8, 27).22b 
As a result of the search for antifungals based on the similarity to the phospholipids, a series 
of bis(alkylpyridinium)alkanes 28 with a twelve carbon spacer between the positive charges 
was found to be potent antifungal agents with MICs in the range of 1.4-2.7 µM against 
reference strains Cryptococcus neoformans and Candida albicans.23 Two most active 
compounds 28a and 28b (Scheme 9) were assayed against a wider range of yeasts and moulds 
and were found to have broad spectrum fungicidal activity, including the emerging pathogen 
S. prolificans.23a In order to understand the mode of action the antifungals were screened for 
the inhibition of the secreted enzyme, fungal phospholipase B (PLB), that is a proven 
virulence determinant of the pathogenic fungi, Candida albicans and Cryptococcus 
neoformans, and which is also secreted by other pathogenic fungi including Aspergillus spp. 
Previous studies on a series of bis(amino)pyridiniumalkanes, based on the known 
disinfectants dequalinium and octenidine, indicated that while these compounds are strongly 
antifungal, they do not inhibit cryptococcal PLB1.23b Interestingly in the most recent study 
there was no clear correlation with antifungal activity. Preliminary experiments however 
indicated that bis(alkylpyridinium)alkanes 28 may play a role in disrupting fungal 
mitochondrial function.23a 
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Scheme 9. Representative antifungal bis(alkylpyridinium)alkanes 28. 
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A novel group of antifungals is represented by dicationic 2,5-bis(4-guanidinophenyl)furans.24 
The fungicidals were screened against Candida albicans and exhibit MICs of 2 µg/mL. The 
compound 29 (Scheme 10) showed in addition good activity against Cryptococcus 
neoformans and Rhizopus arrhizus. 
Scheme 10. Representative potent antifungal dicationic 2,5-bis(4-guanidinophenyl)furan 29. 
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A. El-Galil et al.25a Based on the peptidocalixarene derivatives studied as analogues of 
vancomycin-type antibiotics designed macrocyclic peptidocalixarenes 30 and investigated 
them for antimicrobial activity.25 
Scheme 11. Antifungal macrocycles 30. 
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Among the series several macrocycles showed high antimicrobial activity comparable to 
Ampicillin and Chloramphenicol against Bacillus subtilis, Bacillus aureus, Staphylococcus 
aureus, Escherichia coli, and against fungi: Candida albicans and Aspergillus niger. The 
structure of the most potent antifungal macrocycles 30a and 30b is presented on the scheme 
11. 
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The attempts to use quantitative structure-activity relationships (QSAR) models in order to 
give an insight in the design of potent antifungal agents based on pyridines have been reported 
recently.26 A. Buciński and coworkers performed QSAR studies of antifungal activity against 
Candida albicans of 44 pyridines belonging to a class of quaternary ammonium salts.26a  
Scheme 12. Examples of the pyridines 31 used for QSAR studies.26b 
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Similarly QSAR studies were performed for 5-substituted (arylmethylene) pyridin-2-amine 
derivatives 31 (Scheme 12) to correlate the selected electronic, steric and liphophillic 
parameters with antifungal activity against A. niger, A. flavus, P. crysogenum and F. 
oxysporium.26b  Both studies gave a good correlation of the predicted activity by the artificial 
neural networks and from the biological experiments.  
Scheme 13. Potential fungicides. 
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A series of 2-[(2-chloropyrid)-4-yl]-5-arylamino-1,3,4- thiadiazoles 32 are potent inhibitors of 
R. solani (Palo) at 500 µg/mL. The amide 33 was reported to be more than 91% effective 
against Botrytis on beans at 500 g/ha. Fungicidal 2-methoxyimino-2-
[(pyridinyloxymethyl)phenyl] acetamides 34 showed 75-100% control of plant diseases like 
mildew of wheat, brown rust, glume blotch of wheat and late blight of tomatoes.12 35 was 
reported as a potent fungicide for agricultural purposes.27 Picolinic acid derivatives were 
tested for activity against fungal strains such as Alternaria brassicae or Septoria nodorum, 
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and hydroxypicolin amide derivative 36 was proposed for pharmaceutical usage as fungicide12 
(Scheme 13). 
Fungicides presently available on the market differ widely in chemical structure and 
functional groups. Nevertheless the compounds with the optimum antifungal properties have 
not been found yet and this fact stimulates continuing research for the synthesis of new 
molecules. The pyridine-based active compounds constitute a promising group in the search 
of potent antifungals exerting selective toxicity against fungi without interacting with other 
eukaryotic cells.  
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3. 2 Pyridines as DPP-4 inhibitors for treatment of diabetes mellitus. 
3. 2. 1 Approaches for diabetes treatment. 
Diabetes is a growing health problem, with an estimated 220 million people worldwide 
suffering from this disease, and type 2 diabetes comprises 90% of them.28-29  
M. L. Mohler et al. have recently reported a progress in diabetes treatment. The number of 
exciting approaches to treat the disease was estimated for more than 20. The treatment 
involving incretin actions together with PPAR (peroxisome proliferator-activated receptor)-
activators make up the main classes of medicaments under investigation for controlling blood 
glucose in type 2 diabetes, but the number of cellular processes affected by the disease is so 
high that these approaches are far from exhausting all possibilities. Some other strategies, 
such as affecting glucose production (inhibition of gluconeogenesis, formation of glucose in 
the liver, or glycogenolysis, breakdown of stored glycogen in the liver) or glucokinase 
activators are in earlier stages of clinical research. Other interesting approaches are based on 
sodium-glucose transporter-2 (SGLT2) inhibition or amylin analogues and, as they do not 
intervene with glucose metabolism, might be complementary to the previously mentioned.30 
The field of antidiabetics is vast from both, biological and synthetic point of view. Pyridines 
represent a group of the widely investigated compounds in every emerging target and 
therefore a comprehensive discussion is beyond the scope of this work. Here mainly the DPP-
4 inhibition will be discussed. Nevertheless, it is worth mentioning, that pyridine-based agents 
are extensively investigated for other targets in diabetes field.  
Scheme 14. Pyridine-based PPARs inhibitors. 
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Rosiglitazone 37 and pioglitazone 38 are potent PPARγ agonists currently marketed for the 
treatment of type 2 diabetes (Scheme 14). PPARs regulate the expression of genes that affect 
blood lipid metabolism, the generation of adipocytes, and blood glucose control. The 
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pyridine-2-propanoic acid 39 represents a class of potent dual PPAR agonists. S-enantiomer 
of compound 39 displayed a higher oral efficacy than the rosiglitazone 37 in a mouse model 
of diabetes.31a 2-Sulfonyl-pyridine 40 (GSK3787) was identified as a potent and selective 
ligand for PPARδ with good pharmacokinetic properties.31b 
Scheme 15. Pyridine-based 11b-hydroxysteroid dehydrogenase type 1 inhibitor 41  
(PF-915275). 
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N-(Pyridin-2-yl)arylsulfonamides were disclosed by Pfizer as inhibitors of 11b 
hydroxysteroid dehydrogenase type 1 (11bHSD1), that represent a novel approach to treat 
patients with diabetes and metabolic syndrome by blocking adipogenesis. The studies led to 
the clinical candidate 41 (PF-915275) for the treatment of diabetes and metabolic disorders 
(Scheme 15).32  
Scheme 16. Pyridine-based glucokinase activators. 
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To date, several amide classes of glucokinase activators, including nicotinic acid derivative 42 
(GKA50, AstraZeneca),33 have been discovered, and some of these compounds have entered 
human clinical trials. Glucokinase catalyses the phosphorylation of glucose to glucose 6-
phosphate in glucosensitive cells (Scheme 16). In pancreatic β-cells, this reaction is the rate-
limiting step of insulin release. Small-molecule activators of GK that stimulate β-cell 
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physiology and subsequently enhance the glucose-dependent release of insulin are expected to 
be useful for the diabetes treatment.34  
Besides of 42, numerous further pyridine-based glucokinase activators recently appeared in 
the patent literature. A series of of 2-pyridine-benzimidazoles, represented by compound 43, 
were intensively evaluated for the enzyme activation.35 In 2008 Merck invented a series of 
pyridines delineated by 44 and most recently 2-pyridinecarboxamide derivatives represented 
by disulfanyl-pyridines 45, as glucokinase-activating agents for the therapy of diabetes 
mellitus (Scheme 16).36-37 
 
3. 2. 2 Inhibition of DPP-4 - a novel target for antidiabetics development. 
In 1996 the first in vivo experiments indicated that dipeptidyl peptidase IV (DPP-4) inhibition 
resulted in improved glucose tolerance and could be used as an approach for the development 
of new treatment for type 2 diabetes.38 
DPP-4 is a highly specific atypical serine protease, which specifically cleaves dipeptides from 
proteins and oligopeptides after a penultimate N-terminal proline or alanine. This enzyme was 
described in 1966 for the first time.39 DPP-4 as a complex enzyme is released in almost all 
tissues and organs. It is expressed on the surface of most cell types and can also be found in 
plasma and urine. By its important modulatory activity on a number of chemokines, 
neuropeptides, and peptide hormones it is associated, among other processes, with immune 
regulation, signal transduction, and apoptosis.29,40 Plasma DPP-4 rapidly deactivates incretins.  
Incretin hormones, glucose dependent insulinotropic peptide (GIP) and glucagon-like 
peptide 1 (GLP-1), are defined as intestinal hormones released in response to nutrient 
ingestion, which potentiate the glucose-induced insulin response (the incretin effect).41 A 
higher activity of the incretin hormones should result in an increase of the insulin secretion 
and counterbalance the problems in non-insulin dependent diabetes. But because of the short 
in vivo half-life of about 1.5 min42 it is not useful to administrate the GLP-1 as it is. Therefore 
the synthesis of DPP-4 resistant incretin mimetics, like exenatide was a promising approach. 
But these therapeutic agents as well as synthetic GLP-1 have to be administered parenterally, 
cause some side effects and are only approved in combination with other oral antidiabetic 
agents.43 
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Another therapeutic approach regarding the incretin-effect, the inhibition of DPP-4, has been 
shown to be able to prolong the beneficial effects of primarily GLP-1 and GIP by stabilizing 
the intact (active) form of the hormones.44 The longer activity of the incretins like GLP-1 
permits an increased secretion of insulin and inhibits the glucagon release, which in turn 
decreases the chronically high blood glucose to near-normal levels, shown by HbA1c values. It 
could also be proven that a higher GLP-1 level protects the remaining pancreatic β-cells, 
increases their activity and promotes their growth resulting in an increasing number and mass 
of ß cells. By slowing the rate of gastric emptying and promoting the satiety, GLP-1 is also 
useful for reduction of the caloric intake and in this turn for weight reduction. Since the 
activity of incretin hormones depends on the blood glucose level, there is a lower risk of 
hypoglycemia, compared to conventional anti-diabetic agents.41 
Owing the impressive antidiabetic actions of GLP-1, targeting both fasting and prandial 
glucose concentrations, an effective inhibition of DPP-4 became a pathway for treatment of 
diabetes, particularly non-insulin dependent diabetes and related diseases. Since GLP-1 
inhibits the glucagon release also, inhibitors of DPP-4 should also be usable for the treatment 
of type I diabetes. 
When in 1996 the first in vivo experiments indicated that DPP-4 inhibition results in improved 
glucose tolerance, an elevated interest in the inhibition of DPP-4 enzyme for treatment of 
diabetes was observed.45 
Extensive research efforts from both the academia and the pharmaceutical industry have led to 
launch of Sitagliptin 46 (2006, Merck & Co. Inc.),45c,46a Vildagliptin 47 (2007, Novartis AG)46b 
and Saxagliptin 48 (2009, Brystol-Myers Squibb Co.) (Scheme 17).46c 
Scheme 17. Launched DPP-4 inhibitors. 
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Nevertheless, continuing search for small molecules as potent and selective orally available 
inhibitors remains a major challenge and is indicated by an explosion of patents and 
publications regarding a big variety of scaffolds, in particular from pharmaceutical industry. A 
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lot of efforts were made to prolong the stability and the long-acting potential of conventional 
DPP-4 inhibitors.47 Also some approaches were made on the base of crystal structure analysis 
by target-oriented design.48 A comprehensive review about the recent approaches in medicinal 
chemistry to the inhibition of DPP-4 for treatment of type II diabetes is given by Havale and 
Pal.43 Many DPP-4 inhibitors were developed before the discussion on potential toxicity due 
to the inhibition of other members of DPP family resulting in unforeseen side effects and low 
tolerance.49 In this context especially two closely related proteases, DPP-8 and DPP-9, were 
recently investigated intensively. The high degree of sequence homology between DPP-8, 
DPP-9 and DPP-4 makes selective inhibitor design a challenging task.50 It has become 
necessary to design not only potent, but also more selective inhibitors targeting DPP-4.  
First DPP-4 inhibitors based on the pyridine backbone appeared just after evaluating the DPP-
4 as a target for diabetes treatment. 
In 1999, Novartis reported modification of the previously described DPP-4 inhibitors, L-
amino acids with N-terminal primary amine in the P-2 site. Validation of pyridine collections 
led to the selection of the slow binding inhibitor 49 (NVP-DPP728) as a clinical development 
candidate for type 2 diabetes (Scheme 18).51 
Scheme 18. Structure of NVP-DPP728 49. 
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In 2006, Abbott Laboratories introduced 50 based on 49. SAR of substitutions at the C5 
position of the 2-cyanopyrrolidide led to an extremely potent (KiDPP-4 = 1.0 nM) and selective 
(KiDPP-8 > 30 µM) clinical candidate, ABT-279 50, that is orally available, efficacious, and 
remarkably safe in preclinical safety studies (Scheme 19).51c,52 
Scheme 19. Clinical candidate 50 for type 2 diabetes treatment. 
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In 2003, F. Hoffmann-La Roche AG reported compounds of formula 51.53a The most active 
compound, a substituted pyrimidine 51a had IC50 value in picomolar range (Scheme 20).  
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Scheme 20. Series of pyridines and pyrimidines 51 and 52 developed by F. Hoffmann-
La Roche AG. 
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Further studies made at F. Hoffmann-La Roche AG, starting from another weakly active 
pyrimidine screening hit 52a, were focused on the optimization of the aromatic ring itself, its 
substitution and conformational restrictions. The structure optimization resulted in the 
discovery of the potent DPP-4 inhibitor, pyridine 52b (Scheme 20).53b  
A 2005 patent by Takeda (Japan) disclosed a series of pyridine-based DPP-4 inhibitors 5354a-b 
and in 2006 a second series of pyridyl acetic acid derivatives 54.54c Substituted 3-
aminomethyl pyridines give high flexibility regarding the position 5 on the ring without 
significant influence on the DPP-4 inhibitory activity (53a-c, 54, Scheme 21).  
Scheme 21. Pyridine-based DPP-4 inhibitors 53 and 54 investigated by Takeda. 
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In 2006, another series of pyridines 55 was patented by Eli Lilly & Co as DPP-4 inhibitors.55 
One of the most active analogues is shown on the scheme 22. 
Scheme 22. Structure of the representative potent DPP-4 inhibitor-pyridine 55. 
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The same year, Bristol-Myers Squibb Company reported pyrrolopyridine-based inhibitors of 
DPP-4 56, and methods to synthesize them (Scheme 23).56a 
Scheme 23. Bicyclic pyridines - DPP-4 inhibitors. 
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Most recently, Bristol-Myers Squibb Company extended the previous invention to 6-mem-
bered rings. The patented series exhibit high inhibitory activity, and 57 was one of most active 
analogs (IC50 = 2 nM).56b Simultaneously AstraZeneca reported 58, based on dihydro-1H-
[1,5]naphthyridin-2-one ring as an active DPP-4 inhibitor (Scheme 23).57 
In recent years a remarkable progress has been made towards understanding the biology of 
DPP family and incretins action. The improvement has been reflected in the number of 
creative publications and reviews. First group of early DPP-4 inhibitors were 
dipeptidomimetic compounds bearing structural resemblance to the N-terminal dipeptide of 
the enzyme substrates. The use of high throughput screening in combination with rational 
drug design has resulted in discovery of diverse classes of inhibitors. Among them pyridines 
incessantly attract attention of the pharmaceutical industry by serving as a promising scaffold 
for the development of novel therapeutics. 
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4. Results and disscusion. 
4. 1 Random collection of pyridines and pyrazolopyridines. 
4. 1. 1 Solid phase synthesis of pyridines and pyrazolopyridines. 
As a key intermediate in the synthetic pathway, commercially available or easily accessible 
(E)-2-oxo-4-aryl-but-3-enoic acids 5958 and (E)-4-oxo-4-aryl-but-2-enoic acids 60 were 
chosen (Scheme 24).59  
Scheme 24. General structures of the intermediates. 
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Although the addition of various amines to the related chalcones is well documented,60 the 
synthesis of dicarbonyl systems of 59 and 60 has been poorly studied. From the synthetic 
point of view it would therefore be interesting to evaluate the possibilities to access various 
heterocyclic compounds such as pyridines, pyrazolopyridines, or pyrimidines using 
unsaturated ketoacids 59 and 60.  
Scheme 25. The synthetic pathways. 
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Cyclization reactions leading to the final ring constructions often require harsh conditions, 
such as high temperatures or low pH, therefore Wang resin was chosen to be the most 
appropriate solid support as it is characterized by high physical stability and its compatibility 
with a range of reaction conditions.62 
The approach was initiated by the synthesis of the intermediates 59 and 60 on a solid support. 
However, the attempted coupling of the pyruvic acid or glyoxylic acid to the resin 61 using 
various coupling reagents and bases failed, although attachment of the carboxylic acids to the 
resin is well known and often used.62 Therefore the pathways were modified by direct 
attachment of the intermediates 59 and 60 prepared in solution58-59 to the Wang resin 61. The 
resin was loaded with 50-90% efficacy to give 63 and 67 and no significant loss of the 
starting material purities (purity > 85% as proved by LC-MS analysis of the intermediate after 
cleavage). The next step of the synthesis was the cyclocondensation reaction of 63 and 67 
with the appropriate amines to construct immobilized heterocycles 64 and 68 that, after 
cleavage, gave the desired products 65 and 69. 
Scheme 26. Synthesis of the pyridines 74 and pyrazolopyridines 78. 
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*Oxidation step used if required. 
The pyridines 74 were synthesized by the cyclization of starting materials 63 with enamines 
70 (Scheme 26). In the reaction with enamine 70 substituted with a keto group in position 2, 
the intermediates, dihydropyridines 71, were stable enough to give 72 after cleavage from 
resin 71 (Table 1, 72a-b). The compounds 71 were oxidized with DDQ at room temperature 
to give the desired pyridines 74 in good yields and purities after cleavage (Table 1, 74a-d). 
  
21
Compound 70 with a cyano group in position 2 reacted to give directly cyclocondensed 
products 73 and 74 after cleavage, thus the oxidation step could be avoided (Table 1, 74e-n). 
Table 1. Results of the synthesis of pyridines 72, 74 and pyrazolopyridines 78. 
Compd Ar R1 R2 Yield (%)a Purity (%)b 
72a 4-Chloro-phenyl Me COMe 68 93 
72b 4-Bromo-phenyl Me COMe 68 89 
74a 4-Chloro-phenyl Me COMe 72 86 
74b 2,4-Dichloro-phenyl Me COMe 85 87 
74c 4-Bromo-phenyl Me COMe 93 80 
74d 5-Chloro-thiophen-2-yl Me COMe 99 94 
74e 3-Chloro-phenyl Me CN 74 80 
74f 2,4-Dichloro-phenyl Me CN 80 99 
74g 3,5-Dichloro-phenyl Me CN 99 76 
74h 4-Bromo-phenyl Me CN 67 71 
74i 4-Methoxy-phenyl Me CN 73 86 
74j 2,4-Dimethoxy-3-methyl-phenyl Me CN 38 84 
74k 4-Dimethylamino-phenyl Me CN 56 78 
74l 4,5-Dimethyl-furan-2-yl Me CN 60 84 
74m Thiophen-2-yl Me CN 40 93 
74n 5-Chloro-thiophen-2-yl Me CN 38 73 
78a 4-Fluoro-phenyl Ph Me 85 82 
78b 3-Chloro-phenyl Ph Me 99 79 
78c 2,4-Dichloro-phenyl Me Me 98 82 
78d 2,4-Dichloro-phenyl Ph Me 79 99 
78e 3,5-Dichloro-phenyl Ph Me 99 80 
78f 4-Bromo-phenyl Me Me 99 88 
78g 4-Bromo-phenyl Ph Me 84 91 
78h 4-Methoxy-phenyl Me Me 84 75 
78i 4-Methoxy-phenyl Ph Me 78 88 
78j 2,4-Dimethoxy-3-methyl-phenyl Me Me 72 89 
78k 4-Dimethylamino-phenyl Ph Me 80 77 
78l 4,5-Dimethyl-furan-2-yl Me Me 72 85 
78m 4,5-Dimethyl-furan-2-yl Ph Me 99 88 
78n 
78o 
Thiophen-2-yl 
5-Methyl-thiophen-2-yl 
Me 
Ph 
Me 
Me 
91 
73 
78 
76 
78p 5-Chloro-thiophen-2-yl Me Me 28 80 
aYields refer to isolated products after cleavage from the resin. 
bPurities were determined by HPLC-MS (210 - 400 nm) after cleavage from the resin. 
 
The pyrazolopyridines 78 were prepared analogously by the cyclization step with 
pyrazoloamines 75 (Scheme 26). As it was previously reported,63 the reaction proceeds via 
formation of dihydropyrazolopyridines 76. The amount of non-aromatized 77 in the reaction 
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mixture after cleavage did not exceed 10%. Only synthesis of 78p required oxidation with 
DDQ as the cyclization step gave a mixture of 76 and 77 in the ratio 1:1.  
The products 72, 74 and 78 were obtained in high yields and purities after the cleavage from 
the resin with 20% TFA in DCM (Table 1) and, if required, washing the products with 
acetonitrile (for 72, 78) or with diethyl ether (for 74). 
In an analogous manner solid supported intermediates 67 were used to approach 81 and 85 
(Scheme 27).  
Scheme 27. Synthetic pathway for the synthesis of 81 and 85. 
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*Oxidation step used if required. 
Synthesis of pyridines 81 required the oxidation step only after reaction with enamine 70 
bearing keto group in position 2. To increase purities of pyrazolopyridines 85 oxidation was 
necessary as the amount of non-aromatized 82 in the reaction mixture usually exceeded 40%. 
In case of 67 substituted with a furan or thiophene ring, the intermediates 82 were first formed 
exclusively, which allowed isolation and characterization of 83a and 83b. 
The products 81, 83 and 85 were obtained in high yields and in most cases excellent purities 
(Table 2). To increase the purity washing with acetonitrile or diethyl ether was sufficient. 
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Table 2. Results of the synthesis of pyridines 81 and pyrazolopyridines 83 and 85. 
Compd Ar R1 R2 Yield (%)a Purity (%)b 
81a 2,4-Dichloro-phenyl Me COMe 88 73 
81b 4-Bromo-phenyl Me COMe 36 84 
81c 2,4-Dichloro-phenyl Me CN 80 72 
83a Furan-2-yl Ph Me 56 90 
83b Thiophen-2-yl Ph Me 88 99 
85a 4-Fluoro-phenyl Me Me 89 88 
85b 4-Fluoro-phenyl Ph Me 58 79 
85c 3-Chloro-phenyl Me Me 73 87 
85d 2,4-Dichloro-phenyl H Me 75 79 
85e 2,4-Dichloro-phenyl Me Me 72 89 
85f 2,4-Dichloro-phenyl Ph Me 55 99 
85g 3,4-Dichloro-phenyl Me Me 80 83 
85h 3,4-Dichloro-phenyl Ph Me 56 71 
85i 4-Bromo-phenyl Me Me 49 82 
85j 4-Bromo-phenyl Ph Me 24 95 
85k Furan-2-yl Me Me 65 79 
85l Furan-2-yl Ph Me 57 63 
85m Thiophen-2-yl Me Me 99 96 
85n Thiophen-2-yl Ph Me 54 86 
aYields refer to isolated products after cleavage from the resin. 
bPurities were determined by HPLC-MS (210 - 400 nm) after cleavage from the resin. 
 
The conditions identical to those previously described for pyridines 74, 81 and 
pyrazolopyridines 78, 85 were used to generate pyrimidine and fused pyrimidine ring 
systems. The intermediates 63 were reacted with amines, and series of pyrimidines 86, 
pyrazolopyrimidine 88, benzo-imidazopyrimidine 90 and triazolopyrimidine 92 were obtained 
in excellent yields and purities (Scheme 28). The cyclization with isonicotinamidine after 
heating in DMF for 16 hours afforded 86. In case of the reaction with pyrazol-3-ylamine, 
benzoimidazol-2-ylamine and triazol-3-ylamine only non-aromatized compounds were 
formed and the dihydro-derivatives 87, 89 and 91 were isolated and characterized. In 
contrary, the attempts to prepare a collection of the regioisomers using the intermediate 67 
failed. In most of the cases the reaction mixtures contained less than 40% of the expected 
products. 
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Scheme 28. Synthesis of pyrimidines. 
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4. 1. 2 Synthesis of pyridine derivatives in solution. 
The substitution pattern of the pyridines 74 and 81 offer a number of possibilities of further 
modifications. The most interesting derivatives concerning their potential antifungal64-65 
activity and their novelty as building blocks were chosen using literature database search. 
Initially identical modifications of 74 and 81 were planned to achieve a set of regioisomers 
differing on position 2 and 4 in the pyridine ring. The reactivity of 74 and 81 restricted the 
number of compounds (Scheme 29).  
Scheme 29. Modifications of the pyridines 74 and 81. 
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One of the chosen modifications was the synthesis of pyridine N-oxides 93 and 98. The 
chemistry and applications of heterocyclic N-oxides receive much attention due to their 
application as synthetic intermediates or as protecting groups, oxidants, ligands in metal 
complexes and catalysts but also due to their biological importance.64c The pyridine amides 
94, 96 and 99 are related with vitamins (niacin), as well as other active pyridine-based 
molecules such as phenoxynicotinamide 104, a herbicide, and were used in this dissertation as 
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intermediates (Scheme 30). The structures of dicyanopyridines 95 and 101, are close to those 
of fungicides such as pyridinitrile 10. Tetrazolyl-pyridines, carboxyhydrazides, as well as 
pyridine derivatives with hydroxyamidine motif are known as well for their pharmacological 
activity,65 thus 97, 100 and 102 were prepared. The presence of the cyano next to the carboxy 
group in 81 gave the opportunity for the generation of the fused ring system as in the 
pyrrolopyridines 103, that is related to the adenosine receptor agonist 105 (Scheme 30). 
Scheme 30. Example of the active pyridines. 
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Although solid phase protocols have a number of advantages, one of the main disadvantages 
of the method is the limitation in scaling up the synthesis. As the amount of the starting 
materials 74 and 81 needed for evaluation and then synthesis of the derivative collections was 
in the gram range, the protocols in solution had to be established. 
 
4. 1. 2. 1 Synthesis of pyridine carboxylic acids. 
Treatment of (E)-2-oxo-4-aryl-but-3-enoic acids 59 with potassium t-butoxide in acetonitrile 
at ambient temperature afforded pyridines 74 in good yields (Scheme 31).  
The formation of the product proceeds by condensation of 59 with β-aminocrotonitrile 70a 
generated in situ. When the reaction was performed in dichloromethane or in tetrahydrofuran 
with commercially available β-aminocrotonitrile, no improvement of the yield or the reaction 
time was observed. Depending on the substitution pattern of the aromatic ring, full conversion 
required 3-16 hours. The increase of the amount of t-butoxide did not significantly influence 
the reaction time. The ketoacids 59 with phenyl ring substituted with bromine in para position 
did not react at the described conditions. 
Usage of (E)-4-oxo-4-aryl-but-2-enoic acids 60 under the same reaction conditions allows 
substituent flexibility at the position 2- and 4- of the target molecule 1. Compounds 60 reacted 
with β-aminocrotonitrile 70a to give the regioisomers 81 in good to excellent yields.  
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Scheme 31. Solution phase synthesis of pyridines 74. 
N
Ar
NC
O
OH
NH2
CN
Ar
OH
O
O
59 74
70a
3 eq t-BuOK
MeCN, 16 h
 
Compd Ar Yield (%) 
74m 2-Fluoro-phenyl 61/51* 
74n 4-Fluoro-phenyl 66 
74o 2,4-Difluoro-phenyl 30* 
74e 3-Chloro-phenyl 60 
74p 4-Chloro-phenyl 73 
74f 2,4-Dichloro-phenyl 40* 
74r 
74s 
3,4-Dichloro-phenyl 
2,6-Dichloro-phenyl 
42 
81 
74i 4-Methoxy-phenyl 71/50* 
74t Benzo[1,3]dioxol-5-yl 62 
74k 4-Dimethylamino-phenyl 87 
74u Furan-2-yl 29* 
74m Thiophen-2-yl 62 
74w Thiophen-3-yl 60* 
*Yields refer to 20 mmol scale; 1.5 eq of t-BuOK was used in 
case of 74n and 74f; compounds isolated by crystallization.  
 
Scheme 32. Solution phase synthesis of pyridines 81. 
N
NC
Ar
OHO
NH2
CN
Ar
OH
O
O
60 81
70a
2 eq t-BuOK
MeCN, 16 h
 
Compd Ar Yield (%) 
81d 4-Fluoro-phenyl 74 
81e 
81f 
2,4-Difluoro-phenyl 
2-Fluoro-4-chloro-phenyl 
30* 
40 
81g 3-Chloro-phenyl 67 
81h 4-Chloro-phenyl 86 
81c 2,4-Dichloro-phenyl 81/65* 
81i 3,4-Dichloro-phenyl 54 
81j 4-Bromo-phenyl 72/35* 
81k 4-Methoxy-phenyl 81/55* 
81l Furan-2-yl 63 
81m Thiophen-2-yl 61 
*Yields refer to 20 mmol scale, 1.5 eq of t-BuOK was used; 
compounds isolated by crystallization. 
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Similarly, for 59 differences in the reactivity depending on the substitution of the aromatic 
ring were observed. Nevertheless, 16 hours were sufficient for the full conversion. Two 
equivalents of potassium t-butoxide were used, because an increase of the amount of base lead 
to the formation of byproducts. As for the synthesis of the regioisomers 74, reactions in 
dichloromethane or tetrahydrofuran with commercially available β-aminocrotonitrile did not 
improve reaction times and yields of the pyridines 81. It was observed that the cyano group of 
the regioisomers 81 is particularly sensitive and its hydrolysis appeared during acidic workup. 
Therefore water free 4M HCl/dioxane was used.  
The procedure was easily scaled up to 20 mmol and the products were isolated in good yields 
by crystallization from acetonitrile (Scheme 31: 74m, 74o, 74f, 74i, 74u, 74w; Scheme 32: 
81d, 81c, 81k). 
Scheme 33. Synthesis of 2-aryl pyridines 81 - the mechanism. 
Cl
Cl
OH
O
O
N
NC
OHO
Cl
Cl
NH2
CN
Cl
N
H
NC
OHO
Cl
60a
81c
70a
106
 
The formation of products 74 and 81 can be described as cyclocondensation reactions of the 
corresponding substrates 59 and 60 with β-aminocrotonitrile 70a. The enamine 70a is formed 
in situ by dimerization of acetonitrile catalyzed by potassium t-butoxide. Within the first hour 
60a gave the intermediate/dihydropyridine 106, which slowly aromatised to the pyridine 81c 
(Scheme 33). The aromatization proceeded even under argon atmosphere. 
 
4. 1. 2. 2 Synthesis of pyridine carboxylic acid N-oxides. 
The pyridines were readily converted to the corresponding N-oxides 93 and 98 as outlined in 
Scheme 34.64c 2-Aryl pyridines 74 reacted only at higher temperature. At 100 °C N-oxide 
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formation of 81 was observed as well as hydrolysis of the cyano group to the corresponding 
pyridine dicarboxylic acid 98. The derivatives were isolated in very good yields. 
Scheme 34. Results of the N-oxides synthesis. 
N
Ar
O
OH
NC
N
+
Ar
O
OH
NC
O
H2O2
N Ar
NC
OHO
N
+
Ar
O
OH
OHO
O
H2O2
AcOH, 80 oC, 2h
AcOH, 100 oC, 5h
81
9374
98
Ar
2-Fluoro-phenyl
4-Fluoro-phenyl
4-Chloro-phenyl
2,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
62
60
50
56
88
Ar
4-Fluoro-phenyl
4-Chloro-phenyl
2,4-Dichloro-phenyl
3,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
90
75
88
65
82
Compd
93a
93b
93c
93d
93e
Compd
98a
98b
98c
98d
98e
 
 
4. 1. 2. 3 Synthesis of pyridine carboxylic acid amides. 
Pyridine carboxylic acides 74 and 81 were amidated with amines using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as coupling reagent (Scheme 
35-36) to give 94 and 99 respectively. Both regioisomers were isolated in excellent yields. 
Scheme 35. Results of the amidation of pyridine-2-carboxylic acids to amides 94. 
 
N
Ar
O
N
NC
R
R
N
Ar
NC
O
OH
74
Amine   
PyBOP, NEt3
DCM
94
1
2
 
Compd Ar R1 R2 Yield (%) 
94a-1 2-Fluoro-phenyl H H 90 
94a-2 2-Fluoro-phenyl Me H 89 
94a-3 2-Fluoro-phenyl Cyclopropyl H 99 
94a-4 2-Fluoro-phenyl Pyrrolidin-1-yl  95 
94a-5 2-Fluoro-phenyl Morpholin-4-yl  89 
94a-6 2-Fluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl ester  90 
94b-1 4-Fluoro-phenyl Cyclopropyl H 94 
94b-2 4-Fluoro-phenyl Pyrrolidin-1-yl  99 
94c-1 2,4-Difluoro-phenyl H H 86 
94c-2 2,4-Difluoro-phenyl Me H 75 
94c-3 2,4-Difluoro-phenyl Acetic acid methyl ester H 82 
94c-4 2,4-Difluoro-phenyl Cyclopropyl H 81 
94c-5 2,4-Difluoro-phenyl Me Me 94 
94c-6 2,4-Difluoro-phenyl Pyrrolidin-1-yl  76 
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94c-7 2,4-Difluoro-phenyl Morpholin-4-yl  87 
94c-8 2,4-Difluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl ester H 76 
94c-9 2,4-Difluoro-phenyl 5-Methyl-isoxazol-3-yl H 71 
94d-1 4-Chloro-phenyl H H 73 
94d-2 4-Chloro-phenyl Me H 79 
94e-1 2,4-Dichloro-phenyl H H 80 
94e-2 
94e-3 
2,4-Dichloro-phenyl 
2,4-Dichloro-phenyl 
Me 
Acetic acid methyl ester 
H 
H 
83 
99 
94e-4 2,4-Dichloro-phenyl Acetamide H 99 
94e-5 2,4-Dichloro-phenyl Cyclopropyl H 88 
94e-6 2,4-Dichloro-phenyl Me Me 99 
94e-7 
94e-8 
2,4-Dichloro-phenyl 
2,4-Dichloro-phenyl 
Pyrrolidin-1-yl 
Morpholin-4-yl  
78 
81 
94e-9 2,4-Dichloro-phenyl 1-Piperidine-4-carboxylic acid ethyl ester  87 
94e-10 2,4-Dichloro-phenyl 5-Methyl-isoxazol-3-yl H 85 
94f 4-Bromo-phenyl H H 63 
94g-1 4-Methoxy-phenyl H H 67 
94g-2 4-Methoxy-phenyl Me H 60 
94g-3 4-Methoxy-phenyl Acetic acid methyl ester H 93 
94g-4 4-Methoxy-phenyl Cyclopropyl H 79 
94g-5 4-Methoxy-phenyl Me Me 99 
94g-6 4-Methoxy-phenyl Pyrrolidin-1-yl  99 
94g-7 4-Methoxy-phenyl Morpholin-4-yl  99 
94g-8 
 
4-Methoxy-phenyl 
 
1-Pyrrolidine-2-carboxylic acid methyl 
ester  
80 
 
94g-9 4-Methoxy-phenyl 1-Piperidine-4-carboxylic acid ethyl ester  99 
94g-10 4-Methoxy-phenyl 3-Chloro-benzyl H 99 
94g-11 4-Methoxy-phenyl 3,4-Dichloro-benzyl H 99 
94g-12 4-Methoxy-phenyl Thiophen-2-ylmethyl H 81 
94g-13 4-Methoxy-phenyl Thiazol-2-yl H 79 
94g-14 4-Methoxy-phenyl 2-Thiazol-4-yl-acetic acid ethyl ester H 69 
94g-15 4-Methoxy-phenyl 2,5-Dimethyl-2H-pyrazol-3-yl H 99 
94g-16 4-Methoxy-phenyl 5-Methyl-isoxazol-3-yl H 26 
94h Benzo[1,3]dioxol-5-yl H H 99 
94i-1 4-Trimethylamine-phenyl Cyclopropyl H 86 
94i-2 4-Trimethylamine-phenyl Pyrrolidin-1-yl  66 
94j-1 Furan-2-yl H H 99 
94j-2 Furan-2-yl Me H 99 
94j-3 Furan-2-yl Cyclopropyl H 87 
94j-4 Furan-2-yl Me Me 99 
94j-5 Furan-2-yl Pyrrolidin-1-yl  93 
94j-6 Furan-2-yl Morpholin-4-yl  99 
  
31
94j-7 Furan-2-yl Thiazol-2-yl H 99 
94k Thiophen-2-yl Pyrrolidin-1-yl  81 
94l-1 Thiophen-3-yl Cyclopropyl H 86 
94l-2 Thiophen-3-yl Pyrrolidin-1-yl  80 
94l-3 Thiophen-3-yl Morpholin-4-yl  99 
 
Scheme 36. Results of the amidation of pyridine-4-carboxylic acids 81 to amides 99. 
 
N
NC
N
H
O
Ar
R
N
NC
OHO
Ar
9981
Amine
PyBOP, NEt3
DCM
 
Compd Ar R1 R2 Yield (%) 
99a-1 4-Fluoro-phenyl Pyrrolidin-1-yl   68 
99a-2 4-Fluoro-phenyl 5-Methyl-isoxazol-3-yl H 99 
99b-1 4-Chloro-phenyl H H 99 
99b-2 4-Chloro-phenyl Acetic acid methyl ester H 80 
99b-3 4-Chloro-phenyl Cyclopropyl  95 
99b-4 4-Chloro-phenyl Me Me 80 
99b-5 4-Chloro-phenyl Pyrrolidin-1-yl  99 
99b-6 4-Chloro-phenyl Morpholin-4-yl 
 
92 
99b-7 4-Chloro-phenyl 1-Piperidine-4-carboxylic acid ethyl ester H 99 
99c 2-Fluoro-4-Chloro-phenyl Me H 85 
99d-1 2,4-Dichloro-phenyl H H 89 
99d-2 2,4-Dichloro-phenyl Pyrrolidin-1-yl  90 
99d-3 2,4-Dichloro-phenyl Morpholin-4-yl  83 
99e 3,4-Dichloro-phenyl H H 99 
99f-1 4-Methoxy-phenyl H H 99 
99f-2 4-Methoxy-phenyl Pyrrolidin-1-yl  89 
99f-3 4-Methoxy-phenyl 3,4-Dichloro-benzyl H 99 
99g Thiophen-2-yl H H 86 
 
 
4. 1. 2. 4 Synthesis of pyridine hydrazides. 
The attempts to form the hydrazide directly from acids 74 failed. Compounds 74 were not 
reactive in aqueous solution of hydrazine at 100 °C and occurred to be unstable at higher 
temperatures. The carboxylic acids 81, however, were successfully reacted with hydrazine to 
give the hydrazides 100 in excellent yield (Scheme 37).66 
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Scheme 37. Synthesis of pyridine hydrazides 100. 
N Ar
NC
OHO
N Ar
NC
N
H
O NH2
81
H2O, 150 oC, 24 h
NH2NH2
100
            Ar
4-Chloro-phenyl
3,4-Dichloro-phenyl
Yield (%)
94
75 
Compd
100a
100b
 
 
4. 1. 2. 5 Synthesis of dicyanopyridines. 
The dicyanopyridines 95 and 101 were synthesized in high yields by dehydration of the 
primary amides 94 and 99 respectively with phosphorous oxychloride (Scheme 38).67 All 
products were isolated by a fast filtration on silica gel in very good yields. 
Scheme 38. Dehydration of pyridine primary amides. 
N
Ar
O
NH2
NC
N
Ar
NC
CN
N Ar
NH2O
NC
N Ar
NC
CN
94
POCl3
100 oC, 1 h
 95
            Ar
2-Fluoro-phenyl
2,4-Difluoro-phenyl
4-Chloro-phenyl
2,4-Dichloro-phenyl
4-Bromo-phenyl
Benzo[1,3]dioxol-5-yl
Yield (%)
79
70
86
99
94
99
99 101
POCl3
100 oC, 1 h
            Ar
4-Chloro-phenyl
2,4-Dichloro-phenyl
3,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
84
80
75
99
Compd
95a
95b
95c
95d
95e
95f
Compd
101a
101b
101c
101d
 
 
4. 1. 2. 6 Synthesis of nicotinic amides. 
The cyano group of 74 hydrolyzed to the amides 96 when heated in water at 100 oC for 3 
hours. The amide 94g-11 could be converted to the diamide 96e using the same conditions. 
The nicotinic amides 96 were isolated by a simple extraction and directly characterized 
(Scheme 39). Surprisingly, neither the carboxylic acids 81 nor their amides 99 hydrolyzed to 
the expected amides and started to decompose when the temperature was raised to 120 oC. 
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Scheme 39. Nicotinic amides 96 from cyanopyridines. 
N
Ar
O
N
H
NC
R N
Ar
O
N
HNH2
O
R
N
Ar
O
OH
NC
N
Ar
O
OH
NH2
O
96e94g-11
t-BuOK
H2O, 100 oC, 3 h
t-BuOK
H2O, 100 oC, 3 h
88%
            Ar
2-Fluoro-phenyl
4-Chloro-phenyl
2,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
80
65
99
91
74 96
Compd
96a
96b
96c
96d
 
 
4. 1. 2. 7 Synthesis of pyridine N-hydroxyamidines. 
In order to form N-hydroxyamidines, cyanopyridines 94 and 99 were treated with 
hydroxylamine and potassium t-butoxide in dimethyl sulfoxide at 100 °C (Scheme 40, 43).68  
Scheme 40. Synthesis of N-hydroxyamidines. 
N
Ar
O
N
H
NC
R N
Ar
O
N
HNH2
O
R
N
Ar
NC
CN N
Ar
NC
NH2
N OH N
Ar
CN
N
NH2
OH
NH2OH, t-BuOK
DMSO, 100 oC, 3 h
84% 96e94g-11
95d
NH2OH, Na2CO3
EtOH/H2O, reflux
16 h, 90%
+
107a 107b
1 : 1
 
 
The regioisomers 94 appeared to be sensitive to the conditions and hydrolysed to give the 
diamide 96e although water free conditions were used. Any other combination of bases and 
solvents did not lead to the formation of the hydoxyamidines from 94. Additionally it was 
observed, that 4-aryl pyridines 74 with free carboxy groups stayed unaffected under the 
described conditions, but their regioisomers, 2-aryl pyridines 81 with carboxy group in 
position 4 decomposed.  
  
34 
 
 
Figure 1. LC-MS data for pyridine derivative 107 (MW 321.17). 
Contrary to the amides 94, dicyanopyridine 95d reacted when refluxed with hydroxylamine 
and sodium carbonate to give a mixture of 107a and 107b. The chromatogram (210-400 nm) 
showed one main peak of 107 (Figure 1). 1H and 13C NMR analysis however indicated the 
mixture of 107a and 107b in ratio 1:1 (Figure 2, doubled signals). 
 
 
 
 
 
 
 
 
 
 
Figure 2. 13C NMR experiment for pyridine derivative 107. 
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In contrast, 2-aryl pyridine 99f-2 formed the expected product 102 within 2 hours (Scheme 
41). 
Scheme 41. Synthesis of the N-hydroxyamidine 102. 
N
NC
N
H
O
Ar
R
N
N
H
ON
NH2
OH
Ar
R
DMSO, 100 oC, 2 h
94%99f-2 102
NH2OH, t-BuOK
 
 
4. 1. 2. 8 Synthesis of pyridine tetrazoles. 
Differences in reactivity of both regioisomers were observed during tetrazole synthesis. The 
amides 94 required high temperature and long reaction times for the formation of the 
tetrazoles 97 (Scheme 42).69 
Scheme 42. Synthesis of the tetrazoles 97. 
N
Ar
O
N
NC
R
R
N
O
N
NN
N
N
H
Ar
R
RNaN3, NH4Cl
DMF, 120 oC, 24 h
1
2
1
2
94 97
             Ar
2,4-Dichloro-phenyl
4-Methoxy-phenyl
4-Methoxy-phenyl
Yield (%)
80
89
99
Compd
97a
97b
97c
R
H
H
H
R
H
3,4-Dichlorobenzyl
Methyl-thiophen-2-yl
1 2
 
Interestingly, the dicyano derivative 95d gave tetrazole 108 regioselectively within 3 hours 
when treated with sodium azide at 70 oC (Scheme 43). Reaction time elongation, increase of 
temperature and excess of reagent equivalents did not lead to the di-tetrazole. The basic 
hydrolysis of 108 yielded the tetrazole 109. All derivatives were isolated in excellent yields.  
Scheme 43. Click reaction of the dicyano derivative 95b. 
N
NC
CN
Ar
N
Ar
NC
N N
NH
N
N
Ar
N N
NH
N
O
NH2
t-BuOK
H2O, 100 oC, 3 h
99%
NaN3, NH4Cl
DMF, 70 oC, 2 h
93%
10995d 108
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Scheme 44. Click reaction of  99 and 101. 
N Ar
NC
NO
R
R
N Ar
NO
NN
N
N
H
R
R
N Ar
NC
CN
N Ar
N
NN
NH
NC
N Ar
NN
N
N
H
CN
NaN3, NH4Cl
DMF, 70 oC
NaN3, NH4Cl
DMF, 70 oC, 2 h
85%
x
or
1
2
1
2
99 110
101d
111a
111b
 
N
H
O
NH
NN
N
NC
H
H
H
24.12 162.76
102.58
116.58 128.96
115.12
157.86
111a
 
 
Figure 3. HMBC analysis of the product 111a. 
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In contrast, the regioisomers 99 did not react at 50 oC and started to decompose when the 
temperature was increased (Scheme 44). The dicyanopyridine 101d however reacted 
efficiently to form tetrazole 111 after 2 hours at 70 oC. 
HMBC (Heteronuclear Multiple Bond Coherence) method is a two-dimensional nuclear 
magnetic resonance spectroscopy, that allows the determination of carbon to hydrogen 
connectivity. By performing the HMBC NMR of the tetrazole it was possible to prove the 
structure of the formed product. The main evidence is the correlation signal between protons 
of the methyl group and carbon from the cyano substituent (Figure 3, corresponding groups 
marked in red, the correlation signals marked with red line), that should not be observed if 
111b would have been formed. And vice versa, the protons in the pyridine ring (Figure 3, 
marked in blue) do not correlate with the carbon of the cyano group, thus they are in a 
distance over more than three bonds as in 111a. 
 
4. 1. 2. 9 Synthesis of pyrrolopyridines. 
Tertiary amides 99 cyclized spontaneously in the presence of Raney Nickel and hydrazine 
hydrate, giving an easy access to the pyrrolopyridines 103 (Scheme 45).70 
Scheme 45. Synthesis of  the pyrrolopyridin-1-one 103. 
N Ar
N
H O
N
NC
Ar
NO R
R´
Raney Nickel
NH2NH2  H2O
MeOH
            Ar
4-Chloro-phenyl
2,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
80
66
69
Tertiary amide
99 103
Compd
103a
103b
103c
. 
 
The scope of the reaction was investigated on the benzyl amide 113 prepared from the acid 
112. The hydrogenation product 114 was formed slowly together with cyclization product 115 
that was isolated in 90% yield after 5 days reaction (Scheme 46). 
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Scheme 46. Results of the 2,3-dihydro-isoindol-1-one 115 synthesis. 
OH
O
CN
N
O
CN
NH
N
O
NH2
NH
O
PyBOP, NEt3
DCM, 3 h
 99%
NH2NH2  H2O
Raney Ni
THF, MeOH, 5 d
 90%
+
1 : 9112 113 114 115
.
 
 
Boc-protection71 of the amine 116 prepared from 8170 resulted in the formation of 117. When 
dioxane was used as solvent, up to 20% of cyclized 117 was observed. When 4M aqueous 
NaOH was added to the reaction mixture, the pyrrolopyridin-1-one 117 was obtained 
exclusively. 117 was deprotected quantitatively to give 103 using TFA (Scheme 47). 
Scheme 47. Alternative synthesis of the 2,3-dihydro-pyrrolo[3,4-c]pyridin-1-ones 103. 
N
NH2
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OHO
N Ar
N
O
N Ar
N
H O
N Ar
OHO
NC
Boc2O, NaOH
Dioxane/H2O
60 oC, 16 h 
Boc
25% TFA/DCM
1 h
             Ar
2,4-Dichloro-phenyl
4-Methoxy-phenyl
Yield (%)
99
95
Yield (%)
85
74
81 116 117 103
Compd
117a
117b
Compd
103b
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NiCl2, NaBH4
MeOH, 24 h
or
H2, 10% Pd/C
AcOH, 60 oC, 24 h
 
 
The compound 103b was then further modified by oxidation to give pyrrolo[3,4-c]pyridine-
1,3-dione 118 in good yield (Scheme 48).72 It is worth to note, that the applied conditions 
gave selective oxidation in the pyrrol ring, while the methyl group in α position to the 
pyridine nitrogen stayed unaffected.  
Scheme 48. Synthesis of the pyrrolo[3,4-c]pyridine-1,3-dione 118. 
N Ar
N
H O
N Ar
N
H O
O
118103a
I2, TFA, t-BuI
DMSO, 120 oC, 3h
69%
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4. 1. 3 Antifungal screening. 
The synthesized compounds were tested for antimycotic activity by the Project Partners. The 
fluorimetric HTS assay used at the University of Tübingen as well as at the Fraunhofer 
Institute was based on published procedures.73 The only difference in case of the antimycotic 
screening at the Fraunhofer Institute was usage of HeLa cells instead of CHO cells as HeLa 
cells characterize robust growth behaviour and reproducible sensitivity to the Candida 
albicans strains used. In all cases the compounds were investigated simultaneously for 
activity against pathogens and tolerability by human cells. It is critical to ensure rapid and 
complete destruction of the host cells in the presence of the fungal pathogen (pathogen 
control), but protection from it in the presence of an antifungal compound during the entire 
incubation period of 5 days (drug control). For comparison the well established potent 
antifungal amphotericin B was used (drug control). 
1 3 5 7 9
11
R1
R50%
20%
40%
60%
80%
100%
120%
Screening Results
 
Figure 4. Fluorescence read-out of a high throughput screening plate to identify tolerable and 
active molecules in compound collections. 
 
The compounds were screened at a concentration of 10 µM. No antibacterial or antiviral 
compounds have been identified. At the Fraunhofer Institute one compound 85d exhibited a 
weak antifungal activity with 51% inhibition of the yeast growth (Figure 4). All primary hits 
had to be then retested and evaluated in a dose-response assay in order to determine the IC50 
in the setting of the screening assay (determining the concentration of the compound required 
to ensure vitality of 50% of the host cells due to growth inhibition of the pathogen) and CC50 
of the compound (concentration of the compound resulting in a 50% reduction of the vitality 
of HeLa cells due to the toxicity of the compound). Hits with a high selectivity, defined as the 
N
Cl
OOH
ClN
N
H
85d
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ratio between CC50 and IC50 are then selected for further studies. The pyrazolopyridine 85d 
however appeared to be toxic to the HeLa cells. Due to the weak antimycotic activity and 
toxicity of the hit 85d it was not further investigated. 
The collection of 60 compounds was screened for activity against Candida glabrata. The 
compounds were titrated at 8 different concentrations and coincubated with the yeast cells as 
well as with the immune BMDMs cells (Figure 5 and 6).  
 
Figure 5. Preparation of the 96 well plate: A1-H1 to A10-H10 wells with tested compounds 
(0.0075-128 µM); E11-H11 cell control; A12-D12 contamination control; E12-H12 drug 
control. 
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Figure 6. Absorbance read-out of a screening plate: inhibition of Candida glabrata growth by 
the tested compounds. 
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Compound 78p (Figure 6, row E10) significantly inhibited growth of the wild type Candida 
glabrata after 24 h incubation. However, after 48 h incubation time the fungicidal effect was 
not observed, while the miconazole was still active (Figure 7). The IC50 of the active 
compounds was estimated for over 200 µM. 
 
Compound 78p (row 10)  Miconazole (row 4) 
 
Figure 7. Microtiter plate after 48 h incubation. 
The antifungal screening performed at the two independent institutions lead to two 
pyrazolopyridines 85d and 78p exhibiting antimycotic activity. The compound 85d is active 
against Candida albicans at 10 µM, but is toxic to HeLa cells. The pyrazolopyridine 78p is 
not toxic and inhibits Candida glabrata cell growth. The inhibitory effect is weak (over 200 
µM) and short lasting. 
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4. 2 Novel DPP-4 inhibitors - focused compound collection. 
4. 2. 1 Design of potential DPP-4 inhibitors. 
Human DPP-4 is a non-classical serine protease with the catalytic triad of Ser, Asp, His, found 
in the C-terminal region, in reverse order to the ones found in classical serine proteases. DPP-
4 is a membrane-associated glycoprotein of 766 amino acids consisting of a cytoplasmic tail 
(residues 1-6), a transmembrane region (residues 7-28), and an extracellular part (29-766). 
The extracellular part can be further divided into two domains: the catalytic domain (residues 
508-766) containing the catalytic triad Ser630-Asp708-His740 and the domain consisting of 
the residues 56-497 which also contributes to the inhibitor binding site. The enzyme is widely 
distributed in numerous tissues, and is expressed on epithelial and endothelial cells of tissues 
like intestine, liver, lung, kidney or placenta. DPP-4 is expressed on circulating T-
lymphocytes and has been proven to be synonymous with cell-surface antigen, CD-26. The 
enzyme also exists as a circulating form in plasma, that lacks the hydrophobic transmembrane 
domain, but has identical function as its membrane-bound form.29,45,74 
 
Figure 8. Schematic view on the subunit of DPP-4 with the active site surface colored 
according to the atom types.50a 
 
DPP-4 has many physiological substrates such as chemokines, eotaxin, macrophage-derived 
chemokine, neuropeptides or vasoactive peptides. It is specific to peptides with an amino-
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terminal proline or alanine at position 2 but might cleave substrates with non-preferred amino 
acids at position 2 as well. By cleaving dipeptides Xaa-Pro- or Xaa-Ala- from the N-terminus 
of biologically active peptides, DPP-4 transforms them into an inactive (as in the case of 
incretins) or even antagonistic form.29,74  
DPP-4 is enzymatically active as a homodimer. Since the crystal structure of the enzyme 
(Figure 8), first reported in 2003, a number of X-ray informations for protein-ligand 
complexes were published.50a,74d The catalytic site lies in a large cavity between two 
extracellular domains and can be accessed by two active site openings. The substrate diprotin 
A (IPI) (Figure 8, marked in white) indicates the binding site. The substrate may enter the 
active site at the well accessible and open active site cleft, the dipeptidic product of the 
catalytic reaction may leave the active site cavity via the narrower tunnel that is formed by the 
β-propeller (Figure 8, green arrows).74d  
The molecular recognition of the ligands involves a serine nucleophile within the catalytic 
triad Ser-Asp-His. In several early inhibitors, X-ray structures confirmed that the nitrile 
carbon is in covalent bond distance from the oxygen atom of catalytic serine side chain. 
Several studies confirmed that presence of the nitrile group increases inhibitor activity, even 
up to 1000-fold (Figure 9, marked in green).45a 
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Figure 9. Examples of known DPP-4 inhibitors and their main interaction elements: the 
location of the S1 pocket marked by a curved blue line, the elements interacting with the Glu 
205-206 indicated by a red rectangle, the motif forming a covalent bond to Ser 630 underlined 
in green. 
 
Filling of the S1 pocket is one of the most important interactions. The specificity pocket S1 is 
composed of the side chains of Tyr 631, Val 656, Trp 659, Tyr 666, Val 711. The rigidity of 
this pocket appears to be highly specific to the proline residues, but the asymmetry in the 
pocket allows a possibility of mimicking this part by introducing small substituents such as 
fluorine atoms on the aromatic ring of the inhibitors (Figure 9, marked in blue). 
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Polar side chains of Arg 125 and Asn 710 interact via formation of hydrogen bonds with the 
amido-groups of the inhibitors. The favorable electrostatic interaction of the carbonyl dipole 
with the protein environment was additionally confirmed by SAR studies. 
Besides of the S1 pocket, the second most important point for the high ligand affinity is 
hydrogen bonding ineractions with the side chains of the 205 and 206 glutamate residues. 
Most of the DPP-IV inhibitors discovered so far contain primary or secondary amine group 
that form hydrogen bonds with Glu 205, Glu 206 and, in case of the terminal amine, 
additional interactions via hydrogen bonding with Tyr 662 was observed (Figure 9, marked in 
red). 
Further affinity gains might be achieved by exploring the phenyl rings of Phe 357 and Tyr 547 
are exposed to the ligand binding site. One of the energically favorable arrangements are 
aromatic edge-to-face interactions as indicated for 119 (Figure 9).45,50,74c 
These information about DPP-4 molecular recognition could be graphically summarized as 
presented in the Figure 10. 
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Figure 10. Important interaction elements: the location of the S1 pocket marked by a curved 
blue line, the elements interacting with the Glu 205-206 indicated in red, the motif forming a 
covalent bond to Ser 630 in green, group interacting with Arg 125 and Asn 710 marked in 
magenta. 
 
According to the mentioned information, the biaryl sceleton of the pyridines 74 and 81 
appeared to be a good starting point for the inhibitor design. Incorporating other important 
elements for high affinity binding, the three regioisomers: 5-aminomethyl-6-methyl-4-aryl-
pyridine-2-carboxylic acid amide 120, 6-aminomethyl-2-methyl-4-aryl-nicotinamide 121, 3-
aminomethyl-2-methyl-6-aryl-isonicotinamide 122, were designed (Scheme 49).  
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Scheme 49. General structures of the target molecules. The colors correspond to the 
interaction elements presented in the Figure 10. 
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The calculated logP values for the series 120-122 were in the 2-3 range (OSIRIS Property 
Explorer, Software provided by Actelion Pharmaceuticals Ltd.) and, together with the 
structural elements and molecular weight (250-400 daltons) of the chosen analogs 120-122, 
are in accordance with Lipinski’s rule of five.4  
 
4. 2. 2 Synthesis of potential DPP-4 inhibitors. 
4. 2. 2. 1 Synthesis of 5-aminomethyl-6-methyl-4-aryl-pyridine-2-carboxylic acid amides. 
Two approaches to target the aminomethyl-pyridines 120 are outlined in Scheme 50. In both 
the critical modification was the generation the aminomethyl group from the cyano group of 
74 or 94.75 Although the route A requires more steps, it limits the number of hydrogenations to 
one for each series with different aromatic substituent.  
Scheme 50. Synthetic approaches to the target molecule 120. 
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Table 3. Yields of the synthesis of pyridines 120.  
Compd Ar R1 R2 Yield (%) 
Route A   
123a 4-Fluoro-phenyl     52 
123b 2,4-Difluoro-phenyl   68 
123c 4-Methoxy-phenyl   72 
124a 4-Fluoro-phenyl   68 
124b 2,4-Difluoro-phenyl   62 
124c 4-Methoxy-phenyl   79 
125a-1 4-Fluoro-phenyl Cyclopropyl H 57 
125a-2 4-Fluoro-phenyl Pyrrolidin-1-yl 92 
125a-3 4-Fluoro-phenyl Morpholin-4-yl  84 
125a-4 4-Fluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester  
92 
125b-1 2,4-Difluoro-phenyl Cyclopropyl H 46 
125b-2 2,4-Difluoro-phenyl Acetic acid methyl ester  67 
125b-3 2,4-Difluoro-phenyl Pyrrolidin-1-yl  92 
125b-4 2,4-Difluoro-phenyl Morpholin-4-yl  91 
125b-5 2,4-Difluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester  
76 
125b-6 2,4-Difluoro-phenyl 5-Methyl-isoxazol-3-yl H 58 
125b-7 2,4-Difluoro-phenyl ((R)-3-Boc-amino-pyrrolidin-1-yl)-
methanone  
92 
125c-1 4-Methoxy-phenyl Cyclopropyl 74 
125c-2 4-Methoxy-phenyl Pyrrolidin-1-yl H 72 
125c-3 4-Methoxy-phenyl Morpholin-4-yl  92 
125c-4 4-Methoxy-phenyl 3,4-Dichloro-benzyl H 88 
125c-5 4-Methoxy-phenyl 2,5-Dimethyl-2H-pyrazol-3-yl H 62 
125c-6 4-Methoxy-phenyl 5-Methyl-isoxazol-3-yl H 57 
125c-7 4-Methoxy-phenyl ((R)-3-Boc-amino-pyrrolidin-1-yl)-
methanone  
89 
125c-8 
 
125c-9 
4-Methoxy-phenyl 
 
4-Methoxy-phenyl 
(4-Boc-amino-piperidin-1-yl)-
methanone 
2-(4-Boc-piperazin-1-yl)-ethyl H 
53 
 
92 
120a-1 4-Fluoro-phenyl Cyclopropyl H 99 
120a-2 4-Fluoro-phenyl Pyrrolidin-1-yl 95 
120a-3 4-Fluoro-phenyl Morpholin-4-yl  89 
120a-4 4-Fluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester  
99 
120b-1 2,4-Difluoro-phenyl Cyclopropyl H 86 
120b-2 2,4-Difluoro-phenyl Acetic acid methyl ester H 99 
120b-3 2,4-Difluoro-phenyl Pyrrolidin-1-yl H 95 
120b-4 2,4-Difluoro-phenyl Morpholin-4-yl H 91 
  
47
120b-5 2,4-Difluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester 
H 89 
120b-6 2,4-Difluoro-phenyl 5-Methyl-isoxazol-3-yl  98 
120b-7 2,4-Difluoro-phenyl ((R)-3-amino-pyrrolidin-1-yl)-
methanone  
92 
120c-1 4-Methoxy-phenyl Cyclopropyl 87 
120c-2 4-Methoxy-phenyl Pyrrolidin-1-yl 
H 
 78 
120c-3 4-Methoxy-phenyl Morpholin-4-yl  99 
120c-4 4-Methoxy-phenyl 3,4-Dichloro-benzyl H 99 
120c-5 4-Methoxy-phenyl 2,5-Dimethyl-2H-pyrazol-3-yl H 68 
120c-6 4-Methoxy-phenyl 5-Methyl-isoxazol-3-yl H 87 
120c-7 4-Methoxy-phenyl ((R)-3-Amino-pyrrolidin-1-yl)-
methanone  
82 
120c-8 4-Methoxy-phenyl (4-Amino-piperidin-1-yl)-methanone  79 
120c-9 4-Methoxy-phenyl 2-Piperazin-1-yl-ethyl H 88 
 
Route B     
120d-1 2-Fluoro-phenyl H H 64 
120d-2 2-Fluoro-phenyl Me H 70 
120d-3 2-Fluoro-phenyl Cyclopropyl H 53 
120d-4 2-Fluoro-phenyl Pyrrolidin-1-yl  48 
120d-5 2-Fluoro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester  
25 
120e 4-Chloro-phenyl Me H 38 
120f-1 2,4-Dichloro-phenyl H H 45 
120f-2 2,4-Dichloro-phenyl Me H 51 
120f-3 2,4-Dichloro-phenyl Cyclopropyl H 34 
120f-4 2,4-Dichloro-phenyl Pyrrolidin-1-yl 48 
120f-5 2,4-Dichloro-phenyl Morpholin-4-yl  44 
120f-6 2,4-Dichloro-phenyl 1-Piperidine-4-carboxylic acid ethyl 
ester   
15 
 
Various conditions were investigated for the conversion of the cyano group to the amines. 
Lithium aluminium hydride caused partial -CN hydrogenation and conversion of amide 
carbonyl of 94 to the corresponding alcohol. When 74 was used in the reaction, only reduction 
of the carboxy group occurred. Sodium borohydride with nickel chloride70b partially reduced 
the carbonyl group in the amides 94, and acids 74 gave only a minor amount of the desired 
products. Transfer hydrogenation using palladium on charcoal and formic acid that is known 
for O-benzyl group deprotection76a was also tested. Pyridines 74 without halogens in the 
aromatic ring gave 50% conversion after 2 hours. The reaction time elongation resulted in a 
reverse reaction. The hydrogenation with palladium on charcoal and gaseous hydrogen70a was 
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found to be most convenient, however in case of 74f deactivated by chlorines the method 
failed.  
The further modifications, Boc protection leading to 124, amidation of the protected 
aminomethyl-pyridine 124 that gives 125 and removal of the protecting group to afford 120 
were in most of the cases high yielding and the products relatively easy to purify (Table 3). 
The catalytic hydrogenation with Raney Nickel (Scheme 50, route B)70 was not compatible 
with the amides 94 with several substituents such as 5-methyl-isoxazol-3-yl or 2,5-dimethyl-
2H-pyrazol-3-yl (Scheme 35, entries 94c-9, 94e-10, 94g-15, 94g-16) or with the substrates 
containing ester group (Scheme 35, entries 94a-6, 94c-3) as its hydrolysis was observed. In 
addition, in many cases the conversion was not complete, and/or byproducts were formed 
which were difficult to remove and caused often low yields (Table 3, entries 120d-5, 120e, 
120f-3, 120f-6).  
Synthesis of the aminomethyl-pyridine 120h required a modified approach. The amide 94e-4 
was reduced to give the amine 120g. The primary amide of 120g was then dehydrated to give 
desired product 120h in good yield (Scheme 51).  
Scheme 51. Synthesis of the pyridine 120h. 
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4. 2. 2. 2 Synthesis of 6-aminomethyl-2-methyl-4-aryl-nicotinamides. 
The synthesis of the aminomethyl-pyridines 121 was initiated by the conversion of the 
carboxylic acids 96 to the alcohols 126,76b which were then reacted with thionyl chloride to 
form the corresponding chlorides 127 (Scheme 52). Displacement of the chloride by the 
phthalimide led to 128. Basic hydrolysis of 128 afforded 121 in good to very good yields 
(Table 4).  
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Scheme 52. Synthesis of the target molecule 121. 
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Table 4. Results of the 121 synthesis. 
Compd Ar Yield (%) 
126a 2-Fluoro-phenyl 61 
126b 4-Chloro-phenyl 71 
126c 2,4-Dichloro-phenyl 77 
126d 4-Methoxy-phenyl 99 
127a 2-Fluoro-phenyl 85 
127b 4-Chloro-phenyl 76 
127c 2,4-Dichloro-phenyl 75 
127d 4-Methoxy-phenyl 79 
128a 2-Fluoro-phenyl 65 
128b 4-Chloro-phenyl 82 
128c 2,4-Dichloro-phenyl 80 
128d 4-Methoxy-phenyl 90 
121a 2-Fluoro-phenyl 91 
121b 4-Chloro-phenyl 89 
121c 
121d 
2,4-Dichloro-phenyl 
4-Methoxy-phenyl 
84 
79 
 
 
4. 2. 2. 3 Synthesis of 3-aminomethyl-2-methyl-6-aryl-isonicotinamides. 
3-Aminomethyl-2-methyl-6-aryl-isonicotinamides 122 were synthesized using two alternative 
approaches as for the aminomethyl-pyridine 120 (Scheme 53).  
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Scheme 53. Synthetic approaches to the target molecule 122. 
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Table 5. Yields of the synthesis of pyridines 122. 
Compd Ar R1 R2 Yield (%) 
Route A     
129a 2,4-Dichloro-phenyl   43 
129b 4-Methoxy-phenyl   38 
130a-1 2,4-Dichloro-phenyl Cyclopropyl H 63 
130a-2 2,4-Dichloro-phenyl Pyrrolidin-1-yl  54 
130a-3 2,4-Dichloro-phenyl Morpholin-4-yl  80 
130b-1 4-Methoxy-phenyl Cyclopropyl H 76 
130b-2 4-Methoxy-phenyl Pyrrolidin-1-yl  86 
130b-3 4-Methoxy-phenyl Morpholin-4-yl  92 
122a-1 2,4-Dichloro-phenyl Cyclopropyl H 65 
122a-2 2,4-Dichloro-phenyl Pyrrolidin-1-yl  57 
122a-3 2,4-Dichloro-phenyl Morpholin-4-yl  63 
122b-1 4-Methoxy-phenyl Cyclopropyl H 75 
122b-2 4-Methoxy-phenyl Pyrrolidin-1-yl  83 
122b-3 4-Methoxy-phenyl Morpholin-4-yl  70 
Route B  
122c 4-Fluoro-phenyl Pyrrolidin-1-yl  46 
122d-1 4-Chloro-phenyl Pyrrolidin-1-yl  53 
122d-2 4-Chloro-phenyl Morpholin-4-yl  48 
122d-3 4-Chloro-phenyl 
1-Piperidine-4-carboxylic acid 
ethyl ester 52 
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The hydrogenation of the cyano group of 81 afforded the formation of the corresponding 
amines 116 that were directly Boc protected to give 129. The reaction was performed in 
dioxane without addition of water to avoid the formation of cyclized products 117. 
Compounds 129 were isolated in moderate yields (Table 5) and then amidated to give 130 and 
122 after deprotection. For the catalytic hydrogenation (Scheme 53, route B), the use of 
hydrazine hydrate as a hydrogen source was more efficient than the conditions applied for the 
synthesis of 120. The protocol required acidification of the reaction mixture with TFA in 
order to minimize the formation of the pyrrolopyridines 103. It is important to mention that 
the aminomethyl-pyridines 122 had to be stored as hydrochlorides or trifluoroacetate salts to 
avoid their spontaneous cyclization reaction to form 103. In addition, the method was limited 
only to the tertiary amides (Table 4, 122c, 122d). 
 
4. 2. 3 Biological screening and structure activity relationship. 
The synthesized amines 120-122 and intermediates were evaluated for inhibition of human 
DPP-4 in an in vitro assay. The initial SAR breakthrough was the discovery that the 
aminomethyl-pyridines 120 exhibit high inhibitory activity (Figure 11, position 3-6, 8) 
contrary to the analogs 121 (Figure 11, position 2, 9) and 122 (Figure 11, position 11-13). 
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Figure 11.  Screening results for the inhibition of DPP-4 by aminomethyl-pyridine 
regioisomers 120-122 ( percent inhibition: mean ± standard deviation; N = 3). 
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The substituent pattern appeared to be crucial for the compound activity. The pyridine 120d-1 
with an amine group in the β position to the nitrogen of the pyridine showed an activity with a 
IC50 value under 50 µM, compare to the regioisomer 121a bearing an amine group in the α 
position had a IC50 value over 50 µM (Scheme 54).   
Scheme 54. Differences in DPP-4 inhibition by the regioisomers 120 and 121. 
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Similarly the distance between the amine group and the amide functionality was proven to be 
of great importance. The change of the amide group position from α (as in aminomethyl-
pyridines 120) to β (in pyridines 122) results in a loss of the inhibitory activity (Scheme 55).  
Scheme 55. Differences in DPP-4 inhibition by 120 and 122. 
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A series of aminomethyl-pyridines 120 has been prepared in order to further optimize its 
structure. As expected the intermediates 94 without an amine moiety were not active. 
Interestingly the free carboxylic acids 123 remain inhibitory activity (IC50 < 50 µM).  
Scheme 56. Influence of the aromatic ring substitution on the DPP-4 inhibitory activity.  
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The comparison of the analogs substitution in regard to the phenyl ring in the bicyclic system 
of 120 indicated the importance of the chlorine atom: 120f-4 was more potent (IC50 = 0.050 
µM) compared to 120c-1 and 120b-3 (Scheme 56). 
Representative analogs that possessed superior potency profiles were then investigated for the 
effectiveness in inhibiting DPP-4 in dose dependent experiments (Scheme 57).  
Scheme 57. Influence of the aromatic ring substitution on the DPP-4 inhibitory activity.  
N NH2
Cl
Cl
NH2
O
N N
H
Cl
Cl
NH2
O
N N
H
Cl
Cl
NH2
CN
O
N N
Cl
Cl
NH2
O120f-1 120f-2 120h 120f-4
     IC50 = 16 ± 2 nM                      IC50 = 11 ± 0.5 nM                  IC50 = 10 ± 0.7 nM                          IC50 = 44 ± 5 nM
 
The substitution of the primary amide 120f-1 with the methyl group as in 120f-2 gratified in a 
significant improvement in potency. The analog 120h possessed similar IC50 value compared 
to 120f-2. The increase of the size of the amide group in 120f-4 suffered in its potency and the 
IC50 value dropped down to 44 nM. 
Lineweaver-Burk plot
0
20
40
60
80
100
120
140
160
-0,05 0 0,05 0,1
1/S (1/µM)
1/
v
 
(m
in
/n
m
o
l)
Inhibitor 0 nM
Inhibitor 10 nM
Inhibitor 50 nM
 
Figure 12. Lineweaver-Burk plot for 120f-2 indicating competitive inhibition. 
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One of the most potent analogs, 120f-2 was then chosen to investigate the type of the 
inhibition. Measurement of the inhibitory activity at various inhibitor and substrate 
concentrations allowed data plotting (Figure 12).77 A Lineweaver-Burk plot indicated a 
competitive type of inhibition. This is a typical observation for compounds that bind in the 
same site of the enzyme as the substrate. 
The inhibitory concentration dependent experiment showed clearly that the system is 
characterized by a define degree of inhibition, depending on the inhibitor concentration, 
which is reached within the first 20 minutes and thereafter is independent on time (Figure 13). 
This kind of inhibition is characteristic for reversible inhibitors. 
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Figure 13. Inhibition of DPP-4 by 120f-2. 
The effectiveness of the reversible inhibitors is expressed by the Ki constant that describes 
enzyme-inhibitor affinity. For the Ki of the 120f-2 calculation the data obtained from 
Lineweaver-Burk plot were as follows: 
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wherein Km is the concentration of the substrate that leads to half-maximal velocity (Vm), and 
Kp is the effective Michaelis constant in presence of the inhibitor at concentration i. 
In addition the Ki was calculated from the previous experiments using the equation: 

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IC50 = 11.44 nM 
K
 i = 4.90 ± 0.5 nM 
Where: S - substrate concentration. 
The obtained values remain in good coherence. 
The series of active DPP-4 inhibitors was also tested against DASH family member, DPP-8. 
Selectivity over DPP-8  is of particular concern as inhibition of this enzyme is associated with 
toxicity in preclinical species and the relevance of these toxic effects to humans is not yet 
known.50,74 Selectivity of the early DPP-4 inhibitors was not previously investigated at the 
beginning of DPP-4 research, as the related enzymes FAP, DPP-8 and DPP-9 were not yet 
discovered.50The most active inhibitors were investigated for the DPP-4 selectivity over DPP-
8 in dose dependent experiments. All of the tested compounds showed high selectivity: 2500-
6600 fold compared to DPP-4 (Scheme 58). The secondary amide 120f-2 was slightly more 
selective in comparison to the primary amide 120f-1. The aminomethyl-pyridine 120h was 
almost 2 fold less potent against DPP-8 than the 120f-2. The derivative 120f-4 with a bulkier 
pyrrolidine ring is less preferable due to its lower potency and selectivity. 
Scheme 58. Selectivity of the novel DPP-4 inhibitors. 
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The results from biological screening in comparison to the values from literature of the known 
inhibitors50a are summarized in Table 6. 
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The compounds 120 are highly potent DPP-4 inhibitors with IC50 values in nanomolar range. 
The IC50 levels of novel inhibitors are comparable to the values of drugs (Table 6, 
Vildagliptin, Sitagliptin). In addition the series 120 shows 6600 fold selectivity to DPP-4 over 
DPP-8. 
Table 6. Selectivity of the novel DPP-4 inhibitors 120 over DPP-8 in comparison to 
Vildagliptin and Sitagliptin. 
 
IC50 (Ki)   [µM] Compd DPP-4 DPP-8 
120f-1 0.016 33 
120f-2 0.011 (0.006) 39 
120h 0.010 66 
120f-4 0.044 25 
120a-1 0.080 106 
120a-2 0.686 137 
120b-1 0.937 182 
120b-6 0.674 179 
Vildagliptin50b 0.12 9 
Sitagliptin50b 0.04 > 50 
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5. Summary.  
In this work dedicated to the discovery of novel biologically active compounds, antifungals 
and antidiabetics, the focus was placed on the pyridine motif. The substituted pyridines and 
pyrazolopyridines were chosen as a promising scaffold in a search for novel therapeutics.  
The overview of the pyridine-based antifungals and antidiabetics was reported in the part 
Pyridines as scaffolds for antifungals and antidiabetics. 
Solution and solid phase combinatorial chemistry methods were used to approach target 
compounds. Efficient protocols were evaluated for the synthesis of pyridines and 
pyrazolopyridines applying solid supported 2-oxo-4-aryl-but-3-enoic acids and 4-oxo-4-aryl-
but-2-enoic acids. In addition, the synthetic possibilities of the resin-bound intermediates 
were investigated and resulted in a collection of easily accessible pyrimidines and 
dihydropyrimidines (Chapter 4. 1. 1). 
The solid phase protocol was adapted to the solution phase. A series of pyridines was 
synthesized in gram scale as starting materials for the generation of sub-sets of compounds 
varying only on the pyridine ring substitution. Differences in the reactivity of 2-aryl pyridines 
and 4-aryl pyridines were observed and investigated. Depending on the ring substitution 
pattern, deactivation or activation of certain positions resulted in reactivity limitations, but on 
the other hand, gave a possibility of additional structural variations (Chapter 4. 1. 2).  
Based on the data available for the enzyme DPP-4 in the literature, a series of potential DPP-4 
inhibitors (aminomethyl-pyridines: 5-aminomethyl-6-methyl-4-aryl-pyridine-2-carboxylic 
acid amides, 6-aminomethyl-2-methyl-4-aryl-nicotinamides and 3-aminomethyl-2-methyl-6-
aryl-isonicotinamides) were designed and synthesized. Several synthetic pathways using  
2-aryl pyridines and 4-aryl pyridines as starting materials were evaluated in order to obtain 
analogs.  
All compounds were isolated and analyzed by HPLC-ESI-MS. Representative products were 
characterized using NMR and IR spectroscopy and FT-ICR-MS. For structure confirmation 
additional 2-D NMR experiments were used (COSY and HMBC NMR).  
The synthesized compound collection was evaluated for its antifungal properties in an in vitro 
screening. As a result, two hit structures 6-(2,4-dichloro-phenyl)-3-methyl-1H-pyrazolo[3,4-
b]pyridine-4-carboxylic acid (Candida albicans) and 4-(5-chloro-thiophen-2-yl)-1,3-
dimethyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid (Candida glabrata) were identified. 
The compound 6-(2,4-dichloro-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic 
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acid was disqualified as a lead structure due to its toxic effect on the host cells. Inhibitory 
effect of 4-(5-chloro-thiophen-2-yl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic 
acid on Candida glabrata cells was too weak to consider the compound as a lead structure 
(Chapter 4.1.3). 
The collection of aminomethyl-pyridines was investigated for its DPP-4 inhibitory activity in 
an in vitro assay. The lead structure of 5-aminomethyl-6-methyl-4-aryl-pyridine-2-carboxylic 
acid amides was found and structure activity relationship led to a potent series of the novel 
DPP-4 inhibitors. Furthermore, in vitro experiments proved excellent selectivity (up to 6600 
fold for 5-aminomethyl-4-(2,4-dichloro-phenyl)-6-methyl-pyridine-2-carboxylic acid 
cyanomethyl-amide) of the inhibitors over closely related DPP-8 (Chapter 4. 2. 3). The results 
were described and patented. 
This study clearly confirms the potential of the investigated scaffolds. As the biological 
activity of substituted pyridines highly depends on its substitution pattern. The synthesized 
and described herein compounds should be extensively investigated for other pharmaceutical 
targets. 
Although preliminary biological data of the novel DPP-4 inhibitors are doubtlessly promising, 
the crucial point for their further development is the pharmacological profile of  
5-aminomethyl-6-methyl-4-aryl-pyridine-2-carboxylic acid amides. Therefore additional 
biological experiments are required to further optimize the structure and to identify a clinical 
candidate. 
Apart from the glucose metabolism, a number of different biological functions of DPP-4 have 
been recognized recently. The discoveries attract a great attention to the DPP-4 inhibitors, as 
such compounds could be useful for the treatment of other metabolic, but also autoimmune 
and inflammatory diseases.74b It is therefore important to further study of the described series 
in order to fully explore therapeutic potential of the DPP-4 enzyme. 
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6. Experimental part. 
6. 1 Syntheses. 
6. 1. 1 General. 
Starting materials (E)-2-oxo-4-aryl-but-3-enoic acids 59 and (E)-4-oxo-4-aryl-but-2-enoic 60 
acids were synthesized according to the literature procedures58-59 or were obtained 
commercially and used as received. Other chemicals were used as purchased from 
commercial suppliers. Analytical TLC were performed with ALUGRAM silica gel 60 F254 
plate. Flash chromatographies were performed on Combi Flash 5q 16x with a UV-detector. 
Column chromatographies were carried out using MN silica gel 60 (70-230 mesh ASTM). 
The mass spectra were measured on a Waters LC/MS system (Alliance 2795 HPLC, 
SQD mass detector, PDA 996 detector; Grom-Sil 80 ODS-7 PH 4 µm, 2.0 x 40 mm; ionizing 
voltage 10 eV). Ion mass (m/z) signals are reported as values in atomic mass units. For FT-
ICR-MS measurements the APEX II Bruker Daltonics (4.7 Tesla) spectrometer was used. 1H, 
13C, COSY and HMBC NMR analyses were performed on a Bruker 400 Ultra Shield 
instrument. NMR spectra were performed as DMSO-D6 or CDCl3 solutions (reported in ppm), 
using solvent peak or TMS as the reference. Other NMR solvents were used as needed. When 
peak multiplets are given, the following abbreviations are used: s = singlet, d = doublet, t = 
triplet, m = multiplet, bs = broad singlet, dd = doublet of doublets, dt = doublet of triplets. 
Coupling constants, when given, are reported in Hz. Melting points were measured on Büchi 
Melting Point B-540. IR spectra were Prepared on Bruker - Vector 22. 
 
6. 1. 2 Synthesis protocols. 
6. 1. 2. 1 Synthesis of (E)-2-oxo-4-aryl-but-3-enoic acids 59 - general procedure. 
A solution of KOH (1.5 eq, 45 mmol, 2.52 g) in MeOH (7.5 mL) was added dropwise to a 
solution of pyruvic acid (1 eq, 30 mmol, 2.09 mL) and benzaldehyde (1 eq, 30 mmol) in 
MeOH (15 mL) at 0 °C. The reaction temperature was kept for 1 h at 25 °C and at 0 °C for 16 
h. The yellow solid was filtered off and washed twice with cold MeOH and once with Et2O. 
The crude residue was taken up in water, acidified with 1M HCl and extracted with DCM. 
The combined organic phases were dried over anhydrous Na2SO4 and concentrated to afford 
the product as a solid that was used without further purification. 
 
6. 1. 2. 2 Synthesis of (E)-4-oxo-4-aryl-but-2-enoic acids 60 - general procedure. 
Glyoxylic acid monohydrate (1 eq, 40 mmol, 3.68 g) was added to a solution of acetophenone 
(1 eq, 40 mmol) in acetic acid (50 mL) and concentrated HCl (5 mL). The mixture was 
refluxed for 16 h. After evaporation of the solvent, the residue was taken up in EA, filtered 
and air dried to afford the desired product as a yellow solid that was used in the next step 
without further purification. 
 
6. 1. 2. 3 Synthesis of pyridines 74, 72, 81 and pyrazolopyridines 78, 83, 85 - general 
procedures. 
Method A 
A1. Loading of the Wang resin 
Wang resin (1 eq, 0.5 mmol) in 5 mL PP syringe was first preswollen in DCM for 0.5 h, then 
(E)-2-oxo-4-aryl-but-3-enoic acids 59 or (E)-4-oxo-4-aryl-but-2-enoic acids 60 (2 eq, 1 
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mmol) and DMAP (0.3 eq, 0.15 mmol, 0.018 g) were introduced. DCM (5 mL) and DIC (3 
eq, 1.5 mmol, 0.235 mL) were added and the syringe was shaken for 16 h at rt. The resin was 
filtered and washed with DMF (3x), MeOH (3x), THF (3x), DCM (3x) and finally with dry 
DMF. 
A2. Capping 
The capping of non-loaded hydroxyl functions was performed in dry DMF with DIPEA (10 
eq, 5 mmol, 0.871 mL) and acetic anhydride (10 eq, 5 mmol, 0.472 mL) for 30 min at rt. The 
resin was washed with DMF (3x), MeOH (3x), THF (3x), DCM (3x) and dried. 0.050 g of the 
resin was cleaved to determine the loading. 
A3. Cyclization 
The amine (3eq) and DMF (2mL) were added to resin-bounded keto acids 63 or 67 (0.25 
mmol) in a PP syringe. The suspension was stirred for 16 h at 100 oC. The resin was washed 
with DMF and DCM and dried in vacuo.  
A4. Oxidation 
DDQ (2 eq, 0.5 mmol, 0.114 g) and THF (2 mL) were added to the resin-bound non-
aromatized heterocycle (1 eq, 0.25 mmol) in a 5 mL PP syringe. The suspension was shaken 
for 16 h at rt, then washed with DMF (3x), MeOH (3x), THF (3x), DCM (3x), Et2O (3x) and 
dried in vacuo. 
A5. Cleavage 
To the resin-bound heterocycle (0.1 mmol) was added 20% TFA/DCM (5 mL) and the 
syringe was shaken one hour at rt. The resin was removed by filtration and washed with DCM 
(3x). The solvent was removed in vacuum. The crude product, if required, washed with 
MeCN or Et2O. 
Method B 
Solution phase synthesis of 4-aryl pyridines 74 - general procedure: Potassium  
t-butoxide (3 eq, 3  mmol, 0.337 g) was added portionwise to a solution of (E)-2-oxo-4-(aryl)-
but-3-enoic acid 59 (1 eq, 1 mmol) in MeCN (5 mL) at room temperature. After 16 h (the 
reaction monitored by LC/MS), the solvent was removed under reduced pressure. The crude 
product was taken up in water, acidified with 1M HCl and extracted with DCM. The 
combined organic phases were dried over anhydrous Na2SO4 and concentrated. The solid 
product 3 was isolated by column chromatography with silica gel using a gradient of PE/EA 
(from 4:1 to 1:1). 
Method C 
Solution phase synthesis of 2-aryl pyridines  81 - general procedure: t-BuOK (2 eq, 
2 mmol, 0.224 g) was added portionwise to a solution of (E)-4-oxo-4-(aryl)-but-2-enoic acid 
60 (1 eq, 1 mmol) in MeCN (5 mL) at room temperature. After 16 h (reaction monitored by 
LC/MS) the solvent was removed under reduced pressure. The mixture was suspended in 
dioxane and acidified with water free 4M HCl in dioxane. After evaporation of the solvent, 
the residue was taken up in water and extracted with DCM. The combined organic phases 
were dried over anhydrous Na2SO4 and concentrated. The solid product 81 was isolated by 
flash chromatography using DCM/MeOH gradient (from 99:1 to 95:5). 
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72a; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 68% yield, 93% purity (HPLC-ESI-MS, 210-400 nm), 
C15H14ClNO3, M = 291.74 g/mol, HPLC-ESI-MS: [M + H]+ = 292 m/z. 
N
H O
OH
Br
O
72b
 
72b; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 68% yield, 89% purity (HPLC-ESI-MS, 210-400 nm), 
C15H14BrNO3, M = 336.19 g/mol, HPLC-ESI-MS: [M + H]+ = 336 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 1.97 (s, 3 H), 2.35 (s, 3 H), 4.67 (d, J =  6.10 Hz, 1 H), 5.93 (d, J =  6.10 Hz, 1 
H), 7.13 (m, 2 H), 7.48 (m, 2 H), 8.27 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 19.9 
(CH3), 30.0 (CH3), 39.75 (CH), 105.2 (C), 114.8 (CH), 119.4 (C), 126.9 (C), 129.3 (CH), 
131.5 (CH), 146.5 (C), 148.6 (C), 163.5 (C), 195.8 (C). 
N
O
OH
Cl
O
74a
 
74a; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 72% yield, 86% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12ClNO3, M = 289.72 g/mol, HPLC-ESI-MS: [M + H]+ = 290 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.12 (s, 3 H), 2.51 (s, 3 H), 7.42 (m, 2 H), 7.60 (m, 2 H), 7.87 (s, 1 H). 13C 
NMR (100 MHz, DMSO-D6) δ 22.4 (CH3), 31.8 (CH3), 122.6 (CH), 129.2 (CH), 130.2 (CH), 
134.4 (C), 135.6 (C), 137.9 (C), 145.3 (C), 148.0 (C), 153.7 (C), 165.5 (C), 205.2 (C). 
N
O
OH
Cl
O Cl
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74b; Prepared according to the method A (steps A1 - A3, A5)  using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 85% yield, 87% purity (HPLC-ESI-MS, 210-400 nm), 
C15H11Cl2NO3, M = 324.17 g/mol, HPLC-ESI-MS: [M + H]+ = 324 m/z. 
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74c; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; yellow solid; 93% yield, 80% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12BrNO3, M = 334.17 g/mol, HPLC-ESI-MS: [M + H]+ = 334 m/z. 
N
O
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O
S
Cl
74d
 
74d; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 99% yield, 94% purity (HPLC-ESI-MS, 210-400 nm), 
C13H10ClNO3S, M = 295.75 g/mol, HPLC-ESI-MS: [M + H]+ = 296 m/z. 
N
O
OH
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74e; Prepared according to the method A (steps A1 - A3, A5; 74% yield, 80% purity, HPLC-
ESI-MS, 210-400 nm) using 3-amino-but-2-enenitrile as the amine in the step A3 and method 
B (60% yield); colorless solid; C14H9ClN2O2, M = 272.69 g/mol, HPLC-ESI-MS: [M + H]+ = 
273 m/z; m.p. 206 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.80 (s, 3 H), 7.64 (m, 3 H), 7.79 
(m, 1 H), 7.98 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 (CH3), 109.8 (C), 116.3 (C), 
121.9 (CH), 127.4 (CH), 128.4 (CH), 130.1 (CH), 130.9 (CH), 133.7 (C), 137.4 (C), 150.3 
(C), 152.1 (C), 162.2 (C), 165.1 (C). IR (neat, cm-1) λmax: 3078, 3048, 2886, 2775, 2672, 
2605, 2222, 1705, 1565, 1543, 1447, 1381, 1329, 1270, 1233, 1144, 1108, 908, 879, 798. FT-
ICR-MS: calculated for C14H9ClN2O2H+: 273.0425, found: 273.0426. 
N
O
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74f; Prepared according to the method A (steps A1 - A3, A5; 80% yield, 99% purity, HPLC-
ESI-MS, 210-400 nm) using 3-amino-but-2-enenitrile as the amine in the step A3 and method 
B (40% yield, 20 mmol scale, 1.5 eq t-BuOK, precipitation from MeCN/Et2O); pale solid; 
C14H8Cl2N2O2, M = 307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.80 (s, 3 H), 7.59 (d, J = 8.33 Hz, 1 H), 7.65 (dd, J = 8.42, 2.03 Hz, 1 H), 7.90 
(d, J = 2.02 Hz, 1 H), 7.95 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.6 (CH3), 109.4 (C), 
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115.9 (C), 121.8 (CH), 128.0 (CH), 129.4 (CH), 132.2 (CH), 132.4 (C), 133.9 (C), 135.3 (C), 
150.1 (C), 155.4 (C), 161.2 (C), 166.0 (C). 
N
O
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74g; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3; colorless solid; pale solid; 99% yield, 76% purity (HPLC-ESI-
MS, 210-400 nm), C14H8Cl2N2O2, M = 307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z. 
N
O
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74h; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3; pale solid; 67% yield, 71% purity (HPLC-ESI-MS, 210-400 nm), 
C14H9BrN2O2, M = 317.14 g/mol, HPLC-ESI-MS: [M + H]+ = 317 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.77 (s, 3 H), 7.57 (m, 3 H), 7.74 (m, 2 H), 7.86 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.6 (CH3), 107.1 (C), 170.0 (C), 120.7 (C), 123.8 (CH), 130.7 (CH), 132.1 
(CH), 135.3 (C), 151.9 (C), 157.9 (C), 161.8 (C), 167.1 (C). 
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O
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74i; Prepared according to the method A (steps A1 - A3, A5; 73% yield, 86% purity, HPLC-
ESI-MS, 210-400 nm) using 3-amino-but-2-enenitrile as the amine in the step A3 and method 
B (71% yield - column chromatography; 50% - 20 mmol scale, crystallization from MeCN); 
colorless solid; C15H12N2O3, M = 268.27 g/mol, HPLC-ESI-MS: [M + H]+ = 269 m/z; m.p. 
196 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.77 (s, 3 H), 3.84 (s, 3 H), 7.13 (m, 2 H), 7.67 (m, 
2 H), 7.92 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 (CH3), 55.5 (CH3), 109.2 (C), 
114.6 (CH), 116.8 (C), 121.6 (CH), 127.4 (C), 130.2 (CH), 150.0 (C), 153.3 (C), 161.0 (C), 
162.3 (C), 165.3 (C). IR (neat, cm-1) λmax: 3284, 3174, 2974, 2937, 2871, 2229, 1727, 1602, 
1536, 1499, 1425, 1388, 1336, 1233, 1174, 1130, 1063, 1026, 916, 835. FT-ICR-MS: 
calculated for C15H12N2O3H+: 269.0921, found: 269.0919. 
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74j; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3; pale solid; 38% yield, 84% purity (HPLC-ESI-MS, 210-400 nm), 
C17H16N2O4, M = 312.33 g/mol, HPLC-ESI-MS: [M + H]+ = 313 m/z. 
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O
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74k; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3 and method B (87% yield); pale yellow solid; 56% yield, 78% 
purity (HPLC-ESI-MS, 210-400 nm), C16H15N3O2, M = 281.32 g/mol, HPLC-ESI-MS: [M + 
H]+ = 282 m/z. 
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74l; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3; pale solid; 60% yield, 84% purity (HPLC-ESI-MS, 210-400 nm), 
C14H12N2O3, M = 256.26 g/mol, HPLC-ESI-MS: [M + H]+ = 257 m/z. 
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74m; Prepared according to the method A (steps A1 - A3, A5; 40% yield, 93% purity, HPLC-
ESI-MS, 210-400 nm) using 3-amino-but-2-enenitrile as the amine in the step A3 and method 
B (62% yield); yellow solid; C12H8N2O2S, M = 245.27 g/mol, HPLC-ESI-MS: [M + H]+ = 
245 m/z; m.p. 200 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.77 (s, 3 H), 7.33 (m, 1 H), 7.97 
(m, 2 H), 8.04 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.9 (CH3), 106.8 (C), 116.9 (C), 
120.3 (CH), 129.1 (CH), 130.5 (CH), 131.5 (CH), 136.2 (C), 145.3 (C), 150.3 (C), 163.1 (C), 
165.1 (C). IR (neat, cm-1) λmax: 3336, 3100, 2893, 2849, 2222, 1919, 1764, 1713, 1580, 1536, 
1417, 1388, 1299, 1218, 1144, 849, 798, 702. FT-ICR-MS: calculated for C12H8N2O2SH+: 
245.0379, found: 245.0378. 
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74n; Prepared according to the method A (steps A1 - A3, A5) using 3-amino-but-2-enenitrile 
as the amine in the step A3; brown solid; 38% yield, 73% purity (HPLC-ESI-MS, 210-400 
nm), C12H7ClN2O2S, M = 278.72 g/mol, HPLC-ESI-MS: [M + H]+ = 279 m/z. 
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74m; Prepared according to the method B; colorless solid; 61% yield - column 
chromatography, 51% - 20 mmol scale, crystallization from MeCN; C14H9FN2O2, M = 256.24 
g/mol, HPLC-ESI-MS: [M + H]+ = 257 m/z; m.p. 188.0 °C. 1H NMR (400 MHz, DMSO-D6) 
δ 2.81 (s, 3 H), 7.43 (m, 2 H), 7.63 (m, 2 H), 7.98 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 
23.7 (CH3), 111.0 (C), 115.8 (C), 116.2 (d, 2JC-F = 21.22 Hz, CH), 122.7 (CH), 123.1 (d, 2JC-F 
= 14.63 Hz, C), 125.2 (d, 3JC-F = 3.66 Hz, CH), 131.2 (d, 4JC-F = 2.19 Hz, CH), 132.7 (d, 3JC-F 
= 8.05 Hz, CH), 148.4 (C), 150.4 (C), 158.5 (d, 1JC-F =248.10 Hz, C), 161.9 (C), 165.1 (C). IR 
(neat, cm-1) λmax: 3085,  2882, 2792, 2230, 1945, 1705, 1614, 1581, 1546, 1493, 1452, 1386, 
1255, 1220, 919, 869, 796, 756. FT-ICR-MS: calculated for C14H9FN2O2H+: 257.0721, found: 
257.0721. 
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74n; Prepared according to the method B; colorless solid; 66% yield; C14H9FN2O2, M = 
256.24 g/mol, HPLC-ESI-MS: M = 256.24 g/mol, HPLC-ESI-MS: [M + H]+ = 257 m/z; m.p. 
201 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.79 (s, 3 H), 7.43 (m, 2 H), 7.77 (m, 2 H), 7.96 (s, 
1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 (CH3), 109.7 (C), 116.0 (C), 116.3 (d, 2JC-F = 
21.96, CH), 121.9 (CH), 131.1 (d, 3JC-F = 8.78, CH), 131.8 (d, 4JC-F = 2.93, C), 150.1 (C), 
152.6 (C), 162.2 (C), 163.3 (d, 1JC-F = 248.83, C), 165.2 (C). IR (neat, cm-1) λmax: 3292, 3115, 
3078, 2229, 1757, 1602, 1550, 1506, 1417, 1388, 1344, 1314, 1226, 1159, 1108, 849, 717. 
FT-ICR-MS: calculated for C14H9FN2O2H+: 257.0721,  found: 257.0719. 
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74o; Prepared according to the method B; colorless solid; 30% yield, 20 mmol scale, 1.5 eq t-
BuOK, crystallization from MeCN; C14H8F2N2O2, M = 274.23 g/mol, HPLC-ESI-MS: [M + 
H]+ = 275 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.80 (s, 3 H), 7.32 (m, 1 H), 7.53 (m, 1 H), 
7.71 (m, 1 H), 7.98 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.7 (CH3), 104.9 (t, 2JC-F = 
25.99, CH), 111.1 (C), 112.6 (dd, 2,4JC-F = 22.06, 3.66 Hz, CH), 115.8 (C), 119.8 (dd, 2,4JC-F = 
13.72, 3.66 Hz, C), 122.9 (CH), 132.8 (dd, 3JC-F = 10.22, 3.66 Hz, CH), 147.6 (C), 150.4 (C), 
159.0 (dd, 1,3JC-F = 250.41, 12.81 Hz, C), 162.0 (C), 163.6 (dd, 1,3JC-F = 250.40, 12.08 Hz, C), 
165.1 (C). 
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74p; Prepared according to the method B; colorless solid; 73% yield; C14H9ClN2O2, M = 
272.69 g/mol, HPLC-ESI-MS: [M + H]+ = 273 m/z; m.p. 208 °C. 1H NMR (400 MHz, 
DMSO-D6) δ 2.79 (s, 3 H), 7.66 (m, 2 H), 7.73 (m, 2 H), 7.97 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.8 (CH3), 109.7 (C), 116.3 (C), 121.8 (CH), 129.1 (CH), 130.5 (CH), 134.2 
(C), 135.3 (C), 150.2 (C), 152.4 (C), 162.2 (C), 165.1 (C). IR (neat, cm-1) λmax: 3085, 2982, 
2937, 2864, 2229, 1742, 1713, 1602, 1580, 1543, 1506, 1417, 1226, 1181, 1144, 1085, 1049, 
967, 857. FT-ICR-MS: calculated for C14H9ClN2O2H+: 273.0425, found: 273.0425. 
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74r; Prepared according to the method B; colorless solid; 42% yield; C14H8Cl2N2O2, M = 
307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z. 
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74s; Prepared according to the method B; colorless solid; 81% yield; C14H8Cl2N2O2, M = 
307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z; m.p. 226-227°C (decomp.). 1H NMR 
(400 MHz, DMSO-D6) δ 2.78 (s, 3 H) 7.59 (m, 1 H) 7.70 (m, 2 H) 7.81 (s, 1 H). 13C NMR 
(100 MHz, DMSO-D6) δ 23.5 (CH3), 109.1 (C), 115.4 (C), 121.8 (CH), 128.7 (CH), 132.3 
(C), 132.9 (CH), 133.6 (C), 149.0 (C), 156.4 (C), 161.5 (C), 166.0 (C). IR (neat, cm-1) λmax: 
3144, 2974, 2937, 2878, 2827, 2229, 1683, 1587, 1558, 1477, 1432, 1388, 1226, 1181, 1056, 
1004. FT-ICR-MS: calculated for C14H8Cl2N2O2H+: 307.0036, found: 307.0036 
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74t; Prepared according to the method B; colorless solid; 62% yield, 20 mmol scale, 
crystallization from MeCN; C15H10N2O4, M = 282.26 g/mol, HPLC-ESI-MS: [M + H]+ = 283 
m/z; m.p. 211 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.77 (s, 3 H), 6.14 (s, 2 H), 7.11 (m, 1 
H), 7.19 (m, 1 H), 7.29 (m, 1 H), 7.91 (m, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 
(CH3), 101.9 (CH2), 108.7 (CH), 108.8 (CH), 109.4 (C), 116.6 (C), 121.7 (CH), 123.2 (CH), 
129.0 (C), 147.9 (C), 149.1 (C), 150.0 (C), 153.2 (C), 162.2 (C), 165.2 (C). IR (neat, cm-1) 
λmax: 3306, 3174, 3078, 2974, 2945, 2871, 2229, 1764, 1727, 1587, 1536, 1499, 1447, 1388, 
1336, 1233, 1196, 1152, 1034, 916. FT-ICR-MS: calculated for C15H10N2O4H+: 283.0713, 
found: 283.0712. 
N
O
OH
NC
O
74u
 
74u; Prepared according to the method B; colorless solid; 29% yield (crystallization from 
MeCN); C12H8N2O3, M = 228.21 g/mol, HPLC-ESI-MS: [M + H]+ = 229 m/z. 
N
O
OH
NC
S
74w
 
74w; Prepared according to the method B; pale solid; 60% yield, 20 mmol scale, 
crystallization from MeCN; C12H8N2O2S, M = 244.27 g/mol, HPLC-ESI-MS: [M + H]+ = 245 
m/z. 
N
O
Cl
O OH
Cl
81a
 
81a; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 88% yield, 73% purity (HPLC-ESI-MS, 210-400 nm), 
C15H11Cl2NO3, M = 324.17 g/mol, HPLC-ESI-MS: [M + H]+ = 324 m/z. 
N
O
Br
O OH
81b
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81b; Prepared according to the method A (steps A1 - A3, A5) using 4-amino-pent-3-en-2-one 
in the step A3; brown solid; 36% yield, 84% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12BrNO3, M = 334.17 g/mol, HPLC-ESI-MS: [M + H]+ = 334 m/z. 
N
OH O
NC
Cl
Cl
81c
 
81c; Prepared according to the method A (steps A1 - A3, A5; 80% yield, 72% purity, HPLC-
ESI-MS, 210-400 nm) using 3-amino-but-2-enenitrile
 
as the amine in the step A3 and method 
B (81% yield - column chromatography; 65% - 20 mmol scale, 1.5 eq t-BuOK, crystallization 
from MeCN); red solid; C14H8Cl2N2O2, M = 307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 
m/z; m.p. 180 °C (decomp.). 1H NMR (400 MHz, DMSO-D6) δ 2.80 (s, 3 H), 7.58 (dd, J =  
8.34, 2.02 Hz, 1 H), 7.67 (d, J =  8.33 Hz, 1 H), 7.79 (d, J =  2.02 Hz, 1 H), 8.05 (s, 1 H). 13C 
NMR (100 MHz, DMSO-D6) δ 23.7 (CH3), 105.9 (C), 115.8 (C), 121.8 (CH), 127.9 (CH), 
129.7 (CH), 132.2 (C) , 133.1 (CH), 135.1 (C), 135.8 (C), 142.6 (C), 157.6 (C), 162.9 (C), 
164.3 (C). IR (neat, cm-1) λmax: 3100, 3070, 2882, 2852, 2230, 1750, 1584, 1554, 1404, 1329, 
1224, 1142, 1097, 1037, 872, 819, 789, 722, 609. FT-ICR-MS: calculated for 
C14H8Cl2N2O2H+: 307.0036, found: 307.0037. 
N
OH O
NC
F81d
 
81d; Prepared according to the method C; colorless solid; 74% yield; C14H9FN2O2, M = 
256.24 g/mol, HPLC-ESI-MS: [M + H]+ = 257 m/z; m.p. 286-287 °C  (decomp.). 1H NMR 
(400 MHz, DMSO-D6) δ 2.78 (s, 3 H), 7.33 (m, 2 H), 8.22 (m, 3 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.9 (CH3), 104.9 (C), 116.0 (d, 2JC-F = 21.23 Hz, CH), 116.0 (C), 117.1 (CH), 
129.8 (d, 3JC-F = 9.52 Hz, CH),132.8 (d, 4JC-F = 2.93 Hz, C), 142.8 (C), 157.4 (C), 162.8 (C), 
163.8 (d, 1JC-F = 248.83 Hz, C), 164.5 (C). IR (neat, cm-1) λmax: 3240, 3085, 2229, 1794, 
1727, 1602, 1580, 1558, 1513, 1454, 1403, 1358, 1307, 1226, 1159, 1137, 842, 657. FT-ICR-
MS: calculated for C14H9FN2O2Na+: 279.0540, found: 279.0541. 
N
OH O
NC
F
F
81e
 
81e; Prepared according to the method C; colorless solid; 30% yield, 20 mmol scale, 1.5 eq t-
BuOK, crystallization from MeCN; C14H8F2N2O2, M = 274.23 g/mol, HPLC-ESI-MS: [M + 
H]+ = 274 m/z. 
N
OH O
NC
Cl
F
81f
 
81f; Prepared according to the method B; pale solid; 40% yield; C14H8ClFN2O2, M = 290.68 
g/mol, HPLC-ESI-MS: [M + H]+ = 291 m/z. 
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81g; Prepared according to the method C; colorless solid; 67% yield; C14H9ClN2O2, M = 
272.69 g/mol, HPLC-ESI-MS: [M + H]+ = 273 m/z; m.p. 194 °C. 1H NMR (400 MHz, 
DMSO-D6) δ 2.80 (s, 3 H), 7.57 (m, 2 H), 8.13 (m, 1 H), 8.21 (m, 1 H), 8.30 (s, 1 H). 13C 
NMR (100 MHz, DMSO-D6) δ 23.9 (CH3), 105.7 (C), 115.9 (C), 117.6 (CH), 126.0 (CH), 
127.0 (CH), 130.5 (CH), 131.0 (CH), 134.0 (C), 138.4 (C), 143.2 (C), 156.9 (C), 162.9 (C), 
164.5 (C). IR (neat, cm-1) λmax: 3011, 2819, 2635, 2524, 2214, 1713, 1624, 1572, 1513, 1425, 
1381, 1373, 1322, 1263, 1233, 1144, 1093, 938, 879. FT-ICR-MS: calculated for 
C14H9ClN2O2H+: 273.0425, found: 273.0425. 
N
OH O
NC
Cl81h
 
81h; Prepared according to the method C; brown solid; 86% yield; C14H9ClN2O2, M = 272.69 
g/mol, HPLC-ESI-MS: [M + H]+ = 273 m/z; m.p. 295-297 °C (decomp.). 1H NMR (400 MHz, 
DMSO-D6) δ 2.80 (s, 3 H), 7.58 (m, 2 H), 8.20 (m, 2 H), 8.27 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.9 (CH3), 105.3 (C), 116.0 (C), 117.3 (CH), 129.1 (CH), 129.2 (CH), 135.1 
(C), 135.7 (C), 143.0 (C), 157.2 (C), 162.9 (C), 164.5 (C). IR (neat, cm-1) λmax: 3454, 2805, 
2635, 2236, 1720, 1601, 1575, 1551, 1494, 1431, 1386, 1337, 1248, 1091, 1015, 903, 829, 
746, 667. FT-ICR-MS: calculated for C14H9ClN2O2H+: 273.0425, found: 273.0426. 
N
OH O
NC
Cl
Cl
81i
 
81i; Prepared according to the method C; colorless solid; 54% yield; C14H8Cl2N2O2, M = 
307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z; m.p. 165 °C. 1H NMR (400 MHz, 
DMSO-D6) δ 2.79 (s, 3 H), 7.75 (d, J =  8.65 Hz, 1 H), 8.14 (dd, J =  8.39, 2.03 Hz, 1 H), 
8.31 (s, 1 H), 8.37 (d, J =  2.03 Hz, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 (CH3), 
105.8 (C), 115.8 (C), 117.6 (CH), 127.4 (CH), 129.0 (CH), 131.2 (CH), 132.0 (C), 133.5 (C), 
136.7 (C), 143.1 (C), 155.8 (C), 162.9 (C), 164.4 (C). IR (neat, cm-1) λmax: 3100, 2897, 2860, 
2230, 1705, 1569, 1427, 1329, 1269, 1247, 1149, 1029, 887, 834, 677. FT-ICR-MS: 
calculated for C14H8Cl2N2O2H+: 307.0036, found: 307.0038. 
N
OH O
NC
Br81j
 
81j; Prepared according to the method C; colorless solid; 72% yield - column 
chromatography; 35% - 20 mmol scale, 1.5 eq t-BuOK, crystallization from MeCN; 
C14H9BrN2O2, M = 317.14 g/mol, HPLC-ESI-MS: [M + H]+ = 317 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.73 (s, 3 H), 7.70 (m, 2 H), 8.09 (m, 3 H). 13C NMR (100 MHz, DMSO-D6) δ 
  
70 
23.7 (CH3), 105.6 (C), 116.7 (C), 117.3 (CH), 123.9 (C), 128.1 (CH), 131.9 (CH), 136.3 (C), 
156.1 (C), 161.7 (C), 165.1 (C). 
N
OH O
NC
O81k
 
81k; Prepared according to the method C; yellow solid; 81% yield - column chromatography, 
55% - 20 mmol scale, 1.5 eq t-BuOK, crystallization from MeCN; C15H12N2O3, M = 268.27 
g/mol, HPLC-ESI-MS: [M + H]+ = 269 m/z; m.p. 186 °C. 1H NMR (400 MHz, DMSO-D6) δ 
2.76 (s, 3 H), 3.83 (s, 3 H), 7.06 (m, J =  8.90 Hz, 2 H), 8.14 (m, J =  8.90 Hz, 2 H), 8.17 (s, 1 
H). 13C NMR (100 MHz, DMSO-D6) δ 23.9 (CH3), 55.4 (CH3), 103.8 (C), 114.4 (CH), 116.2 
(C), 116.3 (CH), 128.7 (C), 129.0 (CH), 142.5 (C), 158.2 (C), 161.6 (C), 162.7 (C), 164.7 (C). 
IR (neat, cm-1) λmax: 3011, 2974, 2871, 2842, 2237, 1742, 1602, 1565, 1513, 1454, 1388, 
1322, 1292, 1263, 1226, 1174, 1144, 1026, 820, 672. FT-ICR-MS: calculated for 
C15H12N2O3H+: 269.0921, found: 269.0921. 
N
OH O
NC
O81l
 
81l; Prepared according to the method C; yellow solid; 63% yield; C12H8N2O3, M = 228.21 
g/mol, HPLC-ESI-MS: [M + H]+ = 229 m/z; m.p. 170 °C (decomp.). 1H NMR (400 MHz, 
DMSO-D6) δ 2.72 (s, 3 H), 7.22 (dd, J =  4.83, 3.81 Hz, 1 H), 7.83 (m, 1 H), 8.08 (m, 1 H), 
8.21 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.7 (CH3), 104.1 (C), 115.8 (CH), 116.1 
(C), 129.0 (CH), 129.2 (CH), 131.8 (CH), 142.2 (C), 142.6 (C), 154.3 (C), 163.0 (C), 164.5 
(C). IR (neat, cm-1) λmax: 3182, 3092, 2897, 2222, 1720, 1577, 1532, 1442, 1352, 1322, 1269, 
1239, 1202, 1089, 1037, 917, 707, 662. FT-ICR-MS: calculated for C12H8N2O3H+: 229.0608, 
found: 229.0610. 
N
OH O
NC
S81m
 
81m; Prepared according to the method C; yellow solid; 61% yield; C12H8N2O2S, M = 244.27 
g/mol, HPLC-ESI-MS: [M + H]+ = 245 m/z; m.p. 207-208 °C (decomp.). 1H NMR (400 MHz, 
DMSO-D6) δ 2.74 (s, 3 H), 6.74 (m, 1 H), 7.39 (m, J =  3.31 Hz, 1 H), 7.99 (m, J =  8.39 Hz, 
2 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 (CH3), 104.2 (C), 113.2 (CH), 113.2 (CH), 
115.3 (CH), 116.1 (C), 142.6 (C), 146.5 (CH), 150.3 (C), 151.3 (C), 163.3 (C), 164.3 (C). IR 
(neat, cm-1) λmax: 3152, 3130, 2920, 2852, 2215, 1692, 1592, 1547, 1479, 1404, 1232, 1172, 
1074, 1037, 954, 887, 767, 714. FT-ICR-MS: calculated for C12H8N2O2SH+: 245.0379, found: 
245.0380. 
N
H
OH O
NC
Cl
Cl
106
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106; Prepared according to the method C; Brown crystals (crystallization from MeCN); 
C14H10Cl2N2O2, M = 309.15 g/mol, HPLC-ESI-MS: [M + H]+ = 309 m/z; m.p. 179-181 °C 
(decomp.). 1H NMR (400 MHz, DMSO-D6) δ 2.01 (s, 3 H), 4.02 (d, J =  4.83 Hz, 1 H), 4.71 
(dd, J =  4.83, 1.53 Hz, 1 H), 7.37 (d, J =  8.14 Hz, 1 H), 7.46 (dd, J =  8.19, 2.03 Hz, 1 H), 
7.69 (d, J =  2.03 Hz, 1 H), 8.84 (s, 1 H), 12.61 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 
17.9 (CH3), 41.0 (CH), 73.1 (C), 99.2 (CH), 120.9 (C), 127.5 (CH), 129.2 (CH), 132.3 (CH), 
133.4 (C), 133.6 (C), 134.1 (C), 134.2 (C), 149.7 (C), 173.0 (C). IR (neat, cm-1) λmax: 3262, 
3233, 3115, 3004, 2849, 2620, 2207, 1698, 1668, 1624, 1580, 1513, 1469, 1417, 1381, 1307, 
1248, 1122, 1085, 916. FT-ICR-MS: calculated for C14H10Cl2N2O2H+: 309.0192, found: 
309.0192. 
N
N
N
O
OH
F
78a
 
78a; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; yellow solid; 85% yield, 82% purity (HPLC-
ESI-MS, 210-400 nm), C20H14ClN3O2, M = 363.81 g/mol, [M + H]+ = 364 m/z. 
N
N
N
O
OH
Cl
78b
 
78b; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; yellow solid; 99% yield, 79% purity (HPLC-
ESI-MS, 210-400 nm), C20H14ClN3O2, M = 363.81 g/mol, [M + H]+ = 364 m/z. 
N
N
N
O
OH
Cl
Cl
78c
 
78c; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; pale solid; 98% yield, 82% purity (HPLC-ESI-MS, 
210-400 nm), C15H11Cl2N3O2, M = 336.18 g/mol, [M + H]+ = 336 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.03 (s, 3 H), 4.06 (s, 3 H), 7.54 (m, 1 H), 7.61 (m, 1 H), 7.64 (s, 1 H), 7.86 (m, 
1 H). 13C NMR (100 MHz, DMSO-D6) δ 13.2 (CH3), 33.7 (CH3), 114.1 (C), 116.9 (CH), 
127.7 (CH), 129.0 (CH), 132.3 (CH), 132.8 (C), 134.2 (C), 134.7 (C), 139.4 (C), 141.5 (C), 
147.1 (C), 150.3 (C), 166.0 (C). 
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78d; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; yellow solid; 79% yield, 99% purity (HPLC-
ESI-MS, 210-400 nm), C20H13Cl2N3O2, M = 398.25 g/mol, HPLC-ESI-MS: [M + H]+ = 398 
m/z. 
N
N
N
O
OH
ClCl
78e
 
78e; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; pale solid; 99% yield, 80% purity (HPLC-ESI-MS, 
210-400 nm), C15H11Cl2N3O2, M = 336.18 g/mol, HPLC-ESI-MS: [M + H]+ = 336 m/z. 
N
N
N
O
OH
Br
78f
 
78f; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; colorless solid; 99% yield, 88% purity (HPLC-ESI-
MS, 210-400 nm), C15H12BrN3O2, M = 346.19 g/mol, HPLC-ESI-MS: [M + H]+ = 346 m/z. 
N
N
N
O
OH
Br
78g
 
78g; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; pale solid; 84% yield, 91% purity (HPLC-ESI-
MS, 210-400 nm), C20H14BrN3O2, M = 408.26 g/mol, HPLC-ESI-MS: [M + H]+ = 408 m/z. 
1H NMR (400 MHz, DMSO-D6) δ 2.20 (s, 3 H), 7.32 (m, 1 H), 7.55 (m, 4 H), 7.74 (m, 3 H), 
8.27 (m, 2 H), 13.58 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 15.2 (CH3), 115.5 (C), 118.2 
(CH), 120.5 (CH), 122.9 (C), 125.9 (CH), 129.2 (CH), 131.3 (CH), 131.5 (CH), 135.3 (C), 
138.8 (C), 142.1 (C), 145.1 (C), 147.4 (C), 150.2 (C), 165.9 (C). 
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78h; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; yellow solid; 84% yield, 75% purity (HPLC-ESI-MS, 
210-400 nm), C16H15N3O3, M = 297.32 g/mol, HPLC-ESI-MS: [M + H]+ = 298 m/z. 1H NMR 
(400 MHz, DMSO-D6) δ 2.22 (s, 3 H), 3.83 (s, 3 H), 4.03 (s, 3 H), 7.09 (m, 2 H), 7.51 (m, 2 
H), 7.63 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 15.2 (CH3), 33.6 (CH3), 55.3 (CH3), 
113.6 (C), 114.0 (CH), 116.6 (CH), 128.7 (C), 130.7 (CH), 139.5 (C), 145.9 (C), 146.7 (C), 
150.8 (C), 160.1 (C), 166.3 (C). 
N
N
N
O
OH
O
78i
 
78i; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; yellow solid; 78% yield, 88% purity (HPLC-
ESI-MS, 210-400 nm), C21H17N3O3, M = 359.39 g/mol, HPLC-ESI-MS: [M + H]+ = 360 m/z. 
N
N
N
O
OH
O
O
78j
 
78j; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; brown solid; 72% yield, 89% purity (HPLC-ESI-MS, 
210-400 nm), C18H19N3O4, M = 341.37 g/mol, HPLC-ESI-MS: [M + H]+ = 342 m/z. 
N
N
N
O
OH
N
78k
 
78k; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; pale yellow solid; 80% yield, 77% purity 
(HPLC-ESI-MS, 210-400 nm), C22H20N4O2, M = 372.43 g/mol, HPLC-ESI-MS: [M + H]+ = 
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373 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.34 (s, 3 H), 2.98 (s, 6 H), 6.83 (m, 2 H), 7.43 
(m, 5 H), 7.72 (s, 1 H), 8.31 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 15.8 (CH3), 39.8 
(CH3), 111.7 (CH), 115.6 (C), 117.9 (CH), 120.5 (CH), 123.0 (C), 125.7 (CH), 129.2 (CH), 
130.4 (CH), 139.0 (C), 142.5 (C), 147.2 (C), 150.7 (C), 150.9 (C), 166.3 (C). 
N
N
N
O
OH
O
78l
 
78l; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; brown solid; 72% yield, 85% purity (HPLC-ESI-MS, 
210-400 nm), C15H15N3O3, M = 285.31 g/mol, HPLC-ESI-MS: [M + H]+ = 286 m/z. 
N
N
N
O
OH
O
78m
 
78m; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; brown solid; 99% yield, 88% purity (HPLC-
ESI-MS, 210-400 nm), C20H17N3O3, M = 347.38 g/mol, HPLC-ESI-MS: [M + H]+ = 348 m/z. 
N
N
N
O
OH
S
78n
 
78n; Prepared according to the method A (steps A1-A3, A5) using 2,5-dimethyl-2H-pyrazol-
3-ylamine as the amine in the step A3; pale solid; 91% yield, 78% purity (HPLC-ESI-MS, 
210-400 nm), C13H11N3O2S, M = 273.32 g/mol, HPLC-ESI-MS: [M + H]+ = 274 m/z. 
N
N
N
O
OH
S
78o
 
78o; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; yellow solid; 73% yield, 76% purity (HPLC-
ESI-MS, 210-400 nm), C19H15N3O2S, M = 349.41 g/mol, HPLC-ESI-MS: [M + H]+ = 350 
m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.52 (s, 3 H), 2.56 (s, 3 H), 7.00 (m, 1 H), 7.37 (m, 2 
H), 7.57 (m, 2 H), 7.78 (s, 1 H), 8.27 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 15.1 
(CH3), 15.8 (CH3), 114.9 (C), 118.2 (CH), 120.8 (CH), 126.0 (CH), 127.0 (CH), 129.2 (CH), 
130.8 (CH), 134.2 (C), 138.8 (C), 139.2 (C), 142.3 (C), 143.3 (C), 165.9 (C). 
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78p; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 28% yield, 80% purity (HPLC-ESI-MS, 210-400 nm), 
C13H10ClN3O2S, M = 307.76 g/mol, HPLC-ESI-MS: [M + H]+ = 308 m/z. 1H NMR (400 
MHz, DMSO-D6) δ 2.41 (s, 1 H), 4.03 (s, 3 H), 7.29 (d, J = 3.81 Hz, 1 H) 7.41 (d, J = 3.81 
Hz, 1 H), 7.66 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 15.4 (CH3), 33.7 (CH3), 112.7 (C), 
116.8 (CH), 128.1 (CH), 130.0 (CH), 130.9 (C), 136.0 (C), 137.0 (C), 139.3 (C), 146.8 (C), 
150.9 (C), 165.9 (C). 
N
N
N
OHO
O83a
 
83a; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; brown solid; 56% yield, 90% purity (HPLC-
ESI-MS, 210-400 nm), C18H15N3O3, M = 321.34 g/mol, HPLC-ESI-MS: [M + H]+ = 322 m/z. 
N
N
N
OHO
S83b
 
83b; Prepared according to the method A (steps A1-A3, A5) using 5-methyl-2-phenyl-2H-
pyrazol-3-ylamine as the amine in the step A3; brown solid; 88% yield, 99% purity (HPLC-
ESI-MS, 210-400 nm), C18H15N3O2S, M = 337.40 g/mol, HPLC-ESI-MS: [M + H]+ = 338 
m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.25 (s, 3 H), 2.97 (dd, J = 17.29, 9.41 Hz, 1 H), 3.58 
(dd, J = 17.42, 2.42 Hz, 1 H), 3.94 (dd, J = 9.16, 2.54 Hz, 1 H), 7.21 (m, 1 H), 7.29 (m, 1 H), 
7.48 (m, 3 H), 7.82 (m, 1 H), 7.86 (m, 1 H), 7.90 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 
12.3 (CH3), 28.0 (CH2), 33.7 (CH), 102.0 (C), 121.3 (CH), 125.9 (CH), 128.6 (CH), 128.9 
(CH), 131.1 (CH), 132.2 (CH), 139.0 (C), 144.1 (C), 145.3 (C), 145.6 (C), 161.9 (C), 173.7 
(C).  
N
N
N
OHO
F85a
 
85a; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; brown solid; 89% yield, 88% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12FN3O2, M = 285.28 g/mol, HPLC-ESI-MS: [M + H]+ = 286 m/z. 
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N
N
N
OHO
F85b
 
85b; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; yellow solid; 58% yield, 79% purity (HPLC-ESI-MS, 210-400 nm), 
C13H10ClN3O2S, M = 347.25 g/mol, HPLC-ESI-MS: [M + H]+ = 348 m/z. 1H NMR (400 
MHz, DMSO-D6) δ 2.65 (m, 3 H), 7.33 (m, 3 H), 7.54 (m, 2 H), 8.06 (s, 1 H), 8.21 (m, 4 H). 
13C NMR (100 MHz, DMSO-D6) δ 15.6 (CH3), 111.5 (C), 114.3 (CH), 115.9 (d, 2JC-F = 
21.22, CH), 120.6 (CH), 125.7 (CH), 129.1 (CH), 129.4 (d, 3JC-F = 8.78, CH), 134.0 (d, 4JC-F 
= 2.20, C), 136.0 (C), 138.8 (C), 142.2 (C), 151.2 (C), 154.9 (C), 163.4 (d, 1JC-F = 248.10, C), 
166.5 (C).  
N
N
N
OHO
Cl
85c
 
85c; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 73% yield, 87% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12ClN3O2, M = 301.73 g/mol, HPLC-ESI-MS: [M + H]+ = 302 m/z. 
N
H
N
N
OHO
Cl
Cl85d
 
85d; Prepared according to the method A using 5-methyl-2H-pyrazol-3-ylamine as the amine 
in the step A3; yellow solid; 75% yield, 79% purity (HPLC-ESI-MS, 210-400 nm), 
C14H9Cl2N3O2, M = 322.15 g/mol, HPLC-ESI-MS: [M + H]+ = 322 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.48 (s, 3 H), 6.75 (s, 1 H), 7.53 (s, 1 H), 7.59 (m, 1 H), 7.72 (m, 1 H), 7.80 (m, 
1 H). 13C NMR (100 MHz, DMSO-D6) δ 14.4 (CH3), 97.0 (CH), 108.1 (CH), 127.9 (CH), 
129.6 (CH), 132.3 (C), 132.8 (CH), 135.1 (C), 135.7 (C), 136.4 (C), 149.2 (C), 154.2 (C), 
155.5 (C), 161.4 (C). 
N
N
N
OHO
Cl
Cl85e
 
85e; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 72% yield, 89% purity (HPLC-ESI-MS, 210-400 nm), 
C15H11Cl2N3O2, M = 336.18 g/mol, HPLC-ESI-MS: [M + H]+ = 336 m/z. 
N
N
N
OHO
Cl
Cl85f
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85f; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; yellow solid; 55% yield, 99% purity (HPLC-ESI-MS, 210-400 nm), 
C20H13Cl2N3O2, M = 398.25 g/mol, HPLC-ESI-MS: [M + H]+ = 398 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.71 (s, 3 H), 7.30 (m, 1 H), 7.54 (m, 3 H), 7.75 (m, 2 H), 7.84 (s, 1 H), 8.20 (m, 
2 H). 13C NMR (100 MHz, DMSO-D6) δ 15.7 (CH3), 111.7 (C), 118.4 (CH), 120.8 (CH), 
126.0 (CH), 127.8 (CH), 129.1 (CH), 129.7 (CH), 132.4 (C), 133.2 (CH), 134.6 (C), 135.7 
(C), 136.8 (C), 138.6 (C), 142.4 (C), 150.8 (C), 154.8 (C), 166.3 (C).  
N
N
N
OHO
Cl
Cl
85g
 
85g; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 80% yield, 83% purity (HPLC-ESI-MS, 210-400 nm), 
C15H11Cl2N3O2, M = 336.18 g/mol, HPLC-ESI-MS: [M + H]+ = 336 m/z. 
N
N
N
OHO
Cl
Cl
85h
 
85h; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; brown solid; 56% yield, 71% purity (HPLC-ESI-MS, 210-400 nm), 
C20H13Cl2N3O2, M = 398.25 g/mol, HPLC-ESI-MS: [M + H]+ = 398 m/z. 
N
N
N
OHO
Br85i
 
85i; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 49% yield, 82% purity (HPLC-ESI-MS, 210-400 nm), 
C15H12BrN3O2, M = 346.19 g/mol, HPLC-ESI-MS: [M + H]+ = 346 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.58 (s, 3 H), 3.99 (s, 3 H), 7.65 (m, 2 H), 7.82 (m, 1 H), 8.07 (m, 2 H). 
N
N
N
OHO
Br85j
 
85j; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; yellow solid; 24% yield, 95% purity (HPLC-ESI-MS, 210-400 nm), 
C20H14BrN3O2, M = 408.26 g/mol, HPLC-ESI-MS: [M + H]+ = 408 m/z. 
N
N
N
OHO
O85k
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85k; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; brown solid; 65% yield, 79% purity (HPLC-ESI-MS, 210-400 nm), 
C14H15N3O3, M = 273.29 g/mol, HPLC-ESI-MS: [M + H]+ = 274 m/z. 
N
N
N
OHO
O85l
 
85l; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; brown solid; 57% yield, 63% purity (HPLC-ESI-MS, 210-400 nm), 
C18H13N3O3, M = 319.32 g/mol, HPLC-ESI-MS: [M + H]+ = 320 m/z. 
N
N
N
OHO
S85m
 
85m; Prepared according to the method A using 2,5-dimethyl-2H-pyrazol-3-ylamine as the 
amine in the step A3; pale solid; 99% yield, 96% purity (HPLC-ESI-MS, 210-400 nm), 
C13H11N3O2S, M = 273.32 g/mol, HPLC-ESI-MS: [M + H]+ = 274 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.55 (s, 3 H), 3.98 (s, 3 H), 7.20 (m, 1 H), 7.73 (m, 1 H), 7.96 (s, 1 H), 7.99 (m, 
1 H), 13.95 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 15.3 (CH3), 33.3 (CH3), 109.3 (C), 
112.4 (CH), 127.5 (CH), 128.7 (CH), 129.7 (CH), 135.3 (C), 139.7 (C), 143.5 (C), 150.9 (C), 
151.3 (C), 166.6 (C).  
N
N
N
OHO
S85n
 
85n; Prepared according to the method A using 5-methyl-2-phenyl-2H-pyrazol-3-ylamine as 
the amine in the step A3; solid; 54% yield, 86% purity (HPLC-ESI-MS, 210-400 nm), 
C18H13N3O2S, M = 335.39 g/mol, HPLC-ESI-MS: [M + H]+ = 336 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.64 (s, 3 H), 7.19 (m, 1 H), 7.31 (m, Hz, 1 H), 7.54 (m, 2 H), 7.74 (m, 1 H), 
8.00 (m, 1 H), 8.04 (s, 1 H), 8.25 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 15.6 (CH3), 
111.4 (C), 113.2 (CH), 120.3 (CH), 125.7 (CH), 127.8 (CH), 128.9 (C), 129.1 (CH), 130.2 
(CH), 136.1 (C), 138.9 (C), 142.5 (C), 143.4 (C), 150.8 (C), 151.5 (C), 166.4 (C). 
 
6. 1. 2. 4 Synthesis of pyrimidines. 
N
N
O
OH
N
F
86a
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86a; Prepared according to the method A (steps A1-A3, A5) using isonicotinamidine as the 
amine in the step A3; brown solid; 67% yield, 83% purity (HPLC-ESI-MS, 210-400 nm), 
C16H10FN3O2, M = 295.28 g/mol, HPLC-ESI-MS: [M + H]+ = 396 m/z. 
N
N
O
OH
N
Br
86b
 
86b; Prepared according to the method A (steps A1-A3, A5) using isonicotinamidine as the 
amine in the step A3; brown solid; 92% yield, 86% purity (HPLC-ESI-MS, 210-400 nm), 
C16H10BrN3O2, M = 356.18 g/mol, HPLC-ESI-MS: [M + H]+ = 356 m/z. 
N
H
NN
O
OH
Cl
O O 87a
 
87a; Prepared according to the method A (steps A1-A3, A5) using 5-amino-1H-pyrazole-4-
carboxylic acid ethyl ester as the amine in the step A3; brown solid; 90% yield, 79% purity 
(HPLC-ESI-MS, 210-400 nm), C16H14ClN3O4, M = 347.76 g/mol, HPLC-ESI-MS: [M + H]+ 
= 348 m/z. 
N
H
NN
O
OH
Br
O O 87b
 
87b; Prepared according to the method A (steps A1-A3, A5) using 5-amino-1H-pyrazole-4-
carboxylic acid ethyl ester as the amine in the step A3; pale orange solid; 79% yield, 96% 
purity (HPLC-ESI-MS, 210-400 nm), C16H14BrN3O4, M = 392.21 g/mol, HPLC-ESI-MS: [M 
+ H]+ = 392 m/z. 1H NMR (400 MHz, DMSO-D6) δ 1.27 (t, J = 7.12 Hz, 3 H), 4.23 (q, J = 
6.95 Hz, 2 H), 5.88 (m, 1 H), 6.26 (d, J = 4.07 Hz, 1 H), 7.17 (d, J = 8.39 Hz, 2 H), 7.55 (m, 
2 H), 7.68 (s, 1 H), 7.91 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 14.3 (CH3), 58.6 (CH), 
59.7 (CH2), 94.9 (C), 106.4 (CH), 121.5 (C), 125.5 (C), 129.1 (CH), 131.7 (CH), 140.0 (CH), 
140.1 (C), 141.8 (C), 162.7 (C). 
N
H
NN
O
OH
O O
S
Cl
87c
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87c; Prepared according to the method A (steps A1-A3, A5) using 5-amino-1H-pyrazole-4-
carboxylic acid ethyl ester as the amine in the step A3; brown solid; 68% yield, 81% purity 
(HPLC-ESI-MS, 210-400 nm), C14H12ClN3O4S, M = 353.79 g/mol, HPLC-ESI-MS: [M + H]+ 
= 354 m/z. 1H NMR (400 MHz, DMSO-D6) δ 1.27 (t, J = 7.12 Hz, 3 H), 4.22 (q, J = 7.12 Hz, 
2 H), 5.97 (dd, J = 4.07, 1.78 Hz, 1 H), 6.50 (d, J = 4.32 Hz, 1 H), 7.00 (m, 2 H), 7.72 (s, 1 
H), 7.97 (d, J = 1.53 Hz, 1 H), 14.11 (bs, 1H). 13C NMR (100 MHz, DMSO-D6) δ 14.3 
(CH3), 54.3 (CH), 59.7 (CH2), 70.3 (C), 95.1 (C), 104.7 (CH), 126.4 (C), 126.5 (CH), 126.7 
(CH), 129.1 (C), 140.0 (CH), 140.9 (C), 142.5 (C), 162.6 (C). 
N
NN
O
OH
Cl
O O 88a
 
88a; Prepared according to the method A using 5-amino-1H-pyrazole-4-carboxylic acid ethyl 
ester as the amine in the step A3; pale solid; 86% yield, 91% purity (HPLC-ESI-MS, 210-400 
nm), C16H12ClN3O4, M = 345.74 g/mol, HPLC-ESI-MS: [M + H]+ = 346 m/z. 
N
NN
O
OH
Br
O O 88b
 
88b; Prepared according to the method A using 5-amino-1H-pyrazole-4-carboxylic acid ethyl 
ester as the amine in the step A3; pale solid; 79% yield, 82% purity (HPLC-ESI-MS, 210-400 
nm), C16H12BrN3O4, M = 39ß.20 g/mol, HPLC-ESI-MS: [M + H]+ = 354 m/z. 1H NMR (400 
MHz, DMSO-D6) δ 1.32 (t, J = 6.74 Hz, 3 H), 4.32 (m, 2 H), 7.83 (m, 3 H), 8.07 (m, 2 H), 
8.75 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 14.4 (CH3), 59.8 (CH2), 103.6 (C), 109.0 
(CH), 125.4 (C), 128.8 (C), 131.6 (CH), 131.9 (CH), 147.6 (C), 147.6 (C), 148.0 (CH), 150.6 
(C), 161.3 (C), 164.8 (C). 
N
H
N
N
O
OH
Cl
89a
 
89a; Prepared according to the method A (steps A1-A3, A5) using 1H-benzoimidazol-2-
ylamine as the amine in the step A3; brown solid; 83% yield, 82% purity (HPLC-ESI-MS, 
210-400 nm), C17H12ClN3O2, M = 325.76 g/mol, HPLC-ESI-MS: [M + H]+ = 326 m/z. 
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H
N
N
O
OH
Br
89b
 
89b; Prepared according to the method A (steps A1-A3, A5) using 1H-benzoimidazol-2-
ylamine as the amine in the step A3; brown solid; 82% yield, 95% purity (HPLC-ESI-MS, 
210-400 nm), C17H12BrN3O2, M = 370.21 g/mol, HPLC-ESI-MS: [M + H]+ = 370 m/z. 1H 
NMR (400 MHz, DMSO-D6) δ 6.11 (d, J = 3.81 Hz, 1 H), 6.55 (d, J = 4.07 Hz, 1 H), 7.15 
(m, 3 H), 7.45 (m, 2 H), 7.53 (m, 1 H), 7.58 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 56.3 
(CH), 109.4 (CH), 111.2 (CH), 113.5 (CH), 122.2 (C), 123.0 (CH), 124.2 (CH), 125.2 (C), 
129.4 (CH), 132.1 (CH), 138.0 (C), 144.8 (C), 162.3 (C). 
N
H
N
N
O
OH
S
Cl
89c
 
89c; Prepared according to the method A (steps A1-A3, A5) using 1H-benzoimidazol-2-
ylamine as the amine in the step A3; brown solid; 92% yield, 88% purity (HPLC-ESI-MS, 
210-400 nm), C15H10ClN3O2S, M = 331.78 g/mol, HPLC-ESI-MS: [M + H]+ = 332 m/z. 
N
N
N
O
OH
Cl
90a
 
90a; Prepared according to the method A using 1H-benzoimidazol-2-ylamine as the amine in 
the step A3; brown solid; 65% yield, 91% purity (HPLC-ESI-MS, 210-400 nm), 
C17H10ClN3O2, M = 323.74 g/mol, HPLC-ESI-MS: [M + H]+ = 324 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.51 (s, 3 H), 6.75 (m, 1 H), 7.25 (m, 1 H), 7.48 (s, 1 H), 7.58 (m, 1 H), 7.88 (m, 
5 H). 13C NMR (100 MHz, DMSO-D6) δ 107.7 (CH), 114.9 (CH), 119.6 (CH), 122.3 (CH), 
126.7 (CH), 129.5 (CH), 130.5 (CH), 130.5 (C), 136.2 (C), 149.5 (C), 150.1 (C), 152.8 (C), 
161.1 (C), 164.8 (C). 
N
N
N
O
OH
Br
90b
 
90b; Prepared according to the method A using 1H-benzoimidazol-2-ylamine as the amine in 
the step A3; pale yellow solid; 96% yield, 91% purity (HPLC-ESI-MS, 210-400 nm), 
C17H10BrN3O2, M = 368.19 g/mol, HPLC-ESI-MS: [M + H]+ = 368 m/z. 1H NMR (400 MHz, 
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DMSO-D6) δ 6.75 (m, 1 H) 7.26 (m, 1 H) 7.49 (m, 1 H) 7.58 (m, 1 H) 7.75 (m, 2 H) 7.95 (m, 
3 H). 
N
N
N
O
OH
S
Cl
90c
 
90c; Prepared according to the method A using 1H-benzoimidazol-2-ylamine as the amine in 
the step A3; brown solid; 86% yield, 90% purity (HPLC-ESI-MS, 210-400 nm), 
C15H8ClN3O2S, M = 329.77 g/mol, HPLC-ESI-MS: [M + H]+ = 330 m/z. 
N
H O
OH
NN
N
Cl
91a
 
91a; Prepared according to the method A (steps A1-A3, A5) using [1,2,4]triazol-3-ylamine as 
the amine in the step A3; brown solid; 87% yield, 86% purity (HPLC-ESI-MS, 210-400 nm), 
C12H9ClN4O2, M = 276.68 g/mol, HPLC-ESI-MS: [M + H]+ = 277 m/z. 
N
H O
OH
NN
N
Br
91b
 
91b; Prepared according to the method A (steps A1-A3, A5) using [1,2,4]triazol-3-ylamine as 
the amine in the step A3; brown solid; 81% yield, 93% purity (HPLC-ESI-MS, 210-400 nm), 
C12H9BrN4O2, M = 321.14 g/mol, HPLC-ESI-MS: [M + H]+ = 321 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 5.76 (d, J = 3.05 Hz, 1 H), 6.27 (d, J = 3.56 Hz, 1 H), 7.16 (m, 2 H), 7.56 (m, 2 
H), 7.64 (s, 1 H), 9.97 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 58.7 (CH), 105.6 (CH), 
121.5 (C), 127.8 (C), 129.0 (CH), 131.7 (CH), 140.2 (C), 150.0 (CH), 162.8 (C). 
N
H O
OH
NN
N
S
Cl
91c
 
91c; Prepared according to the method A (steps A1-A3, A5) using [1,2,4]triazol-3-ylamine as 
the amine in the step A3; brown solid; 70% yield, 80% purity (HPLC-ESI-MS, 210-400 nm), 
C10H7ClN4O2S, M = 282.71 g/mol, HPLC-ESI-MS: [M + H]+ = 283 m/z. 
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N
NN
N
O
OH
Cl
92a
 
92a; Prepared according to the method A using [1,2,4]triazol-3-ylamine as the amine in the 
step A3; brown solid; 82% yield, 89% purity (HPLC-ESI-MS, 210-400 nm), C12H7ClN4O2, M 
= 274.67 g/mol, HPLC-ESI-MS: [M + H]+ = 275 m/z. 
N
NN
N
O
OH
Br
92b
 
92b; Prepared according to the method A using [1,2,4]triazol-3-ylamine as the amine in the 
step A3; pale solid; 63% yield, 82% purity (HPLC-ESI-MS, 210-400 nm), C12H7BrN4O2, M = 
319.12 g/mol, HPLC-ESI-MS: [M + H]+ = 319 m/z. 1H NMR (400 MHz, DMSO-D6) δ 7.85 
(m, 2 H), 8.01 (s, 1 H), 8.18 (m, 2 H), 8.88 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 109.0 
(CH), 125.8 (C), 128.6 (C), 131.7 (CH), 131.8 (CH), 147.2 (C), 152.6 (C), 155.3 (C), 157.2 
(CH), 164.7 (C). 
N
NN
N
O
OH
S
Cl
92c
 
92c; Prepared according to the method A using [1,2,4]triazol-3-ylamine as the amine in the 
step A3; brown solid; 74% yield, 98% purity (HPLC-ESI-MS, 210-400 nm), C10H5ClN4O2S, 
M = 280.69 g/mol, HPLC-ESI-MS: [M + H]+ = 281 m/z. 1H NMR (400 MHz, DMSO-D6) δ 
7.45 (d, J = 4.07 Hz, 1 H), 8.41 (s, 1 H), 8.59 (d, J = 4.32 Hz, 1 H), 8.94 (s, 1 H), 14.15 (s, 1 
H). 13C NMR (100 MHz, DMSO-D6) δ 105.0 (CH), 128.0 (C), 128.3 (CH), 133. 5 (CH), 
138.7 (C), 140.8 (C), 152.1 (C), 154.8 (C), 156.8 (CH), 164.8 (C). 
 
6. 1. 2. 5 Synthesis of pyridine N-oxides.  
6. 1. 2. 5. 1 General procedure for the synthesis of pyridine N-oxides 93. 
5-Cyano-6-methyl-4-aryl-pyridine-2-carboxylic acid 74 (1 eq, 0.25 mmol) was dissolved in 
acetic acid (2 mL) and 30% hydrogen peroxide was added (2 mL). The mixture was stirred for 
2 h at 80 ºC and then kept at room temperature for 16 h. The resulting crystals were filtered, 
washed with acetic acid and water, and air dried to give the product 93. 
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N
+
O
OH
NC
O
F
93a
 
93a; colorless crystals; 62% yield, C14H9FN2O3, M = 272.24 g/mol, HPLC-ESI-MS: [M + H]+ 
= 273 m/z. 1H NMR (400 MHz, CDCl3) δ 2.76 (s, 3 H), 7.46 (m, 2 H), 7.65 (m, 2 H), 8.25 (s, 
1 H). 13C NMR (100 MHz, CDCl3) δ 16.9 (CH3), 113.9 (C), 114.4 (C), 116.3 (d, 2JC-F = 21.23 
Hz, CH), 121.9 (d, 2JC-F = 13.9 Hz, C), 125.3 (d, 3JC-F = 3.66 Hz, CH), 126.6 (CH), 131.2 (d, 
4JC-F = 1.46 Hz, CH), 133.1 (d, 3JC-F = 8.05 Hz, CH), 139.1 (C), 139.5 (C), 153.3 (C), 158.6 
(d, 1JC-F =248.10, C), 160.3 (C). 
N
+
O
OH
NC
O
F
93b
 
93b; yellow crystals; 60% yield, C14H9FN2O3, M = 272.24 g/mol, HPLC-ESI-MS: [M + H]+ = 
273 m/z. m.p. 160-162 °C. 1H NMR (400 MHz, CDCl3) δ 2.95 (s, 3 H), 7.29 (m, 2 H), 7.66 
(m, 2 H), 8.45 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 17.2 (CH3), 113.6 (C), 113.6 (C), 
116.9 (d, 2JC-F = 21.95 Hz, CH), 127.3 (CH), 129.6 (d, 4JC-F = 3.66 Hz, C), 130.7 (d, 3JC-F = 
8.78, CH), 138.6 (C), 144.7 (C), 153.8 (C), 160.1 (C), 164.5 (d, 1JC-F = 253.95, C). IR (neat, 
cm-1) λmax: 3347, 3071, 2991, 2926, 2867, 2809, 2221, 1735, 1655, 1510, 1401, 1365, 1292, 
1241, 1161, 1060, 1002, 907, 828, 777. FT-ICR-MS: calculated for C14H9FN2O3Na+: 
295.0489, found: 295.0490. 
N
+
O
OH
NC
O
Cl
93c
 
93c; colorless crystals; 50% yield, C14H9ClN2O3, M = 288.69, HPLC-ESI-MS: [M + H]+ = 
289 m/z. 1H NMR (400 MHz, CDCl3) δ 2.76 (s, 3 H), 7.72 (m, 4 H), 8.23 (s, 1 H). 13C NMR 
(100 MHz, CDCl3) δ 16.9 (CH3), 113.1 (C), 114.4 (C), 125.5 (CH), 129.2 (CH), 130.6 (CH), 
132.8 (C), 135.7 (C), 139.2 (C), 143.5 (C), 153.3 (C), 160.3 (C). 
N
+
O
OH
NC
O
Cl
Cl
93d
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93d; pale crystals; 56% yield, C14H2Cl2N2O3, M = 323.14, HPLC-ESI-MS: [M + H]+ = 323 
m/z. 
N
+
O
OH
NC
O
O
93e
 
93e; yellow crystals; 88% yield, C15H12N2O4, M = 284.27, HPLC-ESI-MS: [M + H]+ = 284 
m/z. 
 
6. 1. 2. 5. 2 General procedure for the synthesis of pyridine N-oxides 98. 
3-Cyano-2-methyl-6-aryl-isonicotinic acid 81 (1 eq, 0.25 mmol) was dissolved in acetic acid 
(2 mL), then 30% hydrogen peroxide was added (2 mL). After stirring for 5 h at 100 ºC the 
mixture was poured on ice/water and extracted with chloroform (3 x 10 mL). The aqueous 
phase was then concentrated in vacuo and dried by lyophilization to afford the product 98. 
N
+
O
OH
OHO
O
F
98a
 
98a; pale solid; 90% yield, C14H10FN2O5, M = 291.24, HPLC-ESI-MS: [M + H]+ = 292 m/z. 
N
+
O
OH
OHO
O
Cl
98b
 
98b; colorless solid; 75% yield, C14H10ClNO5, M = 307.69, HPLC-ESI-MS: [M + H]+ = 307 
m/z. 1H NMR (400 MHz, D2O) δ 2.47 (s, 3 H), 7.45 (m, J = 8.65 Hz, 2 H), 7.52 (m, J = 8.39 
Hz, 2 H), 7.80 (s, 1 H). 
N
+
O
OH
OHO
O
Cl
Cl
98c
 
98c; colorless crystals; 88% yield, C14H9Cl2NO5, M = 342.14, HPLC-ESI-MS: [M + H]+ = 
342 m/z. M.p. 172-173°C (dec.). 1H NMR (400 MHz, D2O) δ 2.49 (s, 3 H), 7.36 (d, J =  8.39 
Hz, 1 H), 7.47 (d, J =  8.14 Hz, 1 H), 7.64 (s, 1 H), 7.85 (s, 1 H). 13C NMR (100 MHz, D2O/ 
DMSO-D6) δ 16.7 (CH3), 128.0 (CH), 129.2 (C), 129.4 (CH), 131.0 (CH), 131.7 (C), 133.3 
(CH), 135.7 (C), 137.8 (C), 140.2 (C), 147.8 (C), 148.4 (C), 168.7 (C), 173.8 (C). IR (neat, 
cm-1) λmax: 3520, 3415, 3175, 3032, 2882, 2785, 1705, 1577, 1412, 1374, 1322, 1262, 1202, 
1142, 1092, 1052, 977, 902, 857, 812, 774, 677. FT-ICR-MS: calculated for C14H9Cl2NO5H+: 
341.9931, found: 341.9929. 
  
86 
N
+
O
OH
OHO
O
Cl
Cl
98d
 
98d; pale solid; 65% yield, C14H9Cl2NO5, M = 342.14, HPLC-ESI-MS: [M + H]+ = 342 m/z.  
N
+
O
OH
OHO
O
O
98e
 
98e; pale solid; 85% yield, C14H9Cl2NO5, M = 303.27, HPLC-ESI-MS: [M + H]+ = 304 m/z. 
 
6. 1. 2. 6 General procedure for the amidation - synthesis of 94 and 99. 
5-Cyano-6-methyl-4-aryl-pyridine-2-carboxylic acid 74 or 3-cyano-2-methyl-6-aryl-
isonicotinic acid 81 (1 eq, 0.15 mmol) was dissolved in 5 mL DCM. Benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (1.1 eq, 0.17 mmol 0.864 g) and 
triethylamine (2 eq, 0.30 mmol, 41 µl) were successively added followed by addition of amine 
or 1-hydroxybenzotriazol ammonium salt (1.5 eq, 0.23 mmol, 0.035 g). After 3 h stirring at 
room temperature (the reaction monitored by TLC), the solvent was removed and the product 
as a solid was isolated by filtration on silica gel. 
N
O
NH2
NC
F
94a-1  
94a-1; pale solid; 90% yield, C14H10FN3O, M = 255.25 g/mol, HPLC-ESI-MS: [M + H]+ = 
256 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.82 (s, 3 H), 6.08 (s, 1 H), 7.22 (m, 2 H), 7.37 (m, 1 
H), 7.45 (m, 1 H), 7.81 (s, 1 H), 8.11 (s, 1 H). 
N
O
N
H
NC
F
94a-2
 
94a-2; colorless solid; 89% yield, C15H12FN3O, M = 269.28 g/mol, HPLC-ESI-MS: [M + H]+ 
= 270 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.86 (s, 3 H), 3.06 (d, J = 5.34 Hz, 3 H), 7.27 (m, 2 
H), 7.43 (m, 1 H), 7.51 (m, 1 H), 8.04 (s, 1 H), 8.16 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 
23.9 (CH3), 26.3 (CH3), 111.4 (C), 115.8 (C), 116.5 (d, 2JC-F = 21.95 Hz, CH), 120.7 (CH), 
123.6 (d, 2JC-F = 14.64 Hz, C), 124.8 (d, 3JC-F = 3.66 Hz, CH), 130.6 (d, 4JC-F = 1.64 Hz, CH), 
132.3 (d, 3JC-F = 8.78 Hz, CH), 149.8 (C), 151.1 (C), 159.1 (d, 1JC-F =251.03, C), 161.2 (C), 
163.3 (C). 
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N
O
N
H
NC
F
93a-3
 
94a-3; pale solid; 99% yield, C17H14FN3O, M = 295.32 g/mol, HPLC-ESI-MS: [M + H]+ = 
296 m/z. 1H NMR (400 MHz,  CDCl3) δ 0.70 (m, 2 H), 0.91 (m, 2 H), 2.85 (s, 3 H), 2.95 (m, 
1 H), 7.28 (m, 2 H), 7.41 (m, 1 H), 7.51 (m, 1 H), 8.04 (s, 1 H), 8.15 (s, 1 H). 13C NMR (100 
MHz, CDCl3) δ 6.6 (CH2), 22.7 (CH), 23.9 (CH3), 111.5 (C), 115.8 (C), 116.5 (d, 2JC-F = 
21.95 Hz, CH), 120.6 (CH), 123.6 (d, 2JC-F = 14.64 Hz, C), 124.8 (d, 3JC-F = 3.66 Hz, CH), 
130.6 (d, 4JC-F = 2.19 Hz, CH), 132.3 (d, 3JC-F = 8.78 Hz, CH), 149.8 (C), 150.9 (C), 159.1 (d, 
1JC-F =251.03, C), 161.2 (C), 164.03 (C). 
N
O
N
NC
F
93a-4
 
94a-4; colorless solid; 95% yield, C18H16FN3O, M = 209.35 g/mol, HPLC-ESI-MS: [M + H]+ 
= 310 m/z. 1H NMR (400 MHz,  CDCl3) δ 1.95 (m, 4 H), 2.86 (s, 3 H), 3.68 (m, 2 H), 3.76 
(m, 2 H), 7.23 (m, 1 H), 7.29 (m, 1 H), 7.42 (m, 1 H), 7.49 (m, 1 H), 7.78 (s, 1 H). 13C NMR 
(100 MHz, CDCl3) δ 23.9 (CH3), 24.0 (CH2), 26.6 (CH2), 47.1 (CH2), 49.1 (CH2), 109.9 (C), 
115.9 (C), 116.4 (d, 2JC-F = 21.22 Hz, CH), 122.3 (CH), 123.7 (d, 2JC-F = 14.64 Hz, C), 124.7 
(d, 3JC-F = 3.66 Hz, CH), 130.6 (d, 4JC-F = 2.19 Hz, CH), 132.1 (d, 3JC-F = 8.78 Hz, CH), 148.9 
(C), 155.9 (C), 159.1 (d, 1JC-F =251.02, C), 161.2 (C), 164.7 (C). 
N
O
N
NC
F
O
94a-5
 
94a-5; colorless solid; 89% yield, C18H16FN3O2, M = 325.35 g/mol, HPLC-ESI-MS: [M + 
H]+ = 326 m/z. 
N
N
NC
F
O
O
O
94a-6
 
94a-6; colorless solid; 90% yield, C22H22FN3O3, M = 395.44 g/mol, HPLC-ESI-MS: [M + 
H]+ = 396 m/z. 
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N
N
H
NC
F
O
94b-1
 
94b-1; colorless solid; 94% yield, C17H14FN3O, M = 295,32 g/mol, HPLC-ESI-MS: [M + H]+ 
= 296 m/z. 1H NMR (400 MHz,  CDCl3) δ 0.68 (m, 2 H), 0.90 (m, 2 H), 2.83 (s, 3 H), 2.94 
(m, 1 H), 7.21 (t, J = 8.65 Hz, 2 H), 7.61 (m, 2 H), 8.03 (s, 1 H), 8.13 (s, 1 H). 13C NMR (100 
MHz, CDCl3) δ 6.6 (CH2), 22.7 (CH), 23.9 (CH3), 109.6 (C), 116.3 (d, 2JC-F = 21.96, CH), 
116.3 (C), 119.3 (CH), 130.6 (d, 3JC-F = 8.78, CH), 131.6 (d, 4JC-F = 3.66, C), 150.9 (C), 153.8 
(C), 161.7 (C), 163.5 (d, 1JC-F = 251.76, C), 165.2 (C).  
N
N
NC
F
O
94b-2
 
94b-2; colorless solid; 99% yield, C18H16FN3O, M = 309.35 g/mol, HPLC-ESI-MS: [M + H]+ 
= 310 m/z. 1H NMR (400 MHz,  CDCl3) δ 1.95 (m, 4 H) 2.85 (s, 3 H) 3.72 (m, 4 H) 7.21 (m, 
2 H) 7.60 (m, J = 8.77, 5.21 Hz, 2 H) 7.78 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.8 
(CH2), 24.1 (CH3), 26.6 (CH2), 47.1 (CH2), 49.1 (CH2), 108.2 (C), 116.3 (d, 2JC-F = 21.96, 
CH), 116.4 (C), 121.3 (CH), 130.5 (d, 3JC-F = 8.78, CH), 131.8 (d, 4JC-F = 2.93, C), 153.1 (C), 
156.0 (C), 161.7 (C), 163.9 (d, 1JC-F = 251.03, C), 165.1 (C).  
N
O
NH2
NC
F
F
94c-1
 
94c-1; pale solid; 86% yield, C14H9F2N3O, M = 273.24 g/mol, HPLC-ESI-MS: [M + H]+ = 
274 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.88 (s, 3 H), 6.11 (s, 1 H), 7.04 (m, 2 H), 7.44 (m, 1 
H), 7.87 (s, 1 H), 8.14 (s, 1 H). 
N
O
N
H
NC
F
F
94c-2
 
94c-2; colorless solid; 75% yield, C15H11F2N3O, M = 287.27 g/mol, HPLC-ESI-MS: [M + H]+ 
= 288 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.86 (s, 3 H), 3.06 (d, J = 5.09 Hz, 3 H), 7.03 (m, 2 
H), 7.42 (m, 1 H), 8.02 (s, 1 H), 8.13 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 24.0 (CH3), 
26.3 (CH3), 105.1 (t, 2JC-F = 25.25, CH), 111.4 (C), 112.4 (dd, 2,4JC-F = 21.79, 3.66 Hz, CH), 
115.6 (C), 119.8 (dd, 2,4JC-F = 14.65, 4.36 Hz, C), 120.4 (CH), 131.7 (dd, 3JC-F = 10.06, 3.66 
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Hz, CH), 148.8 (C), 151.2 (C), 159.6 (dd, 1,3JC-F = 254.23, 12.45 Hz, C), 161.3 (C), 163.2 (C), 
164.2 (dd, 1,3JC-F = 254.07, 11.72 Hz, C). 
N
O
N
H
NC
F
F
O
O
94c-3
 
94c-3; yellow solid; 82% yield, C17H13F2N3O3, M = 345.31 g/mol, HPLC-ESI-MS: [M + H]+ 
= 346 m/z. 
N
O
N
H
NC
F
F
94c-4
 
94c-4; colorless solid; 81% yield, C17H13F2N3O, M = 313,31 g/mol, HPLC-ESI-MS: [M + H]+ 
= 314 m/z. 1H NMR (400 MHz,  CDCl3) δ 0.68 (m, 2 H), 0.89 (m, 2 H), 2.83 (s, 3 H), 2.93 
(m, 1 H), 7.02 (m, 2 H), 7.41 (m, 1 H), 8.03 (s, 1 H), 8.11 (s, 1 H). 13C NMR (100 MHz, 
CDCl3) δ 6.6 (CH2), 22.7 (CH), 23.8 (CH3), 105.1 (t, 2JC-F = 25.25, CH), 111.4 (C), 112.3 (dd, 
2,4JC-F = 21.79, 3.66 Hz, CH), 115.6 (C), 119.8 (dd, 2,4JC-F = 14.65, 4.36 Hz, C), 120.4 (CH), 
131.7 (dd, 3JC-F = 9.50, 4.16 Hz, CH), 148.7 (C), 150.0 (C), 159.5 (dd, 1,3JC-F = 253.19, 12.45 
Hz, C), 161.3 (C), 163.9 (C), 164.2 (dd, 1,3JC-F = 253.66, 12.59 Hz, C). 
N
O
N
NC
F
F
94c-5
 
94c-5; colorless solid; 94% yield, C16H13F2N3O, M = 301.30 g/mol, HPLC-ESI-MS: [M + H]+ 
= 302 m/z. 
N
O
N
NC
F
F
94c-6
 
94c-6; pale solid; 76% yield, C18H15F2N3O, M = 327.34 g/mol, HPLC-ESI-MS: [M + H]+ = 
302 m/z. 
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N
O
N
NC
F
F
O
94c-7
 
94c-7; colorless solid; 87% yield, C18H15F2N3O2, M = 343.34 g/mol, HPLC-ESI-MS: [M + 
H]+ = 344 m/z. 
N
O
N
NC
F
F
O
O
94c-8
 
94c-8; yellow solid; 76% yield, C22H21F2N3O3, M = 413.43 g/mol, HPLC-ESI-MS: [M + H]+ 
= 414 m/z. 
N
N
H
NC
F
F
O N O94c-9
 
94c-9; colorless solid; 71% yield, C18H12F2N4O2, M = 354.32 g/mol, HPLC-ESI-MS: [M + 
H]+ = 355 m/z. 1H NMR (400 MHz,  CDCl3) δ 2.46 (s, 3 H), 2.92 (s, 3 H), 6.85 (s, 1 H), 7.06 
(m, 2 H), 7.46 (m, 1 H), 8.18 (s, 1 H), 10.40 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 12.7 
(CH3), 23.9 (CH3), 96.1 (CH), 105.2 (t, 2JC-F = 25.62, CH), 112.5 (dd, 2,4JC-F = 21.56, 3.66 Hz, 
CH), 115.5 (C), 119.6 (dd, 2,4JC-F = 14.37, 3.66 Hz, C), 121.1 (CH), 131.7 (dd, 3JC-F = 9.80, 
3.30 Hz, CH), 149.2 (C), 149.7 (C), 159.6 (dd, 1,3JC-F = 253.50, 12.45 Hz, C), 160.5 (C), 
161.9 (C), 164.4 (dd, 1,3JC-F = 255.97, 12.44 Hz, C), 170.5 (C).  
N
O
NH2
NC
Cl
94d-1
 
94d-1; colorless solid; 73% yield, C14H10ClN3O, M = 271.71 g/mol, HPLC-ESI-MS: [M + 
H]+ = 272 m/z; m.p. 214-216 °C (dec.). 1H NMR (400 MHz, DMSO-D6) δ 2.81 (s, 3 H), 7.69 
(m, 4 H), 7.96 (s, 2 H), 8.28 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.7 (CH3), 109.2 
(C), 116.5 (C), 119.2 (CH), 129.1 (CH), 130.5 (CH), 134.4 (C), 135.2 (C), 151.8 (C), 152.6 
(C), 161.6 (C), 164.6 (C). IR (neat, cm-1) λmax: 3449, 3360, 3277, 3155, 3041, 2218, 1707, 
1643, 1580, 1535, 1490, 1420, 1382, 1356, 1318, 1241, 1152, 1095, 1018, 910, 852, 827, 699. 
FT-ICR-MS: calculated for C14H10ClN3ONa+: 294.0405, found: 294.0404. 
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N
O
N
H
NC
Cl
94d-2
 
94d-2; colorless solid; 79% yield, C15H12ClN3O, M = 285.74 g/mol, HPLC-ESI-MS: [M + 
H]+ = 286 m/z. 
N
O
NH2
NC
Cl
Cl
94e-1
 
94e-1; colorless solid; 80% yield, C14H9Cl2N3O, M = 306.15 g/mol, HPLC-ESI-MS: [M + 
H]+ = 306 m/z. 1H NMR (400 MHz, CDCl3) δ 2.88 (s, 3 H), 6.14 (s, 1 H), 7.26 (d, J = 8.14 
Hz, 1 H), 7.40 (dd, J = 8.14, 2.03 Hz, 1 H), 7.57 (d, J = 2.03 Hz, 1 H), 7.84 (s, 1 H), 8.10 (s, 
1 H). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH3), 112,0 (C), 115.3 (C), 120.9 (CH), 127.7 
(CH), 130.3 (CH), 131.1 (CH), 133.1 (C), 133.2 (C), 136.8 (C), 150.7 (C), 151.9 (C), 161.5 
(C), 164.9 (C). 
N
O
N
H
NC
Cl
Cl
94e-2
 
94e-2; colorless solid; 83% yield, C15H11Cl2N3O, M = 320.18 g/mol, HPLC-ESI-MS: [M + 
H]+ = 320 m/z. 1H NMR (400 MHz, CDCl3) δ 2.85 (s, 3 H), 3.06 (d, J = 5.09 Hz, 3 H), 7.25 
(d, J = 8.14 Hz, 1 H), 7.39 (dd, J = 8.27, 1.91 Hz, 1 H), 7.56 (d, J = 2.03 Hz, 1 H), 8.03 (m, 
1 H), 8.09 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH3) 26.3 (CH3) 111.6 (C) 115.4 (C) 
120.6 (CH) 127.7 (CH) 130.2 (CH) 131.1 (CH) 133.2 (C) 133.2 (C) 136.7 (C) 151.1 (C) 
151.9 (C) 161.1 (C) 163.2 (C). 
N
O
N
H
NC
Cl
Cl
O
O
94e-3
 
94e-3; colorless solid; 99% yield, C17H13Cl2N3O3, M = 378.22 g/mol, HPLC-ESI-MS: [M + 
H]+ = 378 m/z. 1H NMR (400 MHz, CDCl3) δ 2.87 (s, 3 H), 3.79 (s, 3 H), 4.27 (d, J = 5.85 
Hz, 2 H), 7.25 (d, J = 8.14 Hz, 1 H), 7.39 (dd, J = 8.27, 1.91 Hz, 1 H), 7.56 (d, J = 2.03 Hz, 1 
H), 8.07 (s, 1 H), 8.45 (t, J = 5.34 Hz, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH3), 41.3 
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(CH2), 53.5 (CH3), 112.0 (C), 115.2 (C), 120.8 (CH), 127.7 (CH), 130.2 (CH), 131.1 (CH), 
133.1 (C), 133.1 (C), 136.8 (C), 150.4 (C), 151.9 (C), 161.4 (C), 161.8 (C), 169.8 (C). 
N
O
N
H
NC
Cl
Cl
NH2
O
94e-4
 
94e-4; colorless solid; 99% yield, C16H12Cl2N4O2, M = 363.21 g/mol, HPLC-ESI-MS: [M + 
H]+ = 363 m/z. 
N
O
N
H
NC
Cl
Cl
94e-5
 
94e-5; colorless solid; 88% yield, C17H13Cl2N3O, M = 346.22 g/mol, HPLC-ESI-MS: [M + 
H]+ = 346 m/z. 1H NMR (400 MHz, CDCl3) δ 0.69 (m, 2 H), 0.91 (m, 2 H), 2.84 (s, 3 H), 2.94 
(m, 1 H), 7.24 (d, J = 8.14 Hz, 1 H), 7.39 (dd, J = 8.14, 2.03 Hz, 1 H), 7.56 (d, J = 2.03 Hz, 1 
H), 8.03 (s, 1 H), 8.08 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 6.6 (CH2), 22.7 (CH), 23.8 
(CH3), 111.7 (C), 115.4 (C), 120.4 (CH), 127.7 (CH), 130.2 (CH), 131.1 (CH), 133.2 (C), 
133.1 (C), 136.8 (C), 151.0 (C), 151.9 (C), 161.1 (C), 163.9 (C). 
N
O
N
NC
Cl
Cl
94e-6
 
94e-6; colorless solid; 99% yield, C16H13Cl2N3O, M = 334.21 g/mol, HPLC-ESI-MS: [M + 
H]+ = 334 m/z. 
N
O
N
NC
Cl
Cl
94e-7
 
94e-7; colorless solid; 78% yield, C18H15Cl2N3O, M = 360.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 360 m/z. 1H NMR (400 MHz, CDCl3) δ 1.95 (m, 4 H), 2.85 (s, 3 H), 3.68 (t, J = 6.49 
Hz, 2 H), 3.78 (m, 2 H), 7.26 (d, J = 8.39 Hz, 1 H), 7.39 (dd, J = 8.27, 1.91 Hz, 1 H), 7.56 (d, 
J = 2.03 Hz, 1 H), 7.72 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH2), 23.9 (CH3), 26.6 
(CH2), 47.2 (CH2), 49.1 (CH2), 110.0 (C), 115.5 (C), 122.2 (CH), 127.7 (CH), 130.2 CH), 
131.2 (CH), 133.1 (C), 133.3 (C), 136.6 (C), 151.0 (C), 155.8 (C), 161.1 (C), 164.4 (C). 
  
93
N
O
N
NC
Cl
Cl
O
94e-8
 
94e-8; colorless solid; 81% yield, C18H15Cl2N3O2, M = 376.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 376 m/z. 
N
O
N
NC
Cl
Cl
O
O
94e-9
 
94e-9; yellow solid; 87% yield, C22H21Cl2N3O3, M = 446.34 g/mol, HPLC-ESI-MS: [M + H]+ 
= 446 m/z. 
N
O
N
H
NC
Cl
Cl
N O94e-10
 
94e-10; colorless solid; 85% yield, C18H12Cl2N4O2, M = 387.23 g/mol, HPLC-ESI-MS: [M + 
H]+ = 387 m/z. 
N
O
NH2
NC
Br
94f
 
94f; colorless solid; 63% yield, C14H10BrN3O, M = 316.16 g/mol, HPLC-ESI-MS: [M + H]+ = 
316 m/z. 
N
O
NH2
NC
O
94g-1
 
94g-1; colorless solid; 67% yield, C15H13N3O2, M = 267.29 g/mol, HPLC-ESI-MS: [M + H]+ 
= 268 m/z. 
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N
O
N
H
NC
O
94g-2
 
94g-2; colorless solid; 60% yield, C16H15N3O2, M = 281.32 g/mol, HPLC-ESI-MS: [M + H]+ 
= 282 m/z. 
N
O
N
H
NC
O
O
O
94g-3
 
94g-3; colorless solid; 93% yield, C18H17N3O4, M = 339.35 g/mol, HPLC-ESI-MS: [M + H]+ 
= 340 m/z. 
N
O
N
H
NC
O
94g-4
 
94g-4; colorless solid; 79% yield, C18H17N3O2, M = 307.36 g/mol, HPLC-ESI-MS: [M + H]+ 
= 308 m/z; m.p. 157 °C. 1H NMR (400 MHz, CDCl3) δ 0.63 (m, 2 H), 0.84 (m, 2 H), 2.76 (s, 
3 H), 2.89 (m, 1 H), 3.81 (s, 3 H), 6.98 (m, 2 H), 7.55 (m, 2 H), 8.00 (s, 1 H), 8.08 (s, 1 H). 
13C NMR (100 MHz, CDCl3) δ 6.6 (CH2), 22.7 (CH), 24.0 (CH3), 55.4 (CH3), 109.2 (C), 
114.5 (CH), 116.8 (C), 119.2 (CH), 127.8 (C), 130.1 (CH), 150.6 (C), 154.5 (C), 161.4 (C), 
161.7 (C), 164.3 (C). IR (neat, cm-1) λmax: 3332, 3077, 2920, 2852, 2222, 1660, 1629, 1607, 
1577, 1547, 1509, 1427, 1359, 1277, 1239, 1157, 984, 917, 842, 774, 699. FT-ICR-MS: 
calculated for C18H17N3O2H+: 308.1394, found: 308.1393. 
N
O
N
NC
O
94g-5
 
94g-5; colorless solid; 99% yield, C17H17N3O2, M = 295.34 g/mol, HPLC-ESI-MS: [M + H]+ 
= 296 m/z. 
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94g-6; colorless solid; 99% yield, C19H19N3O2, M = 321.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 322 m/z. 
N
O
N
NC
O
O
94g-7
 
94g-7; colorless solid; 99% yield, C19H19N3O3, M = 337.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 338 m/z. 
N
N
NC
O
O
O O94g-8
 
94g-8; colorless solid; 80% yield, C21H21N3O4, M = 379.42 g/mol, HPLC-ESI-MS: [M + H]+ 
= 380 m/z. 
N
O
N
NC
O
O
O
94g-9
 
94g-9; colorless solid; 99% yield, C23H25N3O4, M = 407.47 g/mol, HPLC-ESI-MS: [M + H]+ 
= 408 m/z. 
N
O
N
H
NC
O
Cl
94g-10
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94g-10; colorless solid; 99% yield, C22H18ClN3O2, M = 391.86 g/mol, HPLC-ESI-MS: [M + 
H]+ = 392 m/z. 
N
O
N
H
NC
O
Cl
Cl
94g-11
 
94g-11; colorless solid; 99% yield, C22H17Cl2N3O2, M = 426.31 g/mol, HPLC-ESI-MS: [M + 
H]+ = 426 m/z; m.p. 152 °C. 1H NMR (400 MHz, CDCl3) δ 2.83 (s, 3 H), 3.87 (s, 3 H), 4.63 
(d, J =  6.36 Hz, 2 H), 7.04 (m, 2 H), 7.20 (m, 1 H), 7.40 (d, J =  8.39 Hz, 1 H), 7.44 (d, J =  
2.03 Hz, 1 H), 7.62 (m, 2 H), 8.17 (s, 1 H), 8.44 (m, 1 H). 13C NMR (100 MHz, CDCl3) δ 
24.0 (CH3), 42.5 (CH2), 55.4 (CH3), 109.5 (C), 114.6 (CH), 116.8 (C), 119.6 (CH), 127.1 
(CH), 127.6 (C), 129.7 (CH), 130.1 (CH), 130.7 (CH), 131.7 (C), 132.8 (C), 138.2 (C), 150.3 
(C), 154.6 (C), 161.5 (C), 161.9 (C), 163.2 (C). IR (neat, cm-1) λmax: 3415, 3385, 2927, 2357, 
2222, 1735, 1682, 1517, 1457, 1352, 1269, 1232, 1179, 1142, 1059, 999, 887, 797. FT-ICR-
MS: calculated for C22H17Cl2N3O2Na+: 448.0590, found: 448.0591.  
N
O
N
H
NC
O
S
94g-12
 
94g-12; colorless solid; 81% yield, C20H17N3O2S, M = 363.44 g/mol, HPLC-ESI-MS: [M + 
H]+ = 364 m/z; m.p. 178 °C. 1H NMR (400 MHz, CDCl3) δ 2.82 (s, 3 H), 3.87 (s, 3 H), 4.84 
(d, J =  6.10 Hz, 2 H), 6.97 (m, 1 H), 7.05 (m, 3 H), 7.24 (m, 1 H), 7.62 (m, 2 H), 8.18 (s, 1 
H), 8.40 (t, J =  5.47 Hz, 1 H). 13C NMR (100 MHz, CDCl3) δ 24.0 (CH3), 38.3 (CH2), 55. 
(CH3), 109.3 (C), 114.5 (CH), 116.8 (C), 119.6(CH), 125.4 (CH), 126.3 (CH), 127.0 (CH), 
127.7 (C), 130.1 (CH), 140.3 (C), 150.5 (C), 154.5 (C), 161.4 (C), 161.8 (C), 162.8 (C). IR 
(neat, cm-1) λmax: 3325, 3077, 2935, 2882, 2222, 1652, 1629, 1599, 1577, 1539, 1517, 1427, 
1359, 1284, 1232, 1142, 1074, 924, 834, 684. FT-ICR-MS: calculated for C20H17N3O2SNa+: 
386.0934, found: 386.0936. 
N
O
N
H
NC
O
S
N
94g-13
 
94g-13; colorless solid; 79% yield, C18H14N4O2S, M = 350.40 g/mol, HPLC-ESI-MS: [M + 
H]+ = 351 m/z. 
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94g-14; colorless solid; 69% yield, C22H20N4O4S, M = 436.49 g/mol, HPLC-ESI-MS: [M + 
H]+ = 437 m/z. 
N
O
N
H
NC
O
N
N
94g-15
 
94g-15; yellow solid; 99% yield, C20H19N5O2, M = 361.41 g/mol, HPLC-ESI-MS: [M + H]+ = 
362 m/z; m.p. 196 °C. 1H NMR (400 MHz, CDCl3) δ 2.26 (s, 3 H), 2.90 (s, 3 H), 3.78 (s, 3 H), 
3.87 (s, 3 H), 6.28 (s, 1 H), 7.05 (m, 2 H), 7.64 (m, 2 H), 8.22 (s, 1 H), 9.80 (s, 1 H). 13C 
NMR (100 MHz, CDCl3) δ 13.9 (CH3), 24.1 (CH3), 35.2 (CH3), 55.4 (CH3), 98.6 (CH), 110.0 
(C), 114.7 (CH), 116.6 (C), 119.8 (CH), 127.3 (C), 130.1 (CH), 135.2 (C), 147.7 (C), 149.5 
(C), 155.0 (C), 160.4 (C), 161.6 (C), 162.0 (C). IR (neat, cm-1) λmax: 3210, 2901, 2856, 1735, 
1661, 1550, 1462, 1417, 1358, 1285, 1211, 1181, 1100, 1041, 982, 717. FT-ICR-MS: 
calculated for C20H19N5O2H+: 362.1612, found: 362.1613. 
N
O
N
H
NC
O
N O
94g-16
 
94g-16; yellow solid; 26% yield, C19H16N4O3, M = 348.36 g/mol, HPLC-ESI-MS: [M + H]+ = 
349 m/z. 
N
O
NH2
NC
O
O
94h
 
94h; pale solid; 99% yield, C15H11N3O3, M = 281.27 g/mol, HPLC-ESI-MS: [M + H]+ = 282 
m/z
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94i-1; yellow solid; 86% yield, C19H20N4O, M = 320.40 g/mol, HPLC-ESI-MS: [M + H]+ = 
321 m/z. 
N
O
N
NC
N
94i-2
 
94i-2; yellow solid; 66% yield, C20H22N4O, M = 334.42 g/mol, HPLC-ESI-MS: [M + H]+ = 
335 m/z. 
N
O
NH2
NC
O
94j-1
 
94j-1; pale solid; 99% yield, C12H9N3O2, M = 227.22 g/mol, HPLC-ESI-MS: [M + H]+ = 228 
m/z. 
N
O
N
H
NC
O
94j-2
 
94j-2; colorless solid; 99% yield, C13H11N3O2, M = 241.25 g/mol, HPLC-ESI-MS: [M + H]+ 
= 242 m/z. 1H NMR (400 MHz, CDCl3) δ 2.83 (s, 3 H), 3.07 (d, J = 5.09 Hz, 3 H), 6.64 (m, 1 
H), 7.61 (m, 1 H), 7.69 (m, 1 H), 8.03 (s, 1 H), 8.48 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 
24.0 (CH3), 26.3 (CH3), 103.8 (C), 113.0 (CH), 114.83 (CH), 114.84 (CH), 117.0 (C), 141.6 
(C), 145.6 (CH), 147.9 (C), 151.2 (C), 162.0 (C), 163.6 (C).   
N
O
N
H
NC
O
94j-3
 
94j-3; colorless solid; 87% yield, C15H13N3O2, M = 267.29 g/mol, HPLC-ESI-MS: [M + H]+ 
= 268 m/z. 
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94j-4; colorless solid; 99% yield, C14H13N3O2, M = 255.28 g/mol, HPLC-ESI-MS: [M + H]+ 
= 256 m/z. 
N
O
N
NC
O
94j-5
 
94j-5; colorless solid; 93% yield, C16H15N3O2, M = 281.32 g/mol, HPLC-ESI-MS: [M + H]+ 
= 282 m/z. 
N
O
N
NC
O
O
94j-6
 
94j-6; colorless solid; 99% yield, C16H15N3O3, M = 297.32 g/mol, HPLC-ESI-MS: [M + H]+ 
= 298 m/z. 
N
O
N
H
NC
O
S
N
94j-7
 
94j-7; pale solid; 99% yield, C15H10N4O2S, M = 310.34 g/mol, HPLC-ESI-MS: [M + H]+ = 
311 m/z. 
N
O
N
NC
S
94k
 
94k; pale solid; 81% yield, C16H15N3OS, M = 297.38 g/mol, HPLC-ESI-MS: [M + H]+ = 298 
m/z. 
N
O
N
H
NC
S
94l-1
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94l-1; colorless solid; 86% yield, C15H13N3OS, M = 283.35 g/mol, HPLC-ESI-MS: [M + H]+ 
= 284 m/z. 
N
O
N
NC
S
94l-2
 
94l-2; colorless solid; 80% yield, C16H15N3OS, M = 297.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 298 m/z. 1H NMR (400 MHz, CDCl3) δ 1.96 (m, 4 H), 2.85 (s, 3 H), 3.73 (m, 4 H), 7.49 
(dd, J = 5.09, 3.05 Hz, 1 H), 7.53 (m, 1 H), 7.87 (s, 1 H), 7.96 (dd, J = 2.92, 1.40 Hz, 1 H). 
13C NMR (100 MHz, CDCl3) δ 24.0 (CH2), 24.2 (CH2), 26.6 (CH3), 47.2 (CH2), 49.1 (CH2), 
107.0 (C), 117.1 (C), 120.5 (CH), 127.1 (CH), 127.2 (CH), 127.2 (CH), 136.2 (C), 147.9 (C), 
156.1 (C), 162.0 (C), 165.0 (C). 
N
O
N
NC
S
O
94l-3
 
94l-3; colorless solid; 99% yield, C16H15N3O2S, M = 313.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 314 m/z. 
N
N O
NC
F99a-1
 
99a-1; colorless solid; 68% yield, C18H16FN3O, M = 309.35 g/mol, HPLC-ESI-MS: [M + H]+ 
= 310 m/z; m.p. 208 °C. 1H NMR (400 MHz, CDCl3) δ 1.98 (m, 4 H) 2.84 (s, 3 H) 3.33 (t, J = 
6.89 Hz, 2 H) 3.70 (t, J = 6.87 Hz, 2 H) 7.16 (m, 2 H) 7.58 (s, 1 H) 8.04 (m, 2 H). 13C NMR 
(100 MHz, CDCl3) δ 24.1 (CH3), 24.3 (CH2), 26.0 (CH2), 46.1 (CH2), 48.3 (CH2), 103.4 (C), 
114.3 (CH), 115.6 (C), 116.1 (d, 2JC-F = 21.95 Hz, CH), 129.5 (d, 3JC-F = 8.79 Hz, CH), 133.3 
(d, 4JC-F = 2.93 Hz, C), 149.81 (C), 158.9 (C), 162.5 (C), 164.3 (C), 164.5 (d, 1JC-F = 251.76 
Hz, C). FT-ICR-MS: calculated for C18H16FN3ONa+: 332.1170, found: 332.1169. 
N
NH O
NC
F
N
O
99a-2
 
99a-2; colorless solid; 99% yield, C18H13FN4O2, M = 336,33 g/mol, HPLC-ESI-MS: [M + 
H]+ = 336 m/z. 
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99b-1; colorless solid; 99% yield, C14H10ClN3O, M = 271.71 g/mol, HPLC-ESI-MS: [M + 
H]+ = 272 m/z; m.p. 203-205 °C (dec.). 1H NMR (400 MHz, DMSO-D6) δ 2.77 (s, 3 H), 7.60 
(m, 2 H), 8.04 (s, 1 H), 8.17 (s, 1 H), 8.21 (m, 2 H), 8.41 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.8 (CH3), 104.6 (C), 115.7 (CH), 116.1 (C), 129.1 (CH), 129.2 (CH), 135.4 
(C), 135.7 (C), 147.5 (C), 156.9 (C), 162.4 (C), 165.5 (C). IR (neat, cm-1) λmax: 3467, 3348, 
3178, 2948, 2859, 2222, 1666, 1570, 1540, 1414, 1311, 1244, 1199, 1073, 1007, 836, 733, 
651. FT-ICR-MS: calculated for C14H10ClN3ONa+: 294.0405, found: 294.0404. 
N
NH O
NC
Cl
O
O
99b-2
 
99b-2; colorless solid; 80% yield, C17H14ClN3O3, M = 343.77 g/mol, HPLC-ESI-MS: [M + 
H]+ = 344 m/z; m.p. 185 °C. FT-ICR-MS: calculated for C17H14ClN3O3Na+: 366.0616, found: 
366.0617. 
N
NH O
NC
Cl99b-3
 
99b-3; colorless solid; 95% yield, C17H14ClN3O, M = 311.27 g/mol, HPLC-ESI-MS: [M + 
H]+ = 312 m/z; m.p. 260-261 °C (decomp.). FT-ICR-MS: calculated for C17H14ClN3ONa+: 
334.0718, found: 334.0719. 
 
 
N
N O
NC
Cl99b-4
 
99b-4; colorless solid; 80% yield, C16H14ClN3O, M = 299.76 g/mol, HPLC-ESI-MS: [M + 
H]+ = 300 m/z. 1H NMR (400 MHz, ACETONE-D6) δ 2.80 (s, 3 H), 2.99 (s, 3 H), 3.11 (s, 3 
H), 7.55 (m, 2 H), 7.93 (s, 1 H), 8.22 (m, 2 H). 13C NMR (100 MHz, ACETONE-D6) δ 24.1 
(CH3), 34.7 (CH3), 38.5 (CH3), 105.0 (C), 115.5 (CH), 116.1 (C), 129.8 (CH), 129.8 (CH), 
136.8 (C), 137.1 (C), 150.9 (C), 158.6 (C), 162.9 (C), 166.3 (C). 
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99b-5; colorless solid; 99% yield, C18H16ClN3O, M = 325.80 g/mol, HPLC-ESI-MS: [M + 
H]+ = 326 m/z; m.p. 201 °C. 1H NMR (400 MHz, CDCl3) δ 1.98 (m, 4 H) 2.84 (s, 3 H) 3.32 
(m, 2 H) 3.70 (m, 2 H) 7.44 (d, J = 8.65 Hz, 2 H) 7.60 (s, 1 H) 7.98 (d, J = 8.65 Hz, 2 H). 13C 
NMR (100 MHz, CDCl3) δ 24.1 (CH3), 24.2 (CH2), 26.0 (CH2), 46.1 (CH2), 48.3 (CH2), 
103.7 (C), 114.5 (CH), 115.5 (C), 128.7 (CH), 129.2 (CH), 135.4 (C), 137.0 (C), 149.8 (C), 
158.7 (C), 162.5 (C), 164.2 (C). FT-ICR-MS: calculated for C18H16ClN3ONa+: 348.0874, 
found: 348.0873. 
N
N O
NC
Cl
O
99b-6
 
99b-6; yellow solid; 92% yield, C18H16ClN3O2, M = 341.80 g/mol, HPLC-ESI-MS: [M + H]+ 
= 342 m/z; 1H NMR (400 MHz, CDCl3) δ  2.85 (s, 3 H), 3.34 (m, 2 H), 3.71 (dd, J = 5.09, 
3.56 Hz, 2 H), 3.83 (m, 4 H), 7.46 (m, 2 H), 7.58 (s, 1 H), 7.99 (m, 2 H). FT-ICR-MS: 
calculated for C18H16ClN3O2Na+: 364.0823, found: 364.0820. 
N
N O
NC
Cl
O
O
99b-7
 
99b-7; colorless solid; 99% yield, C22H22ClN3O3, M = 411.89 g/mol, HPLC-ESI-MS: [M + 
H]+ = 412 m/z; m.p. 170 °C. 1H NMR (400 MHz, CDCl3) δ 1.25 (t, J = 7.12 Hz, 3 H) 1.88 (m, 
3 H) 2.09 (m, 1 H) 2.60 (m, 1 H) 2.84 (s, 3 H) 3.20 (m, 2 H) 3.47 (m, 1 H) 4.15 (q, J = 7.12 
Hz, 2 H) 4.47 (m, 1 H) 7.46 (m, 2 H) 7.55 (s, 1 H) 7.99 (m, 2 H). 13C NMR (100 MHz, 
CDCl3) δ 14.1 (CH3), 24.1 (CH3), 27.5 (CH2), 28.3 (CH2), 40.5 (CH), 41.2 (CH2), 46.3 (CH2), 
60.8 (CH2), 103.7 (C), 114.4 (CH), 115.3 (C), 128.7 (CH), 129.3 (CH), 135.4 (C), 137.1 (C), 
148.9 (C), 158.8 (C), 162.5 (C), 164.5 (C), 173.6 (C). FT-ICR-MS: calculated for 
C22H22ClN3O3Na+: 434.1242, found: 434.1240. 
N
NH O
NC
F
Cl99c
 
99c; colorless solid; 85% yield, C15H11ClFN3O, M = 303.73 g/mol, HPLC-ESI-MS: [M + H]+ 
= 304 m/z. 1H NMR (400 MHz, CDCl3) δ 2.85 (s, 3 H), 3.06 (d, J = 5.09 Hz, 3 H), 7.30 (m, 2 
H), 7.37 (m, 1 H), 8.03 (s, 1 H), 8.12 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH3), 
26.3 (CH3), 111.2 (C), 115.6 (C), 117.4 (d, 2JC-F = 24.88 Hz, CH), 120.5 (CH), 122.2 (d, 2JC-F 
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= 14.63 Hz, C), 125.4 (d, 3JC-F = 3.66 Hz, CH), 131.3 (d, 4JC-F = 2.93 Hz, CH), 137.6 (d, 3JC-F 
= 10.25 Hz, CH), 148.6 (C), 151.2 (C), 159.0 (d, 1JC-F =253.96, C), 161.4 (C), 163.2 (C). 
N
NH2 O
NC Cl
Cl99d-1
 
99d-1; colorless solid; 89% yield, C14H9Cl2N3O, M = 306.15 g/mol, HPLC-ESI-MS: [M + 
H]+ = 306 m/z. 
N
N O
NC Cl
Cl99d-2
 
99d-2; colorless solid; 90% yield, C18H15Cl2N3O, M = 360.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 360 m/z; m.p. 129-132 °C. 1H NMR (400 MHz, CDCl3) δ 1.99 (m, 4 H) 2.85 (s, 3 H) 
3.34 (m, 2 H) 3.69 (m, 2 H) 7.37 (dd, J = 8.39, 2.03 Hz, 1 H) 7.50 (d, J = 2.03 Hz, 1 H) 7.58 
(m, 2 H). 13C NMR (100 MHz, CDCl3) δ 24.0 (CH3), 24.2 (CH2), 26.1 (CH2), 46.1 (CH2), 
48.4 (CH2), 104.6 (C), 115.2 (C), 119.3 (CH), 127.8 (CH), 130.2 (CH), 132.5 (CH), 132.7 
(C), 135.7 (C), 136.3 (C), 148.9 (C), 158.4 (C), 162.6 (C), 163.8 (C). FT-ICR-MS: calculated 
for C18H15Cl2N3ONa+: 382.0484, found: 382.0483. 
N
N O
NC Cl
Cl
O
99d-3
 
99d-3; colorless solid; 83% yield, C18H15Cl2N3O2, M = 376.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 376 m/z; m.p. 131-132 °C. 1H NMR (400 MHz, CDCl3) δ 2.86 (s, 3 H) 3.36 (m, 2 H) 
3.71 (m, 2 H) 3.82 (m, 4 H) 7.38 (dd, J = 8.39, 2.03 Hz, 1 H) 7.51 (d, J = 2.03 Hz, 1 H) 7.56 
(s, 1 H) 7.59 (d, J = 8.39 Hz, 1 H). 13C NMR (100 MHz, CDCl3) δ 24.0 (CH3), 42.4 (CH2), 
47.5 (CH2), 66.5 (CH2), 66.6 (CH2), 104.7 (C), 115.0 (C), 119.5 (CH), 127.8 (CH), 130.2 
(CH), 132.5 (CH), 132.7 (C), 135.4 (C), 136.5 (C), 147.3 (C), 158.5 (C), 162.7 (C), 164.3 (C). 
FT-ICR-MS: calculated for C18H15Cl2N3O2Na+: 398.0434, found: 398.0436. 
N
NH2 O
NC
Cl
Cl
99e
 
99e; colorless solid; 99% yield, C14H9Cl2N3O, M = 306.15 g/mol, HPLC-ESI-MS: [M + H]+ = 
306 m/z. 
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O99f-1
 
99f-1; colorless solid; 99% yield, C15H13N3O2, M = 267.29 g/mol, HPLC-ESI-MS: [M + H]+ 
= 268 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.75 (s, 3 H), 3.83 (s, 3 H), 7.09 (m, 2 H), 7.99 
(s, 1 H), 8.07 (s, 1 H), 8.18 (m, 2 H), 8.38 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.8 
(CH3), 55.4 (CH3), 103.1 (C), 114.4 (CH), 114.6 (CH), 116.4 (C),129.0 (C), 129.1 (CH), 
147.3 (C), 158.0 (C), 161.5 (C), 162.2 (C), 165.8 (C). 
N
N O
NC
O99f-2
 
99f-2; colorless solid; 89% yield, C19H19N3O2, M = 321.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 322 m/z; m.p. 140 °C. 1H NMR (400 MHz, CDCl3) δ 1.97 (m, 4 H), 2.82 (s, 3 H), 3.32 (t, J 
=  6.49 Hz, 2 H), 3.69 (t, J =  6.87 Hz, 2 H), 3.85 (s, 3 H), 6.98 (m, 2 H), 7.55 (s, 1 H), 8.00 
(m, 2 H). 13C NMR (100 MHz, CDCl3) δ 24.1 (CH3), 24.3 (CH2), 26.0 (CH2), 46.0 (CH2), 
48.3 (CH2), 55.4 (CH3), 102.4 (C), 113.7 (CH), 114.4 (CH), 115.8 (C), 129.0 (CH), 129.5 (C), 
149.5 (C), 159.6 (C), 161.9 (C), 162.3 (C), 164.6 (C). IR (neat, cm-1) λmax: 3070, 2974, 2878, 
2222, 1624, 1580, 1543, 1440, 1358, 1322, 1285, 1255, 1226, 1189, 1159, 1078, 975, 849, 
776, 702. FT-ICR-MS: calculated for C19H19N3O2Na+: 344.1370, found: 344.1367. 
N
O
NC
ONH
Cl
Cl
99f-3
 
99f-3; colorless solid; 99% yield, C22H17Cl2N3O2, M = 426.31 g/mol, HPLC-ESI-MS: [M + 
H]+ = 426 m/z; m.p. 242 °C. 1H NMR (400 MHz, DMSO-D6) δ 2.76 (s, 3 H), 3.83 (s, 3 H), 
4.52 (d, J =  5.85 Hz, 2 H), 7.10 (m, 2 H), 7.39 (dd, J =  8.39, 2.03 Hz, 1 H), 7.62 (d, J =  
8.39 Hz, 1 H), 7.66 (d, J =  2.03 Hz, 1 H), 8.11 (s, 1 H), 8.20 (m, 2 H), 9.50 (t, J =  5.85 Hz, 1 
H). 13C NMR (100 MHz, DMSO-D6) δ 23.9 (CH3), 41.8 (CH2), 55.4 (CH3), 103.5 (C), 114.4 
(CH), 114.7 (CH), 116.8 (C), 127.8 (CH), 129.0 (C), 129.1 (CH), 129.5 (CH), 129.6 (C), 
130.6 (CH), 131.0 (C), 139.8 (C), 146.8 (C), 158.1 (C), 161.6 (C), 162.2 (C), 164.2 (C). IR 
(neat, cm-1) λmax: 3454, 3100, 2893, 2834, 2347, 1764, 1698, 1595, 1513, 1425, 1381, 1336, 
1248, 1167, 1130, 1093, 1019.019.8, 835, 753. FT-ICR-MS: calculated for C22H17Cl2N3O2H+: 
426.0771, found: 426.0772. 
N
NH2 O
NC
S
99g
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99g; colorless solid; 86% yield, C12H9N3OS, M = 243.29 g/mol, HPLC-ESI-MS: [M + H]+ = 
244 m/z. 
 
6. 1. 2. 7 General procedure for the synthesis of pyridine hydrazides 100. 
A suspension of 81 (0.3 mmol) in 50% hydrazine/water (2mL) in a sealed tube was heated at 
150 oC for 24 h. The precipitate was filtered, washed with water and air-dried to afford the 
product 100. 
N
NC
N
H
O NH2
Cl100a
 
100a; yellow solid; 94% yield, C14H11ClN4O, M = 286.72 g/mol, HPLC-ESI-MS: [M + H]+ = 
289 m/z; m.p. 336-339 °C (dec.). 1H NMR (400 MHz, DMSO-D6) δ 3.08 (s, 3 H), 5.56 (s, 2 
H), 7.57 (d, J = 8.39 Hz, 2 H), 8.22 (d, J = 8.65 Hz, 2 H), 8.37 (s, 1 H), 12.00 (s, 1 H). 13C 
NMR (100 MHz, DMSO-D6) δ 26.7 (CH3), 112.4 (CH), 118.6 (C), 128.7 (CH), 129.1 (CH), 
134.9 (C), 136.0 (C), 136.5 (C), 146.1 (C), 154.0 (C), 157.3 (C), 157.7 (C).  IR (neat, cm-1) 
λmax: 3295, 3202, 2992, 2906, 2826, 1659, 1609, 1541, 1474, 1412, 1381, 1350, 1165, 1103, 
1035, 998, 825, 782, 733. FT-ICR-MS: calculated for C14H11ClN4OH+: 287.0694, found: 
287.0694. 
N
NC
N
H
O NH2
Cl
Cl
100b
 
100b; yellow solid; 75% yield, C14H10Cl2N4O, M = 321.17 g/mol, HPLC-ESI-MS: [M + H]+ 
= 321 m/z. 
 
6. 1. 2. 8 General procedure for the synthesis of dicyanopyridines 95 and 101. 
5-Cyano-6-methyl-4-aryl-pyridine-2-carboxylic acid amide 94 or 5-cyano-6-methyl-2-aryl-
pyridine-4-carboxylic acid amide 99 (0.2 mmol) was dissolved in POCl3 (2 mL), and the 
mixture was heated at 100 ºC for 1 h. The exess of the reagent was removed in vacuo and the 
product was isolated by column chromatography (PE/EA, 10:1). 
N
NC
CN
F
95a
 
95a; colorless solid; 79% yield, C14H8FN3, M = 237.24 g/mol, HPLC-ESI-MS: [M + H]+ = 
238 m/z. 
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N
F
NC
CN
F
95b
 
95b; pale solid; 70% yield, C14H7F2N3, M = 255.23 g/mol, HPLC-ESI-MS: [M + H]+ = 256 
m/z. 1H NMR (400 MHz, CDCl3) δ 2.90 (s, 3 H), 7.07 (m, 2 H), 7.45 (m, 1 H), 7.65 (s, 1 H). 
13C NMR (100 MHz, CDCl3) δ 24.2 (CH3), 105.4 (t, 2JC-F = 25.62, CH), 112.4 (C), 112.8 (dd, 
2,4JC-F = 22.08, 3.66 Hz, CH), 114.7 (C), 115.9 (C), 118.4 (dd, 2,4JC-F = 15.13, 4.18 Hz, C), 
126.6 (CH), 131.6 (dd,1,3JC-F = 10.12, 2.93 Hz, CH), 135.3 (C), 148.4 (C), 159.6 (dd, 1,3JC-F = 
254.39, 14.44 Hz, C), 164.3 (C), 156.5 (dd, 1,3JC-F = 255.57, 12.45 Hz, C). 
N
Cl
NC
CN
95c
 
95c; colorless solid; 86% yield, C14H8ClN3, M = 253.69 g/mol, HPLC-ESI-MS: [M + H]+ = 
254 m/z; m.p. 174-176 °C. 1H NMR (400 MHz, CDCl3) δ 2.91 (s, 3 H, Me), 7.55 (m, 4 H), 
7.66 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 24.2 (CH3), 110.8 (C), 115.2 (C), 116.0 (C), 
125.5 (CH), 129.7 (CH), 129.8 (CH), 132.5 (C), 135.4 (C), 137.6 (C), 153.4 (C), 164.6 (C).  
IR (neat, cm-1) λmax: 3449, 3363, 3267, 3155, 3089, 2948, 2229, 1807, 1703, 1637, 1585, 
1533, 1481, 1422, 1362, 1318, 1229, 1088, 1007, 822. FT-ICR-MS: calculated for 
C14H8ClN3H+: 254.0480, found: 254.0478. 
N
Cl
NC
CN
Cl
95d
 
95d; colorless solid; 99% yield, C14H7Cl2N3, M = 288.14 g/mol, HPLC-ESI-MS: [M + H]+ = 
288 m/z; 1H NMR (400 MHz, CDCl3) δ 2.91 (s, 3 H), 7.30 (m, 1 H), 7.46 (m, 1 H), 7.62 (m, 2 
H). 13C NMR (100 MHz, CDCl3) δ 24.0 (CH3), 112.8 (C), 114.3 (C), 115.8 (C), 126.6 (CH), 
128.0 (CH), 130.4 (CH), 131.0 (CH), 131.6 (CH), 133.0 (C), 135.0 (C), 137.5 (C), 151.5 (C), 
164.0 (C). 
N
Br
NC
CN
95e
 
95e; colorless solid; 94% yield, C14H8BrN3, M = 298.14 g/mol, HPLC-ESI-MS: [M + H]+ = 
298 m/z; 1H NMR (400 MHz, CDCl3) δ 2.90 (s, 3 H), 7.46 (m, 2 H), 7.64 (s, 1 H), 7.71 (m, 2 
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H). 13C NMR (100 MHz, CDCl3) δ 24.2 (CH3), 110.8 (C), 115.2 (C), 116.0 (C), 125.4 (CH), 
126.0 (C), 129.9 (CH), 132.8 (CH), 132.9 (C), 135.4 (C), 153.5 (C), 164.6 (C). 
N
NC
CN
O
O
95f
 
95f; pale solid; 99% yield, C15H9N3O2, M = 263.26 g/mol, HPLC-ESI-MS: [M + H]+ = 264 
m/z. 
N
Cl
NC
CN
101a
 
101a; colorless solid; 84% yield, C14H8ClN3, M = 253.69 g/mol, HPLC-ESI-MS: [M + H]+ = 
254 m/z; m.p. 193 °C. 1H NMR (400 MHz, CDCl3) δ 2.90 (s, 3 H), 7.50 (m, 2 H), 7.89 (s, 1 
H), 8.01 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 24.3 (CH3), 108.0 (C), 114.0 (C),  
114.1 (C), 119.5 (CH), 124.8 (C), 128.8 (CH), 129.6 (CH), 134.1 (C), 138.2 (C), 159.2 (C), 
163.4 (C). IR (neat, cm-1) λmax: 3378, 3252, 3155, 3096, 2963, 2926, 2229, 1644, 1577, 1540, 
1451, 1407, 1370, 1325, 1236, 1088, 999, 881, 844, 747, 644. FT-ICR-MS: calculated for 
C14H8ClN3Na+: 276.0299, found: 276.0299. 
N
Cl
NC
CN
Cl
101b
 
101b; colorless solid; 80% yield, C14H7Cl2N3, M = 288.14 g/mol, HPLC-ESI-MS: [M + H]+ = 
288 m/z. 1H NMR (400 MHz, CDCl3) δ 2.93 (s, 3 H), 7.43 (dd, J = 8.39, 1.78 Hz, 1 H), 7.55 
(d, J = 1.78 Hz, 1 H), 7.64 (d, J = 8.39 Hz, 1 H), 7.96 (s, 1 H). 13C NMR (100 MHz, CDCl3) 
δ 24.2 (CH3), 108.8 (C), 113.7 (C), 113.8 (C), 123.9 (C), 124.3 (CH), 128.0 (CH), 130.4 
(CH), 132.6 (CH), 132.8 (C), 134.3 (C), 137.2 (C), 158.9 (C), 163.4 (C).  
N
Cl
NC
CN
Cl
101c
 
101c; colorless solid; 75% yield, C14H7Cl2N3, M = 288.14 g/mol, HPLC-ESI-MS: [M + H]+ = 
288 m/z; 1H NMR (400 MHz, CDCl3) δ 2.92 (s, 3 H), 7.62 (m, 1 H), 7.88 (m, 2 H), 8.22 (m, 1 
H). 13C NMR (100 MHz, CDCl3) δ 24.3 (CH3), 108.7 (C), 113.8 (C), 113.9 (C), 119.6 (CH), 
125.1 (C), 126.4 (CH), 129.5 (CH), 131.3 (CH), 134.0 (C), 135.5 (C), 136.3 (C), 157.9 (C), 
163.6 (C). 
N
O
NC
CN
101d
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101d; colorless solid; 99% yield, C15H11N3O, M = 249.27 g/mol, HPLC-ESI-MS: [M + H]+ = 
250 m/z; 1H NMR (400 MHz, CDCl3) δ 2.86 (s, 3 H), 3.89 (s, 3 H), 7.02 (m, 2 H), 7.82 (s, 1 
H) 8.03 (m, 2 H). 13C NMR (100 MHz, CDCl3) δ 24.3 (CH3), 55.5 (CH3), 106.4 (C), 114.3 
(C), 114.5 (C), 114.7 (CH), 118.9 (CH), 124.3 (C), 128.2 (C), 129.3 (CH), 159.9 (C), 162.6 
(C), 163.2 (C). 
 
6. 1. 2. 9 General procedure for the synthesis of  nicotinic amides 96. 
t-BuOK (3 eq, 3.0 mmol, 0.336 g) was added to a suspension of 5-cyano-2-pyridine 
carboxylic acid 74 (1 eq, 1 mmol) in water (15 mL). The mixture was heated at 100 ˚C for 3 
h. After cooling to room temperature the mixture was concentrated in vacuo, acidified with 
1M HCl and extracted with DCM. The combined organic phases were dried over anhydrous 
Na2SO4, concentrated and the residue was used without further purification. 
N
O
NH2
O
OH
F
96a
 
96a; pale solid; 80% yield, C14H11FN2O3, M = 274.25 g/mol, HPLC-ESI-MS: [M + H]+ = 275 
m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.59 (s, 3 H), 7.29 (m, 2 H), 7.47 (m, 2 H), 7.64 (s, 1 
H), 7.79 (s, 1 H), 7.97 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.3 (CH3), 115.8 (d, 2JC-F 
= 21.22 Hz, CH), 123.4 (CH), 124.3 (d, 3JC-F = 3.66 Hz, CH), 124.7 (d, 2JC-F = 14.64 Hz, C), 
130.8 (d, 4JC-F = 2.20 Hz, CH), 131.0 (d, 3JC-F = 8.05 Hz, CH), 135.8 (C), 141.1 (C), 146.8 
(C), 154.9 (C), 158.8 (d, 1JC-F =246.64 Hz, C), 165.7 (C), 168.3 (C). 
N
O
NH2
Cl
O
OH
96b
 
96b; colorless solid; 65% yield, C14H11ClN2O3, M = 290.71 g/mol, HPLC-ESI-MS: [M + H]+ 
= 291 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.57 (s, 3 H), 7.54 (m, 4 H), 7.69 (s, 1 H), 7.81 
(s, 1 H), 7.97 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.2 (CH3), 122.5 (CH), 128.6 
(CH), 130.1 (CH), 133.8 (C), 134.8 (C), 136.3 (C), 145.5 (C), 147.4 (C), 154.8 (C), 165.8 (C), 
168.9 (C). 
N
O
NH2
Cl
O
OH
Cl
96c
 
96c; colorless solid; 99% yield, C14H11Cl2N2O3, M = 325.15 g/mol, HPLC-ESI-MS: [M + 
H]+ = 325 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.59 (s, 3 H), 7.42 (m, 1 H), 7.52 (m, 1 
H), 7.64 (s, 1 H), 7.74 (m, 2 H), 7.93 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.3 
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(CH3), 123.1 (CH), 127.0 (CH), 128.9 (CH), 132.0 (CH), 132.1 (C), 134.2 (C), 134.7 (C), 
135.6 (C), 143.6 (C), 146.8 (C), 154.7 (C), 165.7 (C), 167.8 (C). 
N
O
NH2
O
O
OH
96d
 
96d; colorless solid; 91% yield, C15H14N2O4, M = 286.29 g/mol, HPLC-ESI-MS: [M + H]+ = 
287 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.55 (s, 3 H), 3.79 (s, 3 H), 7.02 (m, 2 H), 7.51 (d, 
2 H), 7.65 (s, 1 H), 7.79 (s, 1 H), 7.93 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.2 (CH3), 
55.3 (CH3), 114.1 (CH), 122.5 (CH), 129.6 (CH), 134.7 (C), 146.2 (C), 147.1 (C), 154.6 (C), 
159.8 (C), 165.9 (C), 169.3 (C). 
N N
HNH2
O
O
O
Cl
Cl
96e
 
96e; colorless solid; 88% yield, C22H19Cl2N3O3, M = 444.32 g/mol, HPLC-ESI-MS: [M + H]+ 
= 444 m/z; m.p. 151 °C. 1H NMR (400 MHz, CDCl3) δ 2.62 (s, 3 H), 3.82 (s, 3 H), 4.58 (d, J 
=  6.36 Hz, 1 H), 5.74 (s, 1 H), 5.81 (s, 1 H), 6.92 (m, 2 H), 7.18 (dd, J =  8.39, 2.03 Hz, 1 H), 
7.39 (d, J =  8.39 Hz, 2 H), 7.45 (m, 3 H), 7.97 (s, 1 H), 8.48 (t, J =  6.36 Hz, 1 H). 13C NMR 
(100 MHz, CDCl3) δ 22.5 (CH3), 42.3 (CH2), 55.3 (CH3), 114.3 (CH), 120.3 (CH), 127.1 
(CH), 129.2 (C), 129.6 (CH), 129.7 (CH), 130.6 (CH), 131.5 (C), 132.7 (C), 132.7 (C), 138.5 
(C), 147.8 (C), 148.4 (C), 154.9 (C), 160.5 (C), 164.0 (C), 170.3 (C). IR (neat, cm-1) λmax: 
3705, 3668, 3351, 3107, 2974, 2864, 1735, 1661, 1506, 1358, 1285, 1240, 1137, 1056, 1026, 
820, 650. FT-ICR-MS: calculated for C22H19Cl2N3O3Na+: 466.0696, found: 466.0696. 
 
6. 1. 2. 10 Synthesis of pyridine N-hydroxyamidine 102. 
N
N
H
ON
NH2
OH
Cl
Cl
O102
 
Hydroxylamine hydrochloride (3 eq, 3 mmol, 0.209 g) and t-BuOK (3 eq, 3 mmol, 0.337 g) 
were successively added to the suspension of 99f-3 (1 eq, 1 mmol, 0.425 g) in DMSO (6 mL). 
The mixture was stirred for 2 h at 100 ºC, cooled to room temperature and diluted with water. 
The yellow precipitate was filtered, washed with water and air dried to give the product 102 
as a yellow solid (0.430 g, 94%). C22H20Cl2N4O3, M = 459.34 g/mol, HPLC-ESI-MS: [M + 
H]+ = 459 m/z; m.p. 270 °C (dec.). 1H NMR (400 MHz, DMSO-D6) δ 2.57 (s, 3 H), 3.81 (s, 3 
H), 4.44 (d, J =  5.85 Hz, 2 H), 5.88 (s, 2 H), 7.05 (m, 1 H), 7.40 (m, 1 H), 7.61 (m, 1 H), 7.73 
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(s, 1 H), 8.08 (m, 2 H), 8.75 (t, J =  5.85 Hz, 1 H), 9.45 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 22.6 (CH3), 41.5 (CH2), 55.3 (CH3), 114.2 (CH), 114.5 (CH), 124.2 (C), 127.5 
(CH), 128.1 (CH), 129.0 (CH), 129.2 (C), 130.3 (C), 130.6 (CH), 130.7 (C), 140.2 (C), 145.5 
(C), 149.8 (C), 155.1 (C), 157.7 (C), 160.5 (C), 166.9 (C). IR (neat, cm-1) λmax: 3484, 3329, 
3210, 2886, 2834, 2783, 1735, 1639, 1558, 1513, 1462, 1417, 1358, 1285, 1255, 1181, 1122, 
1026, 938, 827, 606. FT-ICR-MS: calculated for C22H20Cl2N4O3H+: 459.0985, found: 
459.0986. 
 
6. 1. 2. 11 Synthesis of pyridine tetrazoles. 
General procedure for the synthesis of 97: NH4Cl (5 eq, 0.80 mmol, 0.043 g) and NaN3 
(5eq, 0.80 mmol, 0.052 g) were added to a solution of the amide 94 (1 eq, 0.16 mmol) in 
DMF (2 mL). The mixture was heated in a sealed tube at 120 oC for 24 h. After cooling, the 
solvent was removed in vacuo, the crude residue was taken up in water and treated with 1M 
HCl until a suspension was formed. The solid was filtered, washed with water and Et2O. The 
product was isolated by filtration on silica gel using DCM/MeOH (10:1) as eluent.  
N
O
NH2
NN
N
N
H
Cl
Cl
97a
 
97a; yellow solid; 80% yield, C14H10Cl2N6O, M = 349.18 g/mol, HPLC-ESI-MS: [M + H]+ = 
349 m/z.1H NMR (400 MHz, DMSO-D6) δ 1.47 (s, 3 H), 6.24 (m, 1 H), 6.41 (m, 1 H), 6.62 
(m, 1 H), 6.89 (s, 2 H), 7.28 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.1 (CH3), 120.7 
(CH), 127.3 (CH), 128.9 (CH), 132.1 (CH), 132.2 (C), 134.2 (C), 134.7 (C), 148.2 (C), 150.9 
(C), 157.1 (C), 165.1 (C). 
N
O
N
H
NN
N
N
H
O
Cl
Cl
97b
 
97b; yellow oil; 89% yield, C22H18Cl2N6O2, M = 469.33 g/mol, HPLC-ESI-MS: [M + H]+ = 
469 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.24 (s, 3 H, Me), 3.70 (s, 3 H), 4.51 (d, J = 6.36 
Hz), 6.76 (m, 2 H), 7.07 (m, 2 H), 7.34 (m, 1 H), 7.59 (m, 2 H), 7.84 (s, 1 H), 9.40 (t, J = 6.36 
Hz, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 23.2 (CH3), 41.5 (CH2), 55.0 (CH3), 113.5 (CH), 
119.7 (CH), 127.9 (CH), 129.3 (C), 129.5 (CH), 130.0 (CH), 130.5 (CH), 130.6 (C), 130.8 
(C), 141.0 (C), 146.9 (C), 148.3 (C), 149.6 (C), 156.6 (C), 157.7 (C), 159.0 (C), 164.2 (C).  IR 
(neat, cm-1) λmax: 3289, 3037, 2918, 1837, 1666, 1614, 1511, 1459, 1392, 1340, 1288, 1259, 
1185, 1051, 1022, 829, 755. FT-ICR-MS: calculated for C22H18Cl2N6O2Na+: 491.0761 , 
found: 491.0765. 
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N
O
N
H
NN
N
N
H
O
S
97c
 
97c; Pale solid; 99% yield, C20H18N6O2S, M = 406.47 g/mol, HPLC-ESI-MS: [M + H]+ = 407 
m/z. 
Synthesis of pyridine tetrazole 108: 
N
Cl
Cl
NC
N
H N
N
N
108
 
NH4Cl (5 eq, 1.50 mmol, 0.080 g) and NaN3 (5 eq, 1.50 mmol, 0.098 g)were added to a 
solution of 95d (1 eq, 0.30 mmol, 0.086 g) in DMF (2 mL). The mixture was heated in a 
sealed tube at 70 oC for 2 h. After cooling, the solvent was removed in vacuo, the crude 
residue was filtrated on silica gel with DCM/MeOH (10:1) as eluent. The resulting solid was 
washed with water and air dried to afford product (0.092 g, 93%) as a yellow solid. 
C14H8Cl2N6, M = 331.17 g/mol, HPLC-ESI-MS: [M + H]+ = 331 m/z; 1H NMR (400 MHz, 
DMSO-D6) δ 2.86 (s, 3 H), 7.68 (m, 2 H), 7.93 (m, 1 H), 8.13 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 23.7 (CH3), 109.2 (C), 115.7 (C), 120.3 (CH), 128.0 (CH), 129.5 (CH), 132.2 
(CH), 132.4 (C), 133.5 (C), 135.5 (C), 147.8 (C), 147.8 (C), 150.7 (C), 162.3 (C). 
Synthesis of pyridine tetrazole 109:  
N
Cl
ClO
NH2
N
H N
N
N
109
 
t-BuOK (3 eq, 0.9 mmol, 0.101 g) was added to a solution of 108 (1 eq, 0.3 mmol, 0.099 g) in 
water (5 mL). The mixture was heated at 100 oC for 3 h. After cooling, the mixture was 
acidified with 1M HCl. The precipitate was filtered, washed with water and air dried to afford 
the product (104 mg, 99%) as a yellow solid. C14H10Cl2N6O, M = 349.18 g/mol, HPLC-ESI-
MS: [M + H]+ = 349 m/z; 1H NMR (400 MHz, DMSO-D6) δ 2.69 (s, 3 H), 7.49 (m, 1 H), 7.56 
(m, 1 H), 7.70 (s, 1 H), 7.80 (m, 1 H), 7.95 (s, 1 H), 7.99 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 22.5 (CH3), 120.9 (CH), 127.1 (CH), 129.0 (CH), 132.1 (CH), 132.9 (C), 134.3 
(C), 134.6 (C), 134.7 (C), 142.8 (C), 144.3 (C), 155.0 (C), 155.6 (C), 167.8 (C). 
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N
NC
NH
NN
N
O111a
 
111a; Prepared according to the procedure for 108, using compound 101d as a starting 
material. Pale solid; 85% yield, C15H12N6O, M = 292.30 g/mol, HPLC-ESI-MS: [M + H]+ = 
293 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.78 (s, 3 H), 3.83 (s, 3 H), 7.08 (m, 2 H), 8.14 
(m, 2 H), 8.34 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 24.3 (CH3), 55.4 (CH3), 102.6 (C), 
114.4 (CH), 115.1 (CH), 116.6 (C), 128.9 (CH), 129.0 (C), 138.4 (C), 157.9 (C), 161.4 (C), 
162.8 (C).  
 
6. 1. 2. 12 Synthesis of pyrrolopyridines. 
Method A 
51% aqueous solution of hydrazine (20 eq, 3 mmol) was added dropwise to a suspension of 
the tertiary amide (1 eq, 0.15 mmol) and Raney Nickel (1 mL, 50% slurry in water) dissolved 
in MeOH (50 mL). After stirring for 3-16 h at rt (reaction monitored by TLC), the catalyst was 
filtered off and the solvent was removed under reduced pressure. The residue was taken up in 
water and extracted with DCM/EA. The combined organic phases were dried over anhydrous 
Na2SO4 and concentrated. The product was isolated by column chromatography with 
DCM/MeOH (40:1) as eluent. 
Method B 
B-1a. The cyanopyridine 81 (1 eq, 0.2 mmol) and nickel (II) chloride hexahydrat (1 eq, 0.2 
mmol, 0.048 g) were dissolved in MeOH (5 ml). NaBH4 (7 eq, 1.4 mmol, 0.053 g) was added 
very cautiously while stirring the solution vigorously. The progress of the reaction was 
monitored by LC/MS. After 24 h the reaction mixture was filtered through a celite pad and the 
solvent was removed under vacuum. The residue was taken up in water and extracted with 
DCM. The aqueous layer was lyophilized to give a solid product that was used in the next 
step without further purification. 
B-1b. 5-Cyano-4-aryl-6-methyl-pyridine-2-carboxylic acid 81 (1 eq, 0.25 mmol) was 
dissolved in acetic acid (0.25 mL) and 10% Pd/C (10% m/m) was added. The mixture was 
degassed and hydrogenated under 1.0 atm pressure of H2 for 24 h at 60 ˚C. The catalyst was 
filtered off and the solvent was removed on vacuum. The residue was taken up in water and 
extracted with DCM. Aqueous layer was lyophilized to give a solid product that was used in 
the next step without further purification. 
B-2. Boc2O (1.5 eq, 0.225 mmol, 0.049 g) was added to a solution of 116 (1 eq, 0.15 mmol) in 
dioxane/4M NaOH (10:1, 5.5 mL) and the mixture was stirred for 16 h at 60 ˚C. The solvent 
was removed in vacuo and the product was isolated by filtration on silica gel using 
DCM/MeOH (40:1) as eluent.  
B-3. The Boc-protected pyrrolopyridine 117 (1 eq, 0.10 mmol) was treated with 25% 
TFA/DCM (5 mL) at rt. After 1 h the solvent was removed under reduced pressure, the 
residue was taken up in water and extracted with DCM/EA. The combined organic phases 
were dried over anhydrous Na2SO4 and concentrated. The product was isolated by column 
chromatography with DCM/MeOH (40:1) as eluent. 
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116a; Prepared according to the procedure B-1a using 81c as a starting material; colorless 
solid; 64% yield, C14H12Cl2N2O2, M = 311.17 g/mol, HPLC-ESI-MS: [M + H]+ = 311 m/z. 
N
NH2
OHO
O116b
 
116b; Prepared according to the procedure B-1b using 81k as a starting material; pale solid; 
76% yield, C15H16N2O3, M = 272.31 g/mol, HPLC-ESI-MS: [M + H]+ = 273 m/z. 
N
N
O
Cl
Cl
O
O
117a
 
117a; Prepared according to the procedure B-1a, B-2 using 116a as a starting material; 
colorless solid; 85% yield, C19H18Cl2N2O3, M = 393.27 g/mol, HPLC-ESI-MS: [M + H]+ = 
392 m/z. 1H NMR (400 MHz, CDCl3) δ 1.60 (s, 9 H), 2.66 (s, 3 H), 4.78 (s, 2 H), 7.32 (m, 1 
H), 7.47 (m, 1 H), 7.51 (m, 1 H), 7.88 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 21.1 (CH3), 
28.0 (CH3), 47.9 (CH2), 84.0 (C), 116.9 (CH), 127.4 (CH), 129.9 (CH), 132.3 (C), 132.4 
(CH), 133.0 (C), 135.2 (C), 136.8 (C), 139.3 (C), 150.0 (C), 154.4 (C), 155.7 (C), 165.1 (C). 
N
N
O
O
O
O
117b
 
117b; Prepared according to the procedure B-1b, B-2 using 116b as a starting material; 
colorless solid; 74% yield, C20H22N2O4, M = 354.41 g/mol, HPLC-ESI-MS: [M + H]+ = 355 
m/z. 1H NMR (400 MHz, CDCl3) δ 1.61 (s, 9 H), 2.64 (s, 3 H), 3.86 (s, 3 H), 4.75 (s, 2 H), 
6.99 (m, 2 H), 7.93 (s, 1 H), 8.00 (m, 2 H). 13C NMR (100 MHz, CDCl3) δ 21.3 (CH3), 28.1 
(CH3), 48.0 (CH2), 55.4 (CH3), 83.8 (C), 111.4 (CH), 114.2 (CH), 128.4 (CH), 130.7 (C), 
131.1 (C), 139.9 (C), 150.1 (C), 153.9 (C), 157.4 (C), 160.8 (C), 165.9 (C). 
N
N
H O
Cl103a
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103a; Prepared according to the Method A using 99b-5 as a starting material; colorless solid; 
80% yield, C14H11ClN2O, M = 258.71 g/mol, HPLC-ESI-MS: [M + H]+ = 259 m/z. 1H NMR 
(400 MHz, DMSO-D6) δ 2.56 (s, 3 H), 4.44 (s, 2 H), 7.51 (m, 2 H), 7.97 (s, 1 H), 8.16 (m 2 
H), 8.95 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 20.9 (CH3), 43.8 (CH2), 110.9 (CH), 
128.5 (CH), 128.7 (CH), 133.9 (C), 136.4 (C), 137.2 (C), 141.5 (C), 153.9 (C), 154.0 (C), 
168.7 (C). 
N
N
H O
Cl
Cl
103b
 
103b; Prepared according to the Method A using 99d-2 as a starting material (66% yield) and 
according to the Method B (step B-3) using 117a as a starting material (99% yield); colorless 
solid; C14H10Cl2N2O, M = 293.15 g/mol, HPLC-ESI-MS: [M + H]+ = 293 m/z. 1H NMR (400 
MHz, DMSO-D6) δ 2.57 (s, 3 H), 4.49 (s, 2 H), 7.54 (m, 1 H), 7.62 (m, 1 H), 7.69 (s, 1 H), 
7.74 (m, 1 H), 9.02 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 20.7 (CH3), 43.9 (CH2), 
115.4 (CH), 127.6 (CH), 129.4 (CH), 132.2 (C), 133.1 (CH), 133.9 (C), 136.8 (C), 137.5 (C), 
140.6 (C), 153.8 (C), 154.2 (C), 168.4 (C). 
N
N
H O
O103c
 
103c; Prepared according to the Method A using 99f-2 as a starting material (69% yield) and 
according to the Method B (step B-3) using 117b as a starting material (95% yield); colorless 
solid; C15H14N2O2, M = 254.29 g/mol, HPLC-ESI-MS: [M + H]+ = 255 m/z. 1H NMR (400 
MHz, DMSO-D6) δ 2.56 (s, 3 H), 3.81 (s, 3 H), 4.44 (s, 2 H), 7.03 (m, 2 H), 7.88 (s, 1 H), 
8.10 (m, 2 H), 8.91 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 21.0 (CH3), 43.8 (CH2), 55.2 
(CH3), 109.9 (CH), 114.1 (CH), 128.1 (CH), 130.9 (C), 135.2 (C), 141.4 (C), 153.5 (C), 160.2 
(C), 168.9 (C). 
N
H O
115
 
115; Prepared according to the Method A; colorless solid; 90% yield, C8H7NO, M = 133.15 
g/mol, HPLC-ESI-MS: [M + H]+ = 134 m/z. 1H NMR (400 MHz, CDCl3) δ 4.46 (s, 2 H), 7.47 
(m, 2 H), 7.56 (m, 1 H), 7.68 (s, 1 H), 7.87 (m, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 45.7 
(CH2), 123.2 (CH), 123.7 (CH), 128.0 (CH), 131.7 (CH), 132.1 (C), 143.6 (C), 172.1 (C). 
Synthesis of 118: 
N
N
H O
Cl
ClO
118
 
Iodine (1 eq, 1 mmol, 0.254 g), TFA (3 eq, 3 mmol, 0.222 mL), and t-BuI (0.4 eq, 0.4 mmol, 
0.053 mL) were added to a solution of pyrrolopyridine 103b (1 eq, 1 mmol, 0.293 g) in 
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DMSO (2 mL). The mixture was heated at 120 ˚C for 3 h. After cooling to room temperature 
an aqueous solution of Na2S2O3 (0.1 M, 10 mL). The precipitate was filtered, washed with 
water, MeOH and DCM and air dried to give the product as a pale solid (0.211 g, 69%). 
C14H8Cl2N2O2, M = 307.14 g/mol, HPLC-ESI-MS: [M + H]+ = 307 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.80 (s, 3 H), 7.56 (m, 1 H), 7.65 (m, 1 H), 7.76 (m, 1 H), 7.86 (s, 1 H), 11.66 
(s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 20.6 (CH3), 115.4 (CH), 122.8 (C), 127.8 (CH), 
129.6 (CH), 132.3 (C), 133.1 (CH), 134.8 (C), 136.6 (C), 141.4 (C), 155.8 (C), 159.8 (C), 
167.7 (C), 169.2 (C). 
 
6. 1. 2. 13 Synthesis of 5-aminomethyl-pyridines 120. 
6. 1. 2. 13. 1. Route A. 
General procedure for the synthesis of 123: These compounds were prepared according to 
the procedure for 116 (Method B-1b), using compounds 74 as a starting material. 
N OH
O
NH2
F
123a
 
123a; orange solid; 52% yield, C14H13FN2O2, M = 260.27 g/mol, HPLC-ESI-MS: [M + H]+ = 
261 m/z. 
N OH
O
NH2
F
F
123b
 
123b; pale solid; 69% yield, C14H12F2N2O2, M = 278.26 g/mol, HPLC-ESI-MS: [M + H]+ = 
279 m/z. 
N OH
O
NH2
O
123c
 
123c; pale solid; 72% yield, C15H16N2O3, M = 272.31 g/mol, HPLC-ESI-MS: [M + H]+ = 273 
m/z. 
General procedure for the synthesis of 124 - Boc-protection: Boc2O (1.5 eq, 0.225 mmol, 
0.049 g) was added to a solution of 123 (1 eq, 0.15 mmol, 0.041 g) in dioxane/water (10:1, 
5.5 mL) and the mixture was stirred for 16 h. The solvent was removed under reduced 
pressure and the product was isolated by column chromatography with DCM/MeOH (40:1) as 
eluent. 
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N OH
O
F
BocHN
124a
 
124a; colorless solid; 68% yield, C19H21FN2O4, M = 360.39 g/mol, HPLC-ESI-MS: [M + H]+ 
= 361 m/z. 
N OH
O
BocHN
F
F
124b
 
124b; colorless solid; 62% yield, C19H20F2N2O4, M = 378.38 g/mol, HPLC-ESI-MS: [M + 
H]+ = 379 m/z. 
N OH
O
BocHN
O
124c
 
124c; colorless solid; 79% yield, C20H24N2O5, M = 372.43 g/mol, HPLC-ESI-MS: [M + H]+ = 
373 m/z. 
General procedure for the synthesis of 125: These compounds were prepared according to 
the procedure for 94 and 99, using compounds 124 as a starting material. 
N N
HBocHN
F
O
125a-1
 
125a-1; colorless solid; 57% yield, C22H26FN3O3, M = 399.47 g/mol, HPLC-ESI-MS: [M + 
H]+ = 400 m/z. 1H NMR (400 MHz, CDCl3) δ 0.66 (m, 2 H), 0.86 (m, 2 H), 1.39 (s, 9 H), 2.64 
(s, 3 H), 2.91 (m, 1 H), 4.27 (d, J = 4.6 Hz, 2 H), 4.62 (s, 1 H), 7.11 (m, 2 H), 7.23 (m, 2 H), 
7.81 (s, 1 H), 8.07 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 6.5 (CH2), 22.7 (CH3), 23.9 (CH), 
28.3 (CH3), 39.0 (CH2), 79.8 (C), 115.7 (d, 2JC-F = 22.0 Hz, CH), 121.1 (CH), 130.2 (d, 3JC-F = 
8.05 Hz, CH), 131.7 (C), 134.2 (d, 4JC-F = 3.7 Hz, C), 147.5 (C), 151.0 (C), 155.2 (C), 157.8 
(C), 162.8 (d, 1JC-F =248.8, C), 165.5 (C). 
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N N
O
BocHN
F
125a-2
 
125a-2; colorless solid; 92% yield, C23H28FN3O3, M = 413.50 g/mol, HPLC-ESI-MS: [M + 
H]+ = 414 m/z. 
N N
O
BocHN
F
O
125a-3
 
125a-3; colorless solid; 84% yield, C23H28FN3O4, M = 429.50 g/mol, HPLC-ESI-MS: [M + 
H]+ = 430 m/z. 
N N
O
BocHN
F
O
O
125a-4
 
125a-4; colorless solid; 92% yield, C30H34FN3O5, M = 499.59 g/mol, HPLC-ESI-MS: [M + 
H]+ = 501 m/z. 
N N
HBocHN
F
F
O
125b-1
 
125b-1; colorless solid; 46% yield, C22H25F2N3O3, M = 417.46 g/mol, HPLC-ESI-MS: [M + 
H]+ = 418 m/z. 
N N
HBocHN
F
F
O
O
O
125b-2
 
125b-2; colorless solid; 67% yield, C22H25F2N3O5, M = 449.46 g/mol, HPLC-ESI-MS: [M + 
H]+ = 450 m/z. 
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N N
BocHN
F
F
O
125b-3
 
125b-3; colorless solid; 92% yield, C23H27F2N3O3, M = 431.49 g/mol, HPLC-ESI-MS: [M + 
H]+ = 432 m/z. 
N N
O
BocHN
F
F
O
125b-4
 
125b-4; colorless solid; 91% yield, C23H27F2N3O4, M = 447.49 g/mol, HPLC-ESI-MS: [M + 
H]+ = 448 m/z. 
N N
BocHN
F
F
O
O
O
125b-5
 
125b-5; colorless solid; 76% yield, C27H33F2N3O5, M = 517.58 g/mol, HPLC-ESI-MS: [M + 
H]+ = 519 m/z. 
N N
HBocHN
F
F
N OO125b-6
 
125b-6; colorless solid; 58% yield, C23H24F2N4O4, M = 458.47 g/mol, HPLC-ESI-MS: [M + 
H]+ = 459 m/z. 
N N
O
BocHN
F
F
NHBoc
125b-7
 
125b-7; colorless solid; 92% yield, C29H37F2N3O5, M = 545.64 g/mol, HPLC-ESI-MS: [M + 
H]+ = 547 m/z. 
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N N
H
O
BocHN
O
125c-1
 
125c-1; colorless solid; 74% yield, C23H29N3O4, M = 411.51 g/mol, HPLC-ESI-MS: [M + H]+ 
= 412 m/z. 
N N
O
BocHN
O
125c-2
 
125c-2; colorless solid; 72% yield, C24H31N3O4, M = 425.53 g/mol, HPLC-ESI-MS: [M + H]+ 
= 426 m/z. 
N N
O
BocHN
O
O
125c-3
 
125c-3; colorless solid; 92% yield, C24H31N4O5, M = 441.43 g/mol, HPLC-ESI-MS: [M + H]+ 
= 442 m/z. 
N N
H
O
BocHN
O
Cl
Cl
125c-4
 
125c-4; colorless solid; 88% yield, C27H29Cl2N3O4, M = 530.46 g/mol, HPLC-ESI-MS: [M + 
H]+ = 531 m/z. 
N N
HBocHN
O
O
N
N
125c-5
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125c-5; colorless solid; 62% yield, C25H31N5O4, M = 465.56 g/mol, HPLC-ESI-MS: [M + H]+ 
= 467 m/z. 
 
N N
HBocHN
O
O N O125c-6
 
125c-6; colorless solid; 57% yield, C24H28N4O5, M = 452.52 g/mol, HPLC-ESI-MS: [M + H]+ 
= 454 m/z. 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9 H), 2.42 (s, 3 H), 2.66 (s, 3 H), 3.84 (s, 
3 H), 4.33 (d, J = 4.3 Hz, 2 H), 4.61 (s, 1 H), 6.85 (s, 1 H), 6.95 (m, 2 H), 7.20 (m, 2 H), 7.88 
(s, 1 H), 10.50 (s, 1 H). 13C NMR (100 MHz, CDCl3) δ 12.7 (CH3), 22.5 (CH3), 28.3 (CH3), 
39.1 (CH2), 55.3 (CH3), 79.7 (C), 96.0 (CH), 114.2 (CH), 121.8 (CH), 129.7 (CH), 130.1 (C), 
132.8 (C), 146.0 (C), 152.0 (C), 155.0 (C), 157.6 (C), 158.3 (C), 159.8 (C), 162.1 (C), 170.0 
(C). 
N N
O
BocHN
O
NHBoc
125c-7
 
125c-7; colorless solid; 89% yield, C30H41N3O6, M = 539.68 g/mol, HPLC-ESI-MS: [M + H]+ 
= 541 m/z. 
N N
O
BocHN
O
NHBoc
125c-8
 
125c-8; colorless solid; 53% yield, C30H42N4O4, M = 554.70 g/mol, HPLC-ESI-MS: [M + H]+ 
= 556 m/z. 
N N
H
O
BocHN
O
N
NBoc
125c-9
 
125c-9; colorless solid; 92% yield, C32H46N4O6, M = 539.68 g/mol, HPLC-ESI-MS: [M + H]+ 
= 541 m/z. 
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General procedure for the synthesis of 120 - deprotection: The Boc - protected 
aminomethyl-pyridine 125 (0.10 mmol) was treated with 25% TFA/DCM (5 mL) at rt. After 1 
h the solvent was removed under reduced pressure, the residue was taken up in water and 
extracted with DCM/EA. The combined organic phases were dried over anhydrous Na2SO4 
and concentrated. The product was isolated by column chromatography with DCM/MeOH 
(40:1) as eluent. 
N N
HNH2
F
O
120a-1
 
120a-1; colorless solid; 99% yield, C17H18FN3O, M = 299.35 g/mol, HPLC-ESI-MS: [M + 
H]+ = 300 m/z. 1H NMR (400 MHz, Methanol-D4) δ 0.55 (m, 2 H), 0.70 (m, 2 H), 2.62 (s, 3 
H), 2.74 (m, 1 H), 3.98 (s, 2 H), 7.13 (m, 2 H), 7.28 (m, 2 H), 7.65 (s, 1 H). 13C NMR (100 
MHz, Methanol-D4) δ 6.7 (CH2), 22.8 (CH3), 23.6 (CH), 38.2 (CH2), 117.0 (d, 2JC-F = 22.7 
Hz, CH), 122.2 (CH), 131.2 (C), 131.9 (d, 3JC-F = 8.1 Hz, CH), 135.3 (d, 4JC-F = 2.9 Hz, C), 
149.8 (C), 153.1 (C), 159.8 (C), 164.5 (d, 1JC-F =247.4 Hz, C), 167.7 (C). FT-ICR-MS: 
calculated for C17H18FN3OH+: 300.1507, found: 300.1505. 
N N
O
NH2
F
120a-2
 
120a-2; colorless solid; 95% yield, C18H20FN3O, M = 313.38 g/mol, HPLC-ESI-MS: [M + 
H]+ = 314 m/z. 1H NMR (400 MHz, Methanol-D4) δ 1.96 (m, 4 H), 2.74 (s, 3 H), 3.61 (m, 2 
H), 3.69 (m, 2 H), 3.95 (s, 2 H), 7.25 (m, 2 H), 7.44 (m, 3 H). 13C NMR (100 MHz, Methanol- 
D4) δ 22.5 (CH3), 25.0 (CH2), 27.3 (CH2), 39.1 (CH2), 47.9 (CH2), 50.3 (CH2), 116.8 (d, 2JC-F 
= 22.0 Hz, CH), 123.5 (CH), 131.9 (d, 3JC-F = 8.8 Hz, CH), 132.9 (C), 135.6 (d, 4JC-F = 2.9 
Hz, C), 152.3 (C), 153.6 (C), 159.2 (C), 164.4 (d, 1JC-F = 247.4 Hz, C), 168.2 (C). FT-ICR-
MS: calculated for C18H20FN3OH+: 314.1663, found: 314.1662. 
N N
O
NH2
F
O
120a-3
 
120a-3; colorless solid; 89% yield, C18H20FN3O2, M = 329.38 g/mol, HPLC-ESI-MS: [M + 
H]+ = 330 m/z. 1H NMR (400 MHz, CDCl3) δ 2.70 (s, 3 H), 3.68 (s, 2 H), 3.79 (m, 6 H), 7.12 
(m, 2 H), 7.35 (m, 3 H). 13C NMR (100 MHz, CDCl3) δ 22.5 (CH3), 39.8 (CH2), 42.7 (CH2), 
47.8 (CH2), 66.8 (CH2), 67.0 (CH2), 115.5 (d, 2JC-F = 21.2 Hz, CH), 123.0 (CH), 130.3 (d, 3JC-
F = 8.1 Hz, CH), 134.2 (C), 134.5 (d, 4JC-F = 3.7 Hz, C), 150.0 (C), 151. 0 (C), 157.1 (C), 
162.7 (d, 1JC-F = 248.1 Hz, C), 167.4 (C). FT-ICR-MS: calculated for C18H20FN3O2H+: 
330.1612, found: 330.1611. 
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N N
O
NH2
F
O
O
120a-4
 
120a-4; colorless solid; 99% yield, C22H26FN3O3, M = 399.47 g/mol, HPLC-ESI-MS: [M + 
H]+ = 400 m/z. 1H NMR (400 MHz, CDCl3) δ 1.29 (m, 3 H), 1.82 (m, 3 H), 2.07 (m, 3 H), 
2.59 (m, 1 H), 2.72 (s, 3 H), 3.05 (m, 1 H), 3.21 (m, 1 H), 3.83 (s, 2 H), 3.98 (m, 1 H), 4.16 
(q, J = 7.1 Hz, 2 H), 4.53 (m, 1 H), 7.14 (m, 2 H), 7.28 (s, 1 H), 7.37 (m, 2 H). 13C NMR (100 
MHz, CDCl3) δ  14.1 (CH3), 22.4 (CH3), 27.7 (CH2), 28.4 (CH2), 39.6 (CH2), 41.0 (CH), 41.6 
(CH2), 46.5 (CH2), 60.6 (CH2), 115.5 (d, 2JC-F = 21.2 Hz, CH), 122.2 (CH), 130.3 (d, 3JC-F = 
8.1 Hz, CH), 133.5 (C), 134.5 (d, 4JC-F = 3.7 Hz, C), 149.9 (C), 151.7 (C), 157.3 (C), 162.6 (d, 
1JC-F = 248.1 Hz, C), 167.5 (C), 174.1 (C). FT-ICR-MS: calculated for C22H26FN3O3H+: 
400.2031, found: 400.2032. 
N N
HNH2
F
F
O
120b-1
 
120b-1; colorless solid; 86% yield, C17H17F2N3O, M = 317.34 g/mol, HPLC-ESI-MS: [M + 
H]+ = 318 m/z. 1H NMR (400 MHz, Methanol-D4) δ 0.70 (m, 2 H), 0.86 (m, 2 H), 2.78 (s, 3 
H), 2.89 (m, 1 H), 4.15 (s, 2 H), 7.20 (m, 2 H), 7.45 (m, 1 H), 7.84 (s, 1 H). FT-ICR-MS: 
calculated for C17H17F2N3OH+: 318.1413, found: 318.1412. 
N N
HNH2
F
F
O
O
O
120b-2
 
120b-2; colorless solid; 99% yield, C17H17F2N3O3, M = 349.34 g/mol, HPLC-ESI-MS: [M + 
H]+ = 350 m/z. 1H NMR (400 MHz, CDCl3) δ 2.73 (s, 3 H), 3.74 (s, 2 H), 3.78 (s, 3 H), 4.26 
(d, J = 5.59 Hz, 1 H), 6.95 (m, 2 H), 7.23 (m, 1 H), 7.85 (s, 1 H), 8.52 (t, J = 5.47 Hz, 1 H). 
FT-ICR-MS: calculated for C17H17F2N3O3H+: 350.1311, found: 350.1309. 
 
N N
NH2
F
F
O
120b-3
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120b-3; colorless solid; 95% yield, C18H19F2N3O, M = 331.37 g/mol, HPLC-ESI-MS: [M + 
H]+ = 332 m/z. 
N N
O
NH2
F
F
O
120b-4
 
120b-4; colorless solid; 91% yield, C18H19F2N3O2, M = 347.37 g/mol, HPLC-ESI-MS: [M + 
H]+ = 348 m/z. 1H NMR (400 MHz, CDCl3) δ 2.66 (s, 3 H), 3.69 (m, 10 H), 6.90 (m, 2 H), 
7.22 (m, 2 H). 
N N
NH2
F
F
O
O
O
120b-5
 
120b-5; yellow solid; 89% yield, C22H25F2N3O3, M = 417.46 g/mol, HPLC-ESI-MS: [M + 
H]+ = 418 m/z. 
N N
HNH2
F
F
N OO120b-6
 
120b-6; colorless solid; 98% yield, C18H16F2N4O2, M = 358.35 g/mol, HPLC-ESI-MS: [M + 
H]+ = 359 m/z. 1H NMR (400 MHz, Methanol-D4) δ 2.44 (s, 3 H), 2.85 (s, 3 H), 4.19 (s, 2 H), 
6.77 (s, 1 H), 7.23 (m, 2 H), 7.48 (m, 1 H), 7.98 (s, 1 H). FT-ICR-MS: calculated for 
C18H16F2N4O2H+: 359.1314, found: 359.1311. 
N N
O
NH2
F
F
NH2
120b-7
 
120b-7; pale solid; 92% yield, C18H20F2N4O, M = 346.38 g/mol, HPLC-ESI-MS: [M + H]+ = 
346 m/z. 
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N N
H
O
NH2
O
120c-1
 
120c-1; colorless solid; 87% yield, C18H21N3O2, M = 311.39 g/mol, HPLC-ESI-MS: [M + H]+ 
= 312 m/z. FT-ICR-MS: calculated for C18H21N3O2H+: 312.1707, found: 312.1708. 
N N
O
NH2
O
120c-2
 
120c-2; colorless solid; 78% yield, C19H23N3O2, M = 325.41 g/mol, HPLC-ESI-MS: [M + H]+ 
= 326 m/z. FT-ICR-MS: calculated for C19H23N3O2H+: 326.1863, found: 326.1864. 
N N
O
NH2
O
O
120c-3
 
120c-3; colorless solid; 99% yield, C19H23N3O3, M = 341.41 g/mol, HPLC-ESI-MS: [M + H]+ 
= 342 m/z. 1H NMR (400 MHz, CDCl3) δ 2.63 (s, 3 H), 3.73 (m, 13 H), 6.91 (m, 2 H), 7.23 
(m, 3 H). FT-ICR-MS: calculated for C19H23N3O3H+: 342.1812, found: 342.1811. 
N N
H
O
NH2
O
Cl
Cl
120c-4
 
120c-4; colorless solid; 99% yield, C22H21Cl2N3O2, M = 430.34 g/mol, HPLC-ESI-MS: [M + 
H]+ = 431 m/z. 1H NMR (400 MHz, CDCl3) δ 2.70 (s, 3 H), 3.86 (s, 3 H), 4.62 (d, J = 6.4 Hz, 
2 H), 6.98 (m, 2 H), 7.21 (m, 1 H), 7.29 (m, 2 H), 7.42 (m, 2 H), 7.94 (s, 1 H), 8.54 (t, J = 6.2 
Hz, 1 H). 13C NMR (100 MHz, CDCl3) δ 22.5 (CH3), 39.8 (CH2), 42.2 (CH2), 55.3 (CH3), 
114.0 (CH), 121.8 (CH), 127.1 (CH), 129.6 (CH), 129.7 (CH), 130.5 (CH), 130.8 (C), 131.3 
(C), 132.6 (C), 138.8 (C), 146.7 (C), 151.1 (C), 157.0 (C), 159.7 (C), 164.6 (C). FT-ICR-MS: 
calculated for C22H21Cl2N3O2H+: 430.1084, found: 430.1084. 
  
125
N N
HNH2
O
O
N
N
120c-5
 
120c-5; colorless solid; 68% yield, C20H23N5O2, M = 365.44 g/mol, HPLC-ESI-MS: [M + H]+ 
= 366 m/z. 
N N
HNH2
O
O N O120c-6
 
120c-6; colorless solid; 87% yield, C19H20N4O3, M = 352.40 g/mol, HPLC-ESI-MS: [M + H]+ 
= 353 m/z. 1H NMR (400 MHz, Methanol-D4) δ 2.43 (s, 3 H), 2.95 (s, 3 H), 3.88 (s, 3 H), 4.41 
(s, 2 H), 6.73 (s, 1 H), 7.14 (m, 2 H), 7.47 (m, 2 H), 8.16 (s, 1 H). 13C NMR (100 MHz, 
Methanol-D4) δ 12.4 (CH3), 21.5 (CH3), 37.7 (CH2), 56.1 (CH3), 97.4 (CH), 115.9 (CH), 
124.7 (CH), 129.6 (C), 131.5 (CH), 146.3 (C), 158.1 (C), 158.9 (C), 159.7 (C), 161.5 (C), 
162.5 (C), 171.9 (C). FT-ICR-MS: calculated for C19H20N4O3H+: 353.1608, found: 353.1608. 
N N
O
NH2
O
NH2
120c-7
 
120c-7; colorless solid; 82% yield, C19H24N4O2, M = 340.43 g/mol, HPLC-ESI-MS: [M + H]+ 
= 340 m/z. 
N N
O
NH2
O
NH2
120c-8
 
120c-8; colorless solid; 79% yield, C20H26N4O2, M = 354.46 g/mol, HPLC-ESI-MS: [M + H]+ 
= 355 m/z. FT-ICR-MS: calculated for C20H26N4O2H+: 355.2129, found: 355.2128. 
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N N
H
O
NH2
O
N
NH
120c-9
 
120c-9; colorless solid; 88% yield, C21H29N5O2, M = 383.50 g/mol, HPLC-ESI-MS: [M + H]+ 
= 383 m/z. 
 
6. 1. 2. 13. 2 Route B. 
Raney Nickel (6 mL, 50% slurry in water) was added to a solution of 94 (1 eq, 0.15 mmol, 
0.048 g)  in AcOH (5 mL).  Upon disappearance of the starting material (3-24 h), the catalyst 
was filtered off through celite and the solvent was removed under reduced pressure. The 
residue was taken up in water, using 4M NaOH the solution was adjusted to pH = 8 and 
extracted with DCM/EA. The product, a colorless solid was purified by column 
chromatography with DCM/MeOH (10:1) as eluent. 
N NH2
O
NH2
F
120d-1
 
120d-1; colorless solid; 64% yield, C14H14FN3O, M = 259.29 g/mol, HPLC-ESI-MS: [M + 
H]+ = 260 m/z. 1H NMR (400 MHz, CDCl3) δ 1.35 (s, 2 H), 2.75 (s, 3 H), 3.76 (s, 2 H), 5.98 
(s, 1 H), 7.21 (m, 3 H), 7.41 (m, 1 H), 7.93 (m, 2 H). 13C NMR (100 MHz, CDCl3) δ 22.5 
(CH3), 40.7 (CH2), 115.7 (d, 2JC-F = 22.0 Hz, CH), 122.0 (CH), 124.5 (d, 3JC-F = 3.7 Hz, CH), 
126.1 (d, 2JC-F = 16.8 Hz, C), 130.4 (d, 3JC-F = 8.8 Hz, CH), 130.8 (d, 4JC-F = 2.9 Hz, CH), 
137.6 (C), 144.7 (C), 146.9 (C), 157.1 (C), 158.9 (d, 1JC-F = 245.2 Hz, C), 166.8 (C). 
N N
H
O
NH2
F
120d-2
 
120d-2; pale solid; 70% yield, C15H16FN3O, M = 273.31 g/mol, HPLC-ESI-MS: [M + H]+ = 
274 m/z. 
 
N N
H
O
NH2
F
120d-3
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120d-3; colorless solid; 53% yield, C17H18FN3O, M = 299.35 g/mol, HPLC-ESI-MS: [M + 
H]+ = 300 m/z. 1H NMR (400 MHz, CDCl3) δ 0.64 (m, 2 H), 0.83 (m, 2 H), 1.50 (s, 2 H), 2.67 
(s, 3 H), 2.88 (m, 1 H), 3.69 (s, 2 H), 7.12 (m, 1 H), 7.19 (m, 2 H), 7.37 (m, 1 H), 7.86 (s, 1 
H), 8.10 (s, 1 H).13C NMR (100 MHz, CDCl3) δ 6.5 (CH2), 22.3 (CH3), 22.4 (CH), 40.6 
(CH2), 116.2 (d, 2JC-F = 22.0 Hz, CH), 121.4 (CH), 124.4 (d, 3JC-F = 3.7 Hz, CH), 126.1 (d, 
2JC-F = 16.8 Hz, C), 130.3 (d, 3JC-F = 8.1 Hz, CH), 130.8 (d, 4JC-F = 2.9 Hz, CH), 137.1 (C), 
144.7 (C), 147.1 (C), 156.7 (C), 158.9 (d, 1JC-F = 245.9 Hz, C), 165.5 (C). 
N N
O
NH2
F
120d-4
 
120d-4; colorless solid; 48% yield, C18H20FN3O, M = 313.38 g/mol, HPLC-ESI-MS: [M + 
H]+ = 314 m/z. 1H NMR (400 MHz, CDCl3) δ 1.90 (m, 6 H), 2.70 (s, 3 H), 3.63 (m, 2 H), 3.74 
(m, 4 H), 7.13 (m, 1 H), 7.22 (m, 2 H), 7.38 (m, 1 H), 7.47 (s, 1 H). 13C NMR (100 MHz, 
CDCl3) δ  22.4 (CH3), 24.0 (CH2), 26.5 (CH2), 40.5 (CH2), 46.8 (CH2), 49.1 (CH2), 115.7 (d, 
2JC-F = 21.96 Hz, CH), 123.0 (CH), 124.4 (d, 3JC-F = 3.7 Hz, CH), 126.2 (d, 2JC-F = 16.8 Hz, 
C), 130.3 (d, 3JC-F = 8.8 Hz, CH), 130.9 (d, 4JC-F = 3.7 Hz, CH), 135.1 (C), 144.3 (C), 152.0 
(C), 156.6 (C), 158.9 (d, 1JC-F = 245.9 Hz, C), 166.3 (C).  
N N
O
NH2
F
O
O
120d-5
 
120d-5; colorless solid; 25% yield, C22H26FN3O3, M = 399.47 g/mol, HPLC-ESI-MS: [M + 
H]+ = 400 m/z. FT-ICR-MS: calculated for C22H26FN3O3H+: 400.2031, found: 400.2030. 
N N
H
O
NH2
Cl
120e
 
120e; colorless solid; 38% yield, C15H16ClN3O, M = 289.77 g/mol, HPLC-ESI-MS: [M + H]+ 
= 290 m/z. FT-ICR-MS: calculated for C15H16ClN3OH+: 290.1055, found: 290.1054. 
 
N NH2
O
NH2
Cl
Cl
120f-1
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120f-1; colorless solid; 45% yield, C14H13Cl2N3O, M = 310.19 g/mol, HPLC-ESI-MS: [M + 
H]+ = 310 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.72 (s, 3 H), 3.38 (d, J = 13.2 Hz, 1 H), 
3.63 (d, J = 13.2 Hz, 1 H), 7.49 (d, J = 8.1 Hz, 1 H), 7.54 (m, 1 H), 7.57 (s, 1 H), 7.67 (s, 1 
H), 7.78 (d, J = 1.5 Hz, 1 H), 8.06 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.3 (CH3), 
39.8 (CH2), 120.5 (CH), 127.5 (CH), 128.9 (CH), 132.1 (CH), 132.6 (C), 133.9 (C), 136.1 
(C), 136.8 (C), 146.3 (C), 147.4 (C), 157.7 (C), 165.8 (C). FT-ICR-MS: calculated for 
C14H13Cl2N3OH+: 310.0508, found: 310.0508. 
N N
H
O
NH2
Cl
Cl
120f-2
 
120f-2; colorless solid; 51% yield, C15H15Cl2N3O, M = 324.21 g/mol, HPLC-ESI-MS: [M + 
H]+ = 324 m/z. 1H NMR (400 MHz, CDCl3) δ 2.71 (s, 3 H), 3.02 (d, J = 5.1 Hz, 3 H), 3.60 (d, 
J = 13.5 Hz, 1 H), 3.71 (d, J = 13.5 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 7.32 (dd, J = 8.1, 2.03 
Hz, 1 H), 7.50 (d, J = 2.0 Hz, 1 H), 7.79 (s, 1 H), 8.07 (s, 1 H). 13C NMR (100 MHz, CDCl3) 
δ 22.4 (CH3), 26.1 (CH3), 40.4 (CH2), 121.0 (CH), 127.3 (CH), 129.6 (CH), 131.1 (CH), 
133.3 (C), 135.0 (C), 136.1 (C), 136.6 (C), 147.1 (C), 147.4 (C), 157.0 (C), 164.8 (C). FT-
ICR-MS: calculated for C15H15Cl2N3OH+: 324.0665, found: 324.0666. 
N N
H
O
NH2
Cl
Cl
120f-3
 
120f-3; colorless solid; 34% yield, C17H17Cl2N3O, M = 350.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 350 m/z. 1H NMR (400 MHz, Methanol-D4) δ 0.69 (m, 2 H), 0.84 (m, 2 H), 2.75 (s, 3 
H), 2.88 (m, 1 H), 3.61 (d, J = 13.7 Hz, 1 H), 3.82 (d, J = 14.0 Hz, 1 H), 7.37 (d, J = 8.1 Hz, 1 
H), 7.49 (m, 1 H), 7.66 (d, J = 2.0 Hz, 1 H), 7.68 (s, 1 H). 13C NMR (100 MHz, Methanol- 
D4) δ 6.6 (CH2), 22.6 (CH3), 23.6 (CH), 40.0 (CH2), 121.9 (CH), 128.9 (CH), 130.6 (CH), 
132.9 (CH), 134.4 (C), 136.5 (C), 137.2 (C), 148.9 (C), 149.1 (C), 159.4 (C), 167.8 (C). FT-
ICR-MS: calculated for C17H17Cl2N3OH+: 350.0821, found: 350.0821. 
 
N N
O
NH2
Cl
Cl
120f-4
 
120f-4; colorless solid; 48% yield, C18H19Cl2N3O, M = 364.28 g/mol, HPLC-ESI-MS: [M + 
H]+ = 364 m/z. 1H NMR (400 MHz, Methanol-D4) δ 1.96 (m, 4 H), 2.75 (s, 3 H), 3.62 (t, J = 
6.4 Hz, 2 H), 3.72 (m, 3 H), 3.98 (d, J = 14.2 Hz, 1 H), 7.40 (m, 2 H), 7.51 (dd, J = 8.4, 2.0 
Hz, 1 H), 7.68 (d, J = 2.0 Hz, 1 H). 13C NMR (100 MHz, Methanol-D4) δ 22.5 (CH3), 25.0 
(CH2), 27.4 (CH2), 39.1 (CH2), 48.0 (CH2),  50.4 (CH2), 123.4 (CH), 129.0 (CH), 130.7 (CH), 
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132.4 (C), 133.0 (CH), 134.4 (C), 136.6 (C), 136.8 (C), 149.5 (C), 154.2 (C), 159.4 (C), 167.8 
(C). FT-ICR-MS: calculated for C18H19Cl2N3OH+: 364.0978, found: 364.0980. 
N N
O
NH2
Cl
Cl
O
120f-5
 
120f-5; colorless solid; 44% yield, C18H19Cl2N3O2, M = 380.28 g/mol, HPLC-ESI-MS: [M + 
H]+ = 380.28 m/z. 1H NMR (400 MHz, CDCl3) δ 2.73 (s, 3 H), 3.70 (m, 8 H), 3.79 (s, 2 H), 
7.22 (m, 2 H), 7.35 (dd, J = 8.1, 1.5 Hz, 1 H), 7.51 (d, J = 1.8 Hz, 1 H). 13C NMR (100 MHz, 
CDCl3) δ 22.5 (CH3), 40.2 (CH2), 42.7 (CH2), 47.8 (CH2), 66.7 (CH2), 66.9 (CH2), 122.6 
(CH), 127.3 (CH), 129.6 (CH), 131.1 (CH), 133.2 (C), 135.1 (C), 135.8 (C), 146.8 (C), 151.1 
(C), 157.3 (C), 167.1 (C). FT-ICR-MS: calculated for C18H19Cl2N3O2H+: 380.0927, found: 
380.0928. 
N N
NH2
Cl
Cl
O
O
O
120f-6
 
120f-6; yellow solid; 15% yield, C22H25Cl2N3O3, M = 450.37 g/mol, HPLC-ESI-MS: [M + 
H]+ = 450 m/z. FT-ICR-MS: calculated for C22H25Cl2N3O3H+: 450.1346, found: 450.1349. 
 
6. 1. 2. 13. 3 Synthesis of 120h. 
N
O
N
H
Cl
Cl
NH2
NH2
O
120g
 
120g: To the degassed solution of 94e-4 (1 eq, 0.25 mmol, 0.091 g) in acetic acid (0.25 mL) 
Raney Nickel (6 mL, 50% slurry in water) was added and the mixture was stirred 48 h at 50 
oC under argon. The catalyst was filtered off through celite and the solvent was removed 
under reduced pressure. The residue was taken up in water, using 4M NaOH the solution was 
adjusted to pH = 8 and extracted with DCM/EA. The product, a colorless solid (0.055 g, 
60%), was purified by column chromatography with DCM/MeOH (10:1) as eluent. 
C16H16Cl2N4O2, M = 367.24 g/mol, HPLC-ESI-MS: [M + H]+ = 367 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 1.09 (s, 2 H), 2.75 (s, 3 H), 3.51 (m, 2 H), 3.91 (d, J = 5.1 Hz, 2 H), 7.13 (s, 1 
H), 7.53 (m, 4 H), 7.78 (s, 1 H), 8.77 (t, J = 5.1 Hz, 1 H). 13C NMR (100 MHz, CDCl3) δ 22.2 
(CH3), 31.3 (CH2), 42.0 (CH2), 120.3 (CH), 127.5 (CH), 128.9 (CH), 132.1 (CH), 133.9 (C), 
136.0 (C), 146.4 (C), 146.8 (C), 157.7 (C), 163.5 (C), 170.5 (C). 
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N
O
N
H
Cl
Cl
NH2
CN
120h
 
120h: 120g (0.054 g, 0.15 mmol) was dissolved in POCl3 (2 mL), and the mixture was heated 
at 70 ºC for 2 h. The excess of the reagent was removed in vacuo. The product as a yellow 
solid (0.037 g, 70%) was isolated by column chromatography (MeOH/DCM, 40:1). 
C16H14Cl2N4O, M = 349.22 g/mol, HPLC-ESI-MS: [M + H]+ = 349 m/z. 1H NMR (400 MHz, 
DMSO-D6) δ 2.75 (s, 3 H), 3.40 (m, 1 H), 3.66 (d, J = 12.0 Hz, 1 H), 4.31 (d, J = 5.6 Hz, 2 
H), 7.54 (m, 2 H), 7.60 (s, 1 H), 7.80 (m, 1 H), 9.36 (t, J = 5.7 Hz, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 22.3 (CH3), 27.7 (CH2), 39.6 (CH2), 117.5 (C), 120.8 (CH), 127.6 (CH), 129.0 
(CH), 132.1 (CH), 132.6 (C), 134.0 (C), 135.8 (C), 137.2 (C), 146.1 (C), 146.6 (C), 158.2 (C), 
164.3 (C).  FT-ICR-MS: calculated for C16H14Cl2N4OH+: 349.0617, found: 349.0620. 
 
6. 1. 2. 14 Synthesis of 6-aminomethyl-pyridines 121. 
General procedure for the synthesis of 126: Triethylamine (1.2 eq, 1.2 mmol, 0.167 mL) 
and ethyl chloroformate (1.2 eq, 1.2 mmol, 0.114 mL) were added successively to the solution 
of 96  eq, 1 mmol) in THF (15 mL) and the mixture was stirred at rt for 30 minutes. After 
decreasing the temperature to 0 ˚C, the solution of sodium borohydride (10 eq, 10 mmol, 
0.378 g) in water (5 mL) was added dropwise and the mixture was stirred at 0 ˚C for 
additional 30 minutes. The residue was acidified with 1M HCl, concentrated in vacuo and 
extracted with DCM/EA. The combined organic phases were dried over anhydrous Na2SO4 
and concentrated. The product 126 was isolated by column chromatography with 
DCM/MeOH (10:1) as eluent. 
N
O
NH2
F
OH
126a
 
126a; colorless solid; 61% yield, C14H13FN2O2, M = 260.27 g/mol, HPLC-ESI-MS: [M + H]+ 
= 261 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.50 (s, 3 H), 4.56 (d, J = 5.6 Hz, 2 H), 5.46 (t, 
J = 5.9 Hz, 1 H), 7.26 (m, 3 H), 7.44 (m, 3 H), 7.79 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) 
δ 22.3 (CH3), 63.9 (CH2), 115.7 (d, 2JC-F = 22.0 Hz, CH), 118.5 (CH), 124.1 (d, 3JC-F = 3.7 
Hz, CH), 125.9 (d, 2JC-F = 15.4 Hz, C), 130.5 (d, 3JC-F = 8.1 Hz, CH), 130.9 (d, 4JC-F = 2.9 Hz, 
CH), 131.3 (C), 140.7 (C), 153.3 (C), 158.8 (d, 1JC-F =246.6, C), 160.6 (C), 169.0 (C). 
N
O
NH2
Cl
OH
126b
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126b; colorless solid; 71% yield, C14H13ClN2O2, M = 276.72 g/mol, HPLC-ESI-MS: [M + 
H]+ = 277 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.49 (s, 3 H), 4.57 (d, J = 5.6 Hz, 2 H), 5.49 
(t, J = 5.3 Hz, 1 H), 7.25 (s, 1 H), 7.53 (m, 5 H), 7.83 (s, 1 H). 13C NMR (100 MHz, DMSO-
D6) δ 22.2 (CH3), 63.95 (CH2), 117.6 (CH), 128.5 (CH), 1230.0 (CH), 130.4 (C), 133.3 (C), 
137.4 (C), 144.9 (C), 153.3 (C), 161.1 (C), 169.7 (C). 
N
O
NH2
Cl
Cl
OH
126c
 
126c; colorless solid; 77% yield, C14H12Cl2N2O2, M = 311.17 g/mol, HPLC-ESI-MS: [M + 
H]+ = 311 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.55 (s, 3 H), 4.63 (s, 2 H), 7.23 (s, 1 H), 
7.27 (m, 1 H), 7.31 (m, 1 H), 7.50 (m, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.2 (CH3), 
65.2 (CH2), 120.3 (CH), 128.0 (CH), 130.4 (CH), 132.3 (C), 133.1 (CH), 134.6 (C), 136.3 
(C), 136.8 (C), 146.4 (C), 155.3 (C), 162.1 (C), 172.2 (C). 
N
O
NH2
O
OH
126d
 
126d; colorless solid; 99% yield, C15H16N2O3, M = 272.31 g/mol, HPLC-ESI-MS: [M + H]+ = 
273 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.47 (s, 3 H), 3.79 (s, 3 H), 4.55 (d, J = 5.9 Hz, 2 
H), 5.43 (m, 1 H), 7.01 (m, 2 H), 7.23 (s, 1 H), 7.46 (m, 3 H), 7.77 (s, 1 H). 13C NMR 
(100 MHz, DMSO-D6) δ 22.1 (CH3), 55.2 (CH3), 64.0 (CH2), 113.9 (CH), 117.6 (CH), 129.4 
(CH), 130.4 (C), 130.8 (C), 145.7 (C), 153.1 (C), 159.4 (C), 160.7 (C), 170.1 (C). 
General procedure for the synthesis of 127: Thionyl chloride (4 eq, 2 mmol, 0.145 mL) was 
added to a suspension of 126 (1 eq, 0.5 mmol) in toluene (10 mL) and the mixture was stirred 
at 60 ˚C for 16 h. The solvent was removed under reduced pressure and the product 127 was 
isolated by column chromatography with DCM/MeOH gradient (40:1 to 10:1) as eluent. 
N
O
NH2
F
Cl
127a
 
127a; colorless solid; 85% yield, C14H12Cl2FN2O, M = 278.72 g/mol, HPLC-ESI-MS: [M + 
H]+ = 279 m/z. 1H NMR (400 MHz, CDCl3) δ 2.65 (s, 3 H), 4.64 (s, 2 H), 5.61 (s, 1 H), 5.88 
(s, 1 H), 7.18 (m, 2 H), 7.38 (m, 3 H). 13C NMR (100 MHz, CDCl3) δ 22.6 (CH3), 46.2 (CH2), 
115.9 (d, 2JC-F = 22.0 Hz, CH), 121.56 (CH), 124.5 (d, 3JC-F = 3.7 Hz, CH), 124.8 (d, 2JC-F = 
15.4 Hz, C), 130.8 (d, 4JC-F = 2.9 Hz, CH), 130.9 (d, 3JC-F = 8.1 Hz, CH), 142.3 (C), 155.6 
(C), 156.2 (C), 159.1 (d, 1JC-F =246.6, C), 160.3 (C), 169.5 (C). 
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127b; colorless solid; 76% yield, C14H12Cl2N2O, M = 295.17 g/mol, HPLC-ESI-MS: [M + 
H]+ = 295 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.51 (s, 3 H), 4.77 (s, 2 H), 7.39 (s, 1 H), 
7.53 (m, 4 H), 7.59 (s, 1 H), 7.91 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.1 (CH3), 46.5 
(CH2), 121.0 (CH), 128.5 (CH), 130.0 (CH), 131.7 (C), 133.6 (C), 136.6 (C), 145.5 (C), 154.4 
(C), 155.4 (C), 169.2 (C). 
N
O
NH2
Cl
Cl
Cl
127c
 
127c; colorless solid; 75% yield, C14H11Cl3N2O, M = 329.62 g/mol, HPLC-ESI-MS: [M + H]+ 
= 330 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.53 (s, 3 H), 4.78 (s, 2 H), 7.31 (s, 1 H), 7.40 
(d, J = 8.1 Hz, 1 H), 7.50 (dd, J = 7.5, 2.0 Hz, 1 H), 7.54 (s, 1 H), 7.73 (d, J = 2.0 Hz, 1 H), 
7.86 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.3 (CH3), 46.3 (CH2), 121.5 (CH), 127.0 
(CH), 128.9 (CH), 132.0 (CH), 132.5 (C), 132.8 (C), 134.0 (C), 135.2 (C), 143.7 (C), 154.3 
(C), 154.9 (C), 168.1 (C). 
N
O
NH2
O
Cl
127d
 
127d; colorless solid; 79% yield, C15H15ClN2O2, M = 290.75 g/mol, HPLC-ESI-MS: [M + 
H]+ = 291 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.50 (s, 3 H), 3.79 (s, 3 H), 4.76 (s, 2 H), 
7.01 (m, 2 H), 7.36 (s, 1 H), 7.47 (m, 2 H), 7.55 (s, 1 H), 7.86 (s, 1 H). 13C NMR (100 MHz, 
DMSO-D6) δ 22.3 (CH3), 46.3 (CH2), 55.2 (CH3), 114.0 (CH), 121.0 (CH), 129.5 (CH), 130.1 
(C), 131.6 (C), 146.3 (C), 154.2 (C), 155.1 (C), 159.6 (C), 169.7 (C). 
General procedure for the synthesis of 128: 127 (1 eq, 0.5 mmol) was dissolved in dry 
DMF (2 mL) and a suspension of phthalimide (1.5 eq, 0.75 mmol, 0.110 g) and t-BuOK (1.5 
eq, 0.75 mmol, 0.084 g) in DMF (2 mL) was added. The mixture was stirred at 60 ˚C for 4 h, 
then the solvent was removed under reduced pressure and the product 128 was isolated by 
column chromatography (DCM/MeOH, 40:1). 
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128a; colorless solid; 65% yield, C22H16FN3O3, M = 389.39 g/mol, HPLC-ESI-MS: [M + H]+ 
= 390 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.42 (s, 3 H), 4.90 (s, 2 H), 7.23 (m, 3 H), 7.41 
(m, 3 H), 7.87 (m, 4 H), 7.94 (s, 1 H). 
N
O
NH2
N
O
O
Cl
128b
 
128b; colorless solid; 82% yield, C22H16ClN3O3, M = 405.84 g/mol, HPLC-ESI-MS: [M + 
H]+ = 406 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.40 (s, 3 H), 4.90 (s, 2 H), 7.23 (s, 1 H), 
7.48 (m, 4 H), 7.53 (s, 1 H), 7.88 (m, 5 H). 13C NMR (100 MHz, DMSO-D6) δ 22.7 (CH3), 
42.6 (CH2), 119.1 (CH), 123.6 (CH), 128.7 (CH), 130.4 (CH), 131.4 (C), 132.1 (C), 133.8 
(C), 134.9 (CH), 137.2 (C), 145.6 (C), 154.2 (C), 154.8 (C), 168.2 (C), 169.7 (C). 
N
O
NH2
N
O
O
Cl
Cl
128c
 
128c; colorless solid; 80% yield, C22H15Cl2N3O3, M = 440.29 g/mol, HPLC-ESI-MS: [M + 
H]+ = 440 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.42 (s, 3 H), 4.90 (s, 2 H), 7.16 (s, 1 H), 
7.35 (d, J = 8.4 Hz, 1 H), 7.46 (dd, J = 8.1, 1.8 Hz, 2 H), 7.67 (d, J = 1.8 Hz, 1 H), 7.79 (s, 1 
H), 7.88 (m, 4 H). 13C NMR (100 MHz, DMSO-D6) δ 22.5 (CH3), 46.2 (CH2), 119.2 (CH), 
123.3 (CH), 126.9 (CH), 128.8 (CH), 131.8 (C), 132.1 (CH), 132.8 (C), 133.8 (C), 134.6 
(CH), 135.5 (C), 143.5 (C), 153.8 (C), 154.0 (C), 167.8 (C), 168.3 (C). 
N
O
NH2
N
O
O
O
128d
 
128d; colorless solid; 90% yield, C23H19Cl2N3O4, M = 401.43 g/mol, HPLC-ESI-MS: [M + 
H]+ = 402 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.38 (s, 3 H), 3.76 (s, 3 H), 4.89 (s, 2 H), 
6.98 (m, 2 H), 7.17 (s, 1 H), 7.42 (m, 2 H), 7.48 (s, 1 H), 7.80 (s, 1 H), 7.88 (m, 4 H). 
13C NMR (100 MHz, DMSO-D6) δ 22.3 (CH3), 42.2 (CH2), 55.2 (CH3), 113.9 (CH), 118.8 
(CH), 123.3 (CH), 129.5 (CH), 130.2 (C), 131.0 (C), 131.8 (C), 134.6 (CH), 146.1 (C), 153.7 
(C), 154.1 (C), 159.5 (C), 167.8 (C), 169.8 (C). 
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General procedure for the synthesis of 121: 128 (1 eq, 0.5 mmol) was suspended in 30% 
KOH (5 mL) and the mixture was stirred at 110 ˚C for 4 h. After cooling to room temperature 
the product was extracted with DCM. The combined organic phases were dried over 
anhydrous Na2SO4 and concentrated. The product was purified by column chromatography 
with DCM/MeOH (10:1) as eluent. 
N
O
NH2
F
NH2
121a
 
121a; yellow solid; 91% yield, C14H14FN3O, M = 259.29 g/mol, HPLC-ESI-MS: [M + H]+ = 
260 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.50 (s, 3 H), 3.79 (s, 2 H), 7.27 (m, 3 H), 7.42 
(m, 3 H), 7.76 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.4 (CH3), 47.1 (CH2), 115.6 (d, 
2JC-F = 22.0 Hz, CH), 119.4 (CH), 124.1 (d, 3JC-F = 3.7 Hz, CH), 126.0 (d, 2JC-F = 15.4 Hz, C), 
130.4 (d, 3JC-F = 8.1 Hz, CH), 131.0 (d, 4JC-F = 2.9 Hz, CH), 131.1 (C), 140.7 (C), 153.2 (C), 
158.8 (d, 1JC-F =248.1, C), 161.8 (C), 169.1 (C). 
N
O
NH2
NH2
Cl
121b
 
121b; yellow solid; 89% yield, C14H14ClN3O, M = 275.74 g/mol, HPLC-ESI-MS: [M + H]+ = 
276 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.48 (s, 3 H), 7.27 (s, 1 H), 7.51 (m, 5 H), 7.81 (s, 
1 H). 13C NMR (100 MHz, DMSO-D6) δ 22.2 (CH3), 47.2 (CH2), 118.4 (CH), 128.4 (CH), 
130.0 (CH), 130.1 (C), 133.3 (C), 137.5 (C), 144.8 (C), 153.2 (C), 162.3 (C), 169.8 (C). 
N
O
NH2
NH2
Cl
Cl
121c
 
121c; colorless solid; 84% yield, C14H13Cl2N3O, M = 310.19 g/mol, HPLC-ESI-MS: [M + 
H]+ = 310 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.50 (s, 3 H), 3.80 (s, 2 H), 7.18 (s, 1 H), 
7.44 (m, 3 H), 7.72 (m, 2 H). 13C NMR (100 MHz, DMSO-D6) δ 22.4 (CH3), 47.0 (CH2), 
118.9 (CH), 126.8 (CH), 128.8 (CH), 130.8 (C), 132.1 (CH), 132.8 (C), 133.6 (C), 136.0 (C), 
143.1 (C), 153.1 (C), 161.7 (C), 168.7 (C). 
N
O
NH2
NH2
O
121d
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121d; yellow solid; 79% yield, C15H17N3O2, M = 271.32 g/mol, HPLC-ESI-MS: [M + H]+ = 
272 m/z. 1H NMR (400 MHz, DMSO-D6) δ 2.46 (s, 3 H), 3.77 (s, 2 H), 3.78 (s, 3 H), 6.99 (d, 
J = 8.7 Hz, 2 H), 7.24 (s, 1 H), 7.46 (m, 3 H), 7.74 (s, 1 H). 13C NMR (100 MHz, DMSO-D6) 
δ 22.2 (CH3), 47.2 (CH2), 55.2 (CH3), 113.8 (CH), 118.4 (CH), 129.5 (CH), 130.1 (C), 130.9 
(C), 145.6 (C), 153.1 (C), 159.4 (C), 161.9 (C), 170.3 (C). 
 
6. 1. 2. 15 Synthesis of 3-aminomethyl-pyridines 122. 
6. 1. 2. 15. 1 Route A. 
General procedure for the synthesis of 129 - Boc-protection: Boc2O (1.5 eq, 0.225 mmol, 
0.049 g) was added to a solution of 116 (1 eq, 0.15 mmol) in dioxane (5  mL) and the mixture 
was stirred for 16 h at 60 ºC. The solvent was removed under reduced pressure and the 
product was isolated by column chromatography with DCM/MeOH (40:1) as eluent. 
N
BocHN
OHO
Cl
Cl
129a
 
129a; pale solid; 43% yield, C19H20Cl2N2O4, M = 411.29 g/mol, HPLC-ESI-MS: [M + H]+ = 
411 m/z. 
N
BocHN
OHO
O129b
 
129b; colorless solid; 38% yield, C20H24N2O5, M = 372.43 g/mol, HPLC-ESI-MS: [M + H]+ = 
373 m/z. 
General procedure for the synthesis of 130: These compounds were prepared according to 
the procedure for 94 and 99, using compound 129 as a starting material. 
N
BocHN
NHO
Cl
Cl
130a-1
 
130a-1; colorless solid; 63% yield, C22H25Cl2N3O3, M = 450.37 g/mol, HPLC-ESI-MS: [M + 
H]+ = 450 m/z. 
N
BocHN
NO
Cl
Cl
130a-2
 
130a-2; colorless solid; 54% yield, C23H27Cl2N3O3, M = 464.40 g/mol, HPLC-ESI-MS: [M + 
H]+ = 464 m/z. 
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N
BocHN
NO
Cl
O
Cl
130a-3
 
130a-3; colorless solid; 80% yield, C23H27Cl2N3O5, M = 480.40 g/mol, HPLC-ESI-MS: [M + 
H]+ = 480 m/z. 
N
BocHN
NHO
O130b-1
 
130b-1; colorless solid; 76% yield, C23H29N3O4, M = 411.51 g/mol, HPLC-ESI-MS: [M + 
H]+ = 412 m/z. 
N
BocHN
NO
O130b-2
 
130b-2; colorless solid; 86% yield, C24H31N3O4, M = 425.53 g/mol, HPLC-ESI-MS: [M + 
H]+ = 426 m/z. 
N
BocHN
NO
O
O
130b-3
 
130b-3; colorless solid; 92% yield, C24H31N3O5, M = 441.53 g/mol, HPLC-ESI-MS: [M + 
H]+ = 442 m/z. 
General procedure for the synthesis of 122 - deprotection: These compounds were 
prepared according to the procedure for 120a-c, using compound 130 as a starting material. 
N
NH2
NHO
Cl
Cl
122a-1
 
122a-1; colorless solid; 65% yield, C17H17Cl2N3O, M = 350.25 g/mol, HPLC-ESI-MS: [M + 
H]+ = 350 m/z. 
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N
NH2
NO
Cl
Cl
122a-2
 
122a-2; yellow solid; 57% yield, C18H19Cl2N3O, M = 364.28 g/mol, HPLC-ESI-MS: [M + 
H]+ = 364 m/z. 
 
N
NH2
NO
Cl
O
Cl
120a-3
 
122a-3; colorless solid; 63% yield, C18H19Cl2N3O2, M = 380.28 g/mol, HPLC-ESI-MS: [M + 
H]+ = 380 m/z. 
 
N
NH2
NHO
O122b-1
 
122b-1; colorless solid; 75% yield, C18H21N3O2, M = 311.39 g/mol, HPLC-ESI-MS: [M + 
H]+ = 312 m/z. 
N
NH2
NO
O122b-2
 
122b-2; yellow solid; 83% yield, C19H23N3O2, M = 325.41 g/mol, HPLC-ESI-MS: [M + H]+ = 
326 m/z. 
N
NH2
NO
O
O
122b-3
 
122b-3; yellow solid; 70% yield, C19H23N3O3, M = 341.41 g/mol, HPLC-ESI-MS: [M + H]+ = 
442 m/z. 
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6. 1. 2. 15. 2 Route B. 
51% aqueous solution of hydrazine (20 eq, 3 mmol, 0.20 mL) was added dropwise with in 
20 min to a suspension of 99 (1 eq, 0.15 mmol) and Raney Nickel (1 mL, 50% slurry in water) 
dissolved in THF (60 mL). The catalyst was then filtered off and the solution was acidified 
with TFA (5 mL). The solvent was removed under reduced pressure and the product was 
purified by column chromatography with DCM/MeOH (10:1) as eluent. 
N
NO
NH2
F122c
 
122c; colorless solid; 46% yield, C18H20FN3O, M = 313.38 g/mol, HPLC-ESI-MS: [M + H]+ 
= 314 m/z. 
N
NO
NH2
Cl122d-1
 
122d-1; colorless solid; 53% yield, C18H20ClN3O, M = 329.83 g/mol, HPLC-ESI-MS: [M + 
H]+ = 330 m/z. 1H NMR (400 MHz, CDCl3) δ 1.99 (m, 4 H), 2.78 (s, 3 H), 3.43 (t, J = 6.6 Hz, 
2 H), 3.67 (t, J = 7.0 Hz, 2 H), 4.18 (s, 2 H), 7.49 (m, 2 H), 7.87 (s, 1 H), 8.08 (m, 2 H). 
13C NMR (100 MHz, CDCl3) δ 22.8 (CH3), 25.2 (CH2), 27.1 (CH2), 39.2 (CH2), 47.4 (CH2), 
30.5 (CH2), 117.0 (CH), 123.7 (C), 129.7 (CH), 130.0 (CH), 137.1 (C), 137.8 (C), 148.4 (C), 
157.7 (C), 161.9 (C), 168.7 (C). 
N
NO
NH2
Cl
O
122d-2
 
122d-2; colorless solid; 48% yield, C18H20ClN3O2, M = 345.83 g/mol, HPLC-ESI-MS: [M + 
H]+ = 346 m/z. 
N
NO
NH2
Cl
O
O
122d-3
 
122d-3; colorless solid; 52% yield, C22H26ClN3O3, M = 415.92 g/mol, HPLC-ESI-MS: [M 
+ H]+ = 416 m/z. 
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6. 2 Biological screening. 
Antimycotic assay: 10 000 HeLa cells (Human cervix carcinoma [ATCC, Cat. No. CCL-2]) 
per well or CHO cells were seeded in a 96 well plate in the presence or absence of 10 µM 
compound, infected with Candida albicans (SC5314) [CFU 5-500 (optimum 50, 50 µL 1000 
CFU/mL)] and incubated at 37°C 5% CO2 in a total volume of 200 µL media (RPMI 1640, 
10% FCS, 1% glutamine) for 5 days .  
a) Experiment description. 
Dye: Fluorescein diacetat Cells: HeLa Cell control: A1:H1 
Filter:  Ex.485  Em.538 m.o.i.: 0.005 Microbe control: A2:D2 
Experiment 
no.: 
can train 1 Microbe: 
Candida 
albicans 
SC 5314 
Drug control: E2:H2 
Name: Doris Incubation: 5 Days Compound position: A3-H12 
Date: 16-21.10.2008 Incubation time: 10-15 min 
  
Concentration: 
10 µM 
b) Fluorescence measurement. 
Crude Date  (fluorescence) 
1 2 3 4 5 6 7 8 9 10 11 12   
16578 2669 819 997 1716 1151 1784 1175 529 1616 2031 2250 A 
14928 2620 425 1006 1996 1067 1743 802 1156 1361 672 273 B 
16272 2156 1320 2215 739 1334 908 1719 1807 2053 1033 310 C 
16576 2722 1119 930 1247 497 9393 2243 2069 1556 1864 2146 D 
15268 15759 1233 1690 1232 3887 580 1033 2556 1433 1740 3046 E 
14819 15032 1886 1611 2348 1867 3130 2323 1558 578 3909 650 F 
16596 15846 1455 2080 2793 1700 1856 2818 1517 2156 522 3000 G 
17218 15705 1409 2362 2049 1483 2444 2207 1006 2310 2894 2096 H 
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c) Antimicrobial activity. 
Antimicrobial activity (percent of cell control) 
1 2 3 4 5 6 7 8 9 10 11 12   
104% 1% -13% -11% -6% -10% -6% -10% -15% -7% -4% -2% A 
92% 1% -16% -11% -4% -11% -6% -13% -10% -9% -14% -17% B 
102% -3% -9% -2% -13% -9% -12% -6% -5% -4% -11% -17% C 
104% 1% -11% -12% -10% -15% 51% -2% -4% -7% -5% -3% D 
94% 98% -10% -6% -10% 10% -15% -11% 0% -8% -6% 4% E 
91% 93% -5% -7% -1% -5% 4% -2% -7% -15% 10% -14% F 
104% 99% -8% -3% 2% -6% -5% 2% -8% -3% -15% 3% G 
109% 98% -8% -1% -4% -8% -1% -2% -11% -2% 3% -3% H 
Figure 14. Plot of absorbance at 405 nm versus time. 
  
To monitor the immediate effect of C. albicans on the host cells the individual wells were 
microscopically analysed after 18 h of incubation for growth of C. albicans and the state of 
the host cells. After 5 days the activities of the compounds were determined by analysing the 
relative number and vitality of surviving human cell lines as measured by hydrolysis of 
fluorescein diacetate. The wells of the plate were washed with phosphate-buffered saline 
(PBS, 200 µL) and then filled with 200 µL PBS containing 10 µg/mL fluorescein diacetate.  
After a 45-min incubation at room temperature, fluorescence [RFU (relative fluorescence 
units)] was measured at 485 nm excitation and 538 nm emission wavelength (Figure 14). The 
activity was calculated using the equation: 
( ) ( )controlmicrobecontrolcell
welltest
RFURFU
RFU
Activity
−−
−
−
=%  . 
A cut off of 40% of total fluorescence intensity per well in comparison to the control wells 
containing only host cells was chosen to select compounds preventing growth of C. albicans 
to a significant extend without strongly impairing the vitality of the host cells. 
Absorbance based antimicotic assay: Immune cells (BMDMs, bone marrow-derived 
macrophages - 2.5x103 cells/mL) in YPD media were dispensed in a 96 well plate. The cells 
were infected with Candida glabrata and incubated at 30 °C in a total volume of 200 µL 
media in the presence of the appropriate compound at eight different concentrations. After 2 
days the plate was shaken on a MixMate and the absorbance (OD600) was measured with 
Vicor plate reader.  
In vitro DPP-4 inhibition assay: The screening of the compounds for DPP-4 inhibitory 
activity was performed by using a DPP-4 drug discovery kit (AK499-0001, Enzo Life 
Sciences). The inhibition of the human recombinant DPP-4 activity was measured by 
following the increase of absorbance upon cleavage of the chromogenic substrate Gly-Pro-
pNA (pNA is p-nitroaniline) according to the protocol of the manufacturer (Scheme 59). 
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 Scheme 73. DPP-4 catalyzed hydrolysis of  chromogenic substrate - Gly-Pro-p-nitroanilin. 
NH2 N
O N
HO
NO2
NH2 N
O
O OH NH2
NO2
DPP-4
+
p-Nitroanilin
 
 
In order to determine the range over which the reaction was linear, the absorbance at 405 nm 
was continuously measured for 60 min (Figure 15). As an optimal time for the experiment 16 
min were chosen.  
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Figure 15. Plot of absorbance at 405 nm versus time. 
 
Reactions were carried out at 37 ˚C in Tris buffer (50 mM, pH 7.5) containing 0.18 mU/well 
of enzyme, 50 µM of substrate (the final substrate concentration was chosen around Km value 
obtained under the assay conditions) and variable concentration of the inhibitor. For the 
compound dilutions DMSO was used and its final solvent concentration did not exceed 1%. 
Enzyme DPP-4 was first preincubated with the compounds for 10 min prior the substrate 
addition. After preincubation period the substrate was added and the reaction was followed by 
continuous absorbance measurement at 405 nm for 16 min using a MRX Revelation plate 
reader (Dynex Technologies). The experiment was repeated 3 times for each test compound 
and the values were averaged.  
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DPP-4 inhibition by 120h
y = 0,003x + 0,0411
y = 0,0018x + 0,0414
y = 0,0006x + 0,0405
y = 0,0004x + 0,0421
0,038
0,048
0,058
0,068
0,078
0,088
0,098
0 5 10 15
Time (min)
A
bs
o
rb
a
n
ce
 
at
 
40
5 
n
m
Negative
control
0.010 µM
0.050 µM
0.0250 µM
 
Figure 16. DPP-4 assay: inhibition of DPP-4 by 120h. 
 
To obtain the IC50 values the active compounds were titrated up to eight concentrations 
(Figure 16). The IC50 values were calculated from the trend line of the curve generated after 
plotting the percentage of activity versus inhibitor concentration. Percent remaining activity in 
presence of the inhibitor was calculated using the equation: 100% ⋅=
V
VActivity i , 
where Vi is the initial velocity in presence of the inhibitor at concentration i, V is the initial 
velocity of the negative control (enzyme without inhibitor).  
The type of inhibition was determined by measuring the rate of hydrolysis of Gly-Pro-pNA at 
four different concentrations of substrate and inhibitor. To calculate the initial rate of pNA 
formation the absorption at 405 nm was converted to nanomoles of pNA using a standard 
calibration curve (Figure 17). 
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Figure 17. UV-absorption measurement of p-nitroaniline release: calibration curve. 
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For each concentration of inhibitor the initial rates were used for Lineweaver-Burk plots 
(Figure 18). The inhibition constant Ki was obtained from the expression: 






−





=
1
m
p
i
K
K
iK  
where Km is concentration of substrate that leads to half-maximal velocity, and Kp is the 
effective Michaelis constant in presence of the inhibitor at concentration i. 
 
a) Release of pNA at the different substrate concentration (10, 50, 100 and 150 µM) without 
inhibitor. 
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b) Release of pNA at the different substrate concentration with the inhibitor at 10 nM 
concentration. 
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c) Release of pNA at the different substrate concentration with the inhibitor at 50 nM 
concentration. 
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d) Lineweaver-Burk plot - competitive inhibition. 
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Figure 18. Data analysis for the inhibition type and Ki calculation. 
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MKm µ5.37=  





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K
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nMKi 25.5 ±=  
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IC50 = 11.44 nM 
nMK i 5.09.4 ±=  
Type of inhibition: competitive 
In vitro DPP-8 inhibition assay: The screening of the compounds for DPP-8 inhibitory 
activity was performed using human recombinant DPP-8, supplied by Enzo Life Sciences. 
The substrate used for the screening was Gly-Pro-pNA. As DPP-8 catalytic efficiency for this 
substrate is 2-fold lower in comparison to DPP-4 the assay condition had to be modified. The 
substrate concentration, 300 µM, was chosen around Km value (221 µM) obtained under assay 
conditions. The release of the pNA was investigated at different substrate concentrations 
(Figure 19). The Km value was then generated from Lineweaver-Burk plot (Figure 20). Other 
parameters and conditions of the assay were identical as previously described. Under this 
assay condition the enzyme activity as well as its inhibition by P32/98 (positive control) could 
be clearly observed (Figure 21). 
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Figure 19. Evaluation of the assay conditions for DPP-8 inhibitory screening. 
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Figure 20. Lineweaver-Burk plot of the substrate cleavage by DPP-8.  
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Figure 21. DPP-8 inhibition by P32/98. 
 
The aminomethyl-pyridines 120 were investigated for its DPP-8 inhibitory activity. IC50 
values were calculated after plotting the data for up to eight inhibitor concentrations. The 
assay was repeated 3 times for each test compound and the values were averaged. 
Toxicity of the compounds: The toxicity of the compounds at 10 µM was investigated with 
HeLa cells (Human cervix carcinoma [ATCC Cat.No. CCL-2]) at the Fraunhofer Institute in 
Stuttgart. 
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